



**EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol**

**EFSA Publication; Tetens, Inge**

*Link to article, DOI:*  
[10.2903/j.efsa.2010.1461](https://doi.org/10.2903/j.efsa.2010.1461)

*Publication date:*  
2010

*Document Version*  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

*Citation (APA):*  
EFSA Publication (2010). EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. Parma, Italy: European Food Safety Authority. (The EFSA Journal; No. 1461). DOI: 10.2903/j.efsa.2010.1461

**DTU Library**  
Technical Information Center of Denmark

---

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## SCIENTIFIC OPINION

### Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, *trans* fatty acids, and cholesterol<sup>1</sup>

EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA)<sup>2, 3</sup>

European Food Safety Authority (EFSA), Parma, Italy

#### ABSTRACT

This Opinion of the EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA) deals with the setting of Dietary Reference Values (DRVs) for fats. A lower bound of the reference intake range for total fat of 20 energy % (E%) and an upper bound of 35 E% are proposed. Fat intake in infants can gradually be reduced from 40 E% in the 6-12 month period to 35-40 E% in the 2<sup>nd</sup> and 3<sup>rd</sup> year of life. For specific fatty acids the following is proposed: saturated fatty acid (SFA) and *trans* fatty acid intake should be as low as possible; not to set any DRV for *cis*-monounsaturated fatty acids; not to formulate a DRV for the intake of total *cis*-polyunsaturated fatty acids (PUFA); not to set specific values for the n-3/n-6 ratio; to set an Adequate Intake (AI) of 4 E% for linoleic acid (LA); not to set any DRV for arachidonic acid; not to set an UL for total or any of the n-6 PUFA; to set an AI for alpha-linolenic acid (ALA) of 0.5 E%; not to set an UL for ALA; to set an AI of 250 mg for eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) for adults; to set an AI of 100 mg DHA for infants (>6 months) and young children <24 months; to increase by 100-200 mg preformed DHA in addition to the AI for adults as an adequate supply of n-3 long chain PUFA during pregnancy and lactation; not to set any DRV for conjugated linoleic acid. For cholesterol it was decided not to propose a reference value beside the limitation on the intake of SFA.

#### KEY WORDS

Fat, fatty acids, total fat, saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), n-3 PUFA, n-6 PUFA, cholesterol, *trans*-fatty acids (TFA), conjugated linoleic acid (CLA), dietary requirements, blood lipids, lipid profile, glucose tolerance, insulin sensitivity, body weight, type 2 diabetes, blood pressure, cardiovascular disease, coronary heart disease.

---

1 On request from the European Commission, Question No EFSA-Q-2008-466, adopted on 04 December 2009.

2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.

Correspondence: [nda@efsa.europa.eu](mailto:nda@efsa.europa.eu)

3 Acknowledgement: The Panel wishes to thank for the preparation of this Opinion: Carlo Agostoni, Henk van den Berg, Jean-Louis Bresson, Jean-Michel Chardigny, Albert Flynn, Karin Hulshof, Ambroise Martin, Ronald Mensink, Hildegard Przyrembel and EFSA's staff member Silvia Valtueña Martínez.

Suggested citation: EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, *trans* fatty acids, and cholesterol. EFSA Journal 2010; 8(3):1461. [107 pp.]. doi:10.2903/j.efsa.2010.1461. Available online: [www.efsa.europa.eu](http://www.efsa.europa.eu)

## SUMMARY

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on Population Reference Intakes for the European population, including fat.

Dietary fats or lipids include triacylglycerols, phosphatidylcholine and cholesterol. Along with proteins, carbohydrates, and alcohol, fats are a major energy source for the body. Fatty acids are also involved in many other vital processes in the body (e.g. structural components of cell membranes, precursors for bioactive molecules, regulators of enzyme activities, regulation of gene expression).

Fatty acids can be classified according to their number of double bonds. Saturated fatty acids (SFA) have no double bonds, while monounsaturated fatty acids (MUFA) have one double bond and polyunsaturated fatty acids (PUFA) have two or more double bonds. These double bonds can have either the *cis* or *trans* configuration. Most unsaturated fatty acids in the diet have the *cis* configuration, but *trans* fatty acids (TFA) are also present as either *trans*-MUFA or *trans*-PUFA. *Trans*-PUFA have at least one *trans* double bond and may therefore also have double bonds in the *cis* configuration.

In most countries, separate dietary recommendations exist for total fat intake, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, and *trans* fatty acids. For this purpose, polyunsaturated fatty acids are frequently subdivided into n-6 polyunsaturated fatty acids, n-3 polyunsaturated fatty acids, and n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA). This latter class of fatty acids has 20 or more carbon atoms. Except for the n-3 long-chain polyunsaturated fatty acids, recommendations are expressed as percentage of total dietary energy (E%) or as grams per day.

Due to its physical properties, cholesterol is also a fat. It does not provide energy, but plays a central role in many metabolic processes. Recommendations are expressed in milligrams per day (mg/day) or in milligrams per megajoule (mg/MJ).

### Total fat

Fat is an important dense source of energy and facilitates the absorption of fat-soluble dietary components such as vitamins. Fats and oils are also important sources of essential fatty acids (EFA). High-fat diets may decrease insulin-sensitivity and are positively associated with changes in fasting and postprandial factor VII, which may increase cardiovascular risk. However, a precise dose-response relationship can not be defined. There is evidence that a moderate fat intake (<35 E%) is accompanied by a reduced energy intake and therefore moderate weight reduction and/or prevention of weight gain. However, there are not sufficient data to define a Lower Threshold Intake (LTI) or Tolerable Upper Intake Level (UL) for total fat. The Panel concludes that only a Reference Intake range can be established for total fat intake, partly based on practical considerations (e.g. current levels of intake, achievable dietary patterns). At the lowest observed intake of total fat (20 E%) in European countries no overt signs of deficiencies have been observed nor adverse effects on blood lipids. Total fat intakes > 35 E% may be compatible with both good health and normal body weight depending on dietary patterns and the level of physical activity. The Panel proposes to set for adults a lower bound of the Reference Intake range of 20 E% and an upper bound of 35 E%.

Fat intake in infants, which is high during the breastfeeding period, can gradually be reduced in the second half of the first year of life from the start of the complementary feeding period up to three years of age: 40 E% in the 6 to 12 month period and 35 to 40 E% in the 2<sup>nd</sup> and 3<sup>rd</sup> year of life. Fat intakes below 25 E% have been associated with low vitamin levels in some young children.

## Saturated fatty acids

SFA are synthesised by the body and are not required in the diet. Therefore, no Population Reference Intake (PRI), Average Requirement (AR), Lower Threshold Intake (LTI), or Adequate Intake (AI) is set.

There is a positive, dose-dependent relationship between the intake of a mixture of saturated fatty acids and blood low density lipoprotein (LDL) cholesterol concentrations, when compared to carbohydrates. There is also evidence from dietary intervention studies that decreasing the intakes of products rich in saturated fatty acids by replacement with products rich in n-6 polyunsaturated fatty acids (without changing total fat intake) decreased the number of cardiovascular events. As the relationship between saturated fatty acids intake and the increase in LDL cholesterol concentrations is continuous, no threshold of saturated fatty acids intake can be defined below which there is no adverse effect. Thus, also no Tolerable Upper Intake Level can be set.

The Panel concludes that saturated fatty acids intake should be as low as is possible within the context of a nutritionally adequate diet<sup>4</sup>. Limiting the intake of saturated fatty acids should be considered when establishing nutrient goals and recommendations.

## Cis-monounsaturated fatty acids (cis-MUFA)

*Cis*-monounsaturated fatty acids are synthesised by the body, have no known specific role in preventing or promoting diet-related diseases, and are therefore not indispensable constituents of the diet. The Panel proposes not to set any Dietary Reference Value for *cis*- monounsaturated fatty acids.

## Cis-polyunsaturated fatty acids (cis-PUFA)

In view of the different metabolic effects of the various dietary *cis*- polyunsaturated fatty acids, the Panel proposes not to formulate a Dietary Reference Value for the intake of total *cis*- polyunsaturated fatty acids. Also, the Panel proposes not to set specific values for the n-3/n-6 ratio as there are insufficient data on clinical and biochemical endpoints in humans to recommend a ratio independent of absolute levels of intake.

## n-6 polyunsaturated fatty acids (n-6 PUFA)

Linoleic acid (LA) cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is therefore an EFA. However, there are not sufficient scientific data to derive an Average Requirement, a Lower Threshold Intake or a Population Reference Intake.

There is a negative (beneficial), dose-dependent relationship between the intake of linoleic acid and blood LDL cholesterol concentrations, while this relationship is positive for HDL cholesterol concentrations. In addition, linoleic acid (LA) lowers fasting blood triacylglycerol concentrations when compared to carbohydrates. There is also evidence that replacement of saturated fatty acids by n-6 polyunsaturated fatty acids (without changing total fat intake) decreases the number of cardiovascular events in the population. As the relationship between linoleic acid intake and the blood lipid profile is continuous, no threshold value of linoleic acid intake can be identified below which the risk for cardiovascular events increases.

The Panel proposes to set an Adequate Intake for linoleic acid of 4 E%, based on the lowest estimated mean intakes of the various population groups from a number of European countries, where overt LA deficiency symptoms are not present.

---

<sup>4</sup> Nutritionally adequate diets“ are the subject of food-based dietary guidelines and mean a dietary pattern which provides all essential nutrients in adequate amounts as well as energy delivering macronutrients in proportions that are known to maintain health

Arachidonic acid (ARA) is synthesised by the body from linoleic acid and is therefore not an essential fatty acid despite its important role in maintaining “metabolic integrity”. The Panel proposes not to set any Dietary Reference Value for arachidonic acid.

Finally, there is at present no consistent evidence that the intake of any of the n-6 polyunsaturated fatty acids has detrimental effects on health (e.g. in promoting diet-related diseases). The Panel proposes not to set a Tolerable Upper Intake Level UL for total or any of the n-6 polyunsaturated fatty acids.

### **n-3 polyunsaturated fatty acids (n-3 PUFA)**

Alpha-linolenic acid (ALA) cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is therefore considered to be an EFA. However, there are not sufficient scientific data to derive an Average Requirement, a Lower Threshold Intake or a Population Reference Intake.. The Panel proposes to set an Adequate Intake for alpha-linolenic acid of 0.5 E%, based on the lowest estimated mean intakes of the various population groups from a number of European countries, where overt alpha-linolenic acid deficiency symptoms are not present. There is no convincing evidence that the intake of alpha-linolenic acid has detrimental effects on health (e.g. in promoting diet-related diseases). The Panel, therefore, proposes not to set a Tolerable Upper Intake Level for alpha-linolenic acid.

The human body can synthesise eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from alpha-linolenic acid. Intervention studies have demonstrated beneficial effects of preformed n-3 long-chain polyunsaturated fatty acids on recognised cardiovascular risk factors, such as a reduction of plasma triacylglycerol concentrations, platelet aggregation, and blood pressure. These effects were observed at intakes  $\geq 1$ g per day, well above levels that were associated with lower cardiovascular disease (CVD) risk in epidemiological studies. With respect to cardiovascular diseases, prospective epidemiological and dietary intervention studies indicate that oily fish consumption or dietary n-3 long-chain polyunsaturated fatty acids supplements (equivalent to a range of 250 to 500 mg of eicosapentaenoic acid plus docosahexaenoic acid daily) decrease the risk of mortality from coronary heart disease (CHD) and sudden cardiac death. An intake of 250 mg per day of eicosapentaenoic acid plus docosahexaenoic acid appears to be sufficient for primary prevention in healthy subjects. Therefore, and taking into account that available data are insufficient to derive an Average Requirement, the Panel proposes to set an Adequate Intake of 250 mg for eicosapentaenoic acid plus docosahexaenoic acid for adults based on cardiovascular considerations.

To this intake 100 to 200 mg of preformed docosahexaenoic acid should be added during pregnancy and lactation to compensate for oxidative losses of maternal dietary docosahexaenoic acid and accumulation of docosahexaenoic acid in body fat of the foetus/infant.

In older infants, docosahexaenoic acid intakes at levels of 50 to 100 mg per day have been found effective for visual function in the complementary feeding period and are considered to be adequate for that period.

The Panel proposes an Adequate Intake of 100 mg docosahexaenoic acid for older infants (>6 months of age) and young children below the age of 24 months.

The currently available evidence does not permit to define an age specific quantitative estimate of an adequate dietary intake for eicosapentaenoic acid and docosahexaenoic acid for children aged 2 to 18 years. However, dietary advice for children should be consistent with advice for the adult population (i.e., 1 to 2 fatty fish meals per week or ~250 mg of eicosapentaenoic acid plus docosahexaenoic acid per day).

### ***Trans* fatty acids (TFA)**

*Trans* fatty acids are not synthesised by the human body and are not required in the diet. Therefore, no Population Reference Intake, Average Requirement, or Adequate Intake is set.

Consumption of diets containing *trans*-monounsaturated fatty acids, like diets containing mixtures of saturated fatty acids, increases blood total and LDL cholesterol concentrations in a dose-dependent manner, compared with consumption of diets containing *cis*-monounsaturated fatty acids or *cis*-polyunsaturated fatty acids. Consumption of diets containing *trans*-monounsaturated fatty acids also results in reduced blood HDL cholesterol concentrations and increases the total cholesterol to HDL cholesterol ratio. The available evidence indicates that *trans* fatty acids from ruminant sources have adverse effects on blood lipids and lipoproteins similar to those from industrial sources when consumed in equal amounts. Prospective cohort studies show a consistent relationship between higher intakes of *trans* fatty acids and increased risk of coronary heart disease. The available evidence is insufficient to establish whether there is a difference between ruminant and industrial *trans* fatty acids consumed in equivalent amounts on the risk of coronary heart disease.

Dietary *trans* fatty acids are provided by several fats and oils that are also important sources of essential fatty acids and other nutrients. Thus, there is a limit to which the intake of *trans* fatty acids can be lowered without compromising adequacy of intake of essential nutrients. Therefore, the Panel concludes that *trans* fatty acids intake should be as low as is possible within the context of a nutritionally adequate diet. Limiting the intake of *trans* fatty acids should be considered when establishing nutrient goals and recommendations.

### **Conjugated linoleic acids (CLA)**

There is no convincing evidence that any of the conjugated linoleic acids isomers in the diet play a role in prevention or promotion of diet-related diseases. The Panel therefore proposes not to set any Dietary Reference Value for conjugated linoleic acids.

### **Cholesterol**

Cholesterol is synthesised by the body and is not required in the diet. Therefore, no Population Reference Intake, Average Requirement, or Adequate Intake is set.

Although there is a positive dose-dependent relationship between the intake of dietary cholesterol with blood LDL cholesterol concentrations, the main dietary determinant of blood LDL cholesterol concentrations is saturated fat intake. Furthermore, most dietary cholesterol is obtained from foods which are also significant sources of dietary saturated fatty acids, e.g. dairy and meat products. Therefore the Panel decided not to propose a reference on cholesterol intake beside its conclusion on the intake of saturated fatty acids.

## TABLE OF CONTENTS

Abstract .....	1
Summary .....	2
Table of contents .....	6
Background as provided by the European Commission .....	9
Terms of reference as provided by European Commission .....	9
Assessment .....	11
1. Introduction .....	11
2. Categories, structure and function .....	12
2.1. Triacylglycerols and fatty acids .....	12
2.1.1. Saturated fatty acids (SFA) .....	14
2.1.2. Monounsaturated fatty acids (MUFA) .....	14
2.1.3. Polyunsaturated fatty acids (PUFA) .....	14
2.1.4. <i>Trans</i> fatty acids (TFA) .....	15
2.1.5. Conjugated linoleic acid (CLA) .....	15
2.2. Sterols .....	16
3. Dietary sources and intake data .....	16
3.1. Dietary sources .....	16
3.1.1. Saturated fatty acids (SFA) .....	17
3.1.2. Monounsaturated fatty acids (MUFA) .....	17
3.1.3. Polyunsaturated fatty acids (PUFA) .....	17
3.1.4. <i>Trans</i> fatty acids (TFA) .....	18
3.1.5. Conjugated linoleic acid (CLA) .....	19
3.1.6. Cholesterol .....	19
3.2. Intake data .....	19
3.2.1. Total fat .....	20
3.2.2. Saturated fatty acids (SFA) .....	20
3.2.3. Monounsaturated fatty acids (MUFA) .....	20
3.2.4. Polyunsaturated fatty acids (PUFA) .....	21
3.2.5. <i>Trans</i> fatty acids (TFA) .....	21
3.2.6. Cholesterol .....	22
4. Overview of Dietary Reference Values and recommendations .....	22
4.1. Adults .....	23
4.1.1. Total fat .....	23
4.1.2. Saturated fatty acids (SFA) .....	24
4.1.3. Monounsaturated fatty acids (MUFA) .....	24
4.1.4. Polyunsaturated fatty acids (PUFA) .....	25
4.1.5. <i>Trans</i> fatty acids (TFA) .....	27
4.1.6. Cholesterol .....	28
4.2. Infants and children .....	28
4.2.1. Total fat .....	28
4.2.2. Saturated fatty acids (SFA) .....	28
4.2.3. Monounsaturated fatty acids (MUFA) .....	28
4.2.4. Polyunsaturated fatty acids (PUFA) .....	29
4.2.5. Cholesterol .....	30
5. Criteria (endpoints) on which to base Dietary Reference Values .....	32
5.1. Dietary requirements .....	32
5.1.1. Total fat .....	32
5.1.2. <i>cis</i> -Polyunsaturated fatty acids (PUFA) .....	34
5.2. Blood lipids and lipoproteins .....	36
5.2.1. Total fat .....	37



5.2.2.	Saturated fatty acids (SFA) .....	37
5.2.3.	<i>Cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA) .....	37
5.2.4.	<i>cis</i> -Polyunsaturated fatty acids ( <i>cis</i> -PUFA) .....	37
5.2.5.	<i>Trans</i> fatty acids (TFA).....	38
5.2.6.	Conjugated linoleic acid (CLA) .....	39
5.2.7.	Cholesterol.....	39
5.2.8.	Conclusion.....	39
5.3.	Haemostatic function .....	39
5.3.1.	Total fat .....	39
5.3.2.	Saturated fatty acids (SFA) .....	40
5.3.3.	<i>Cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA) .....	40
5.3.4.	Polyunsaturated fatty acids (PUFA).....	40
5.3.5.	<i>Trans</i> fatty acids (TFA).....	40
5.3.6.	Conjugated linoleic acid (CLA) .....	40
5.3.7.	Conclusion.....	41
5.4.	Inflammation and immune function.....	41
5.4.1.	Saturated fatty acids (SFA), <i>cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA).....	41
5.4.2.	<i>Trans</i> fatty acids (TFA).....	41
5.4.3.	Conjugated linoleic acid (CLA) .....	41
5.4.4.	Conclusion.....	41
5.5.	Blood pressure .....	42
5.5.1.	Total fat .....	42
5.5.2.	Saturated fatty acids (SFA) .....	42
5.5.3.	<i>Cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA) .....	42
5.5.4.	Polyunsaturated fatty acids.....	42
5.5.5.	<i>Trans</i> fatty acids (TFA).....	42
5.5.6.	Conjugated linoleic acid (CLA) .....	43
5.5.7.	Conclusion.....	43
5.6.	Glucose tolerance and insulin sensitivity .....	43
5.6.1.	Total fat .....	43
5.6.2.	Saturated fatty acids (SFA), <i>cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA).....	43
5.6.3.	n-3 polyunsaturated fatty acids (n-3 PUFA) .....	43
5.6.4.	<i>Trans</i> fatty acids (TFA).....	44
5.6.5.	Conjugated linoleic acid (CLA) .....	44
5.6.6.	Conclusion.....	44
5.7.	Body weight control and energy balance.....	44
5.7.1.	Total fat .....	44
5.7.2.	Saturated fatty acids (SFA), <i>cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA).....	45
5.7.3.	n-3 polyunsaturated fatty acids (n-3 PUFA) .....	45
5.7.4.	<i>Trans</i> fatty acids (TFA).....	46
5.7.5.	Conjugated linoleic acid (CLA) .....	46
5.7.6.	Conclusion.....	46
5.8.	Cardiovascular disease.....	46
5.8.1.	Total fat, saturated fatty acids (SFA), <i>cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA).....	46
5.8.2.	n-3 polyunsaturated fatty acids (n-3 PUFA) .....	47
5.8.3.	<i>Trans</i> fatty acids (TFA).....	48
5.8.4.	Cholesterol.....	48
5.8.5.	Conclusion.....	48



5.9.	Type 2 diabetes mellitus .....	48
5.9.1.	Total fat, saturated fatty acids (SFA), <i>cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA), and n-6 polyunsaturated fatty acids (n-6 PUFA) .....	48
5.9.2.	n-3 polyunsaturated fatty acids (n-3 PUFA) .....	49
5.9.3.	<i>Trans</i> fatty acids (TFA).....	49
5.9.4.	Cholesterol.....	49
5.9.5.	Conclusion.....	49
5.10.	Cancer .....	49
5.10.1.	Conclusion.....	50
5.11.	Nervous system function .....	50
5.12.	Cognitive decline and dementia.....	50
6.	Key data on which to base Dietary Reference Values .....	51
6.1.	Total fat.....	51
6.2.	Saturated fatty acids (SFA).....	51
6.3.	<i>Cis</i> -monounsaturated fatty acids ( <i>cis</i> -MUFA).....	52
6.4.	<i>Cis</i> -polyunsaturated fatty acids ( <i>cis</i> -PUFA) .....	52
6.4.1.	n-6 polyunsaturated fatty acids (n-6 PUFA) .....	52
6.4.2.	n-3 polyunsaturated fatty acids (n-3 PUFA) .....	53
6.5.	<i>Trans</i> fatty acids (TFA) .....	53
6.6.	Conjugated linoleic acid (CLA).....	54
6.7.	Cholesterol.....	54
	Conclusions and recommendations.....	54
	References .....	59
	Annexes.....	76
	Glossary / Abbreviations.....	106

## BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The scientific advice on nutrient intakes is important as the basis of Community action in the field of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European Community dates from 1993. There is a need to review and if necessary to update these earlier recommendations to ensure that the Community action in the area of nutrition is underpinned by the latest scientific advice.

In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community<sup>5</sup>. The report provided reference intakes for energy, certain macronutrients and micronutrients, but it did not include certain substances of physiological importance, for example dietary fibre.

Since then new scientific data have become available for some of the nutrients, and scientific advisory bodies in many EU member states and in the US have reported on recommended dietary intakes. For a number of nutrients these newly established (national) recommendations differ from the reference intakes in the SCF (1993) report. Although there is considerable consensus between these newly derived (national) recommendations, differing opinions remain on some of the recommendations. Therefore, there is a need to review the existing EU reference intakes in the light of new scientific evidence, and taking into account the more recently reported national recommendations. There is also a need to include dietary components that were not covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be appropriate to establish reference intakes for other (essential) substances with a physiological effect.

In this context the EFSA is requested to consider the existing population reference intakes for energy, micro- and macronutrients and certain other dietary components, to review and complete the SCF recommendations, in the light of new evidence, and in addition advise on a population reference intake for dietary fibre.

For communication of nutrition and healthy eating messages to the public it is generally more appropriate to express recommendations for the intake of individual nutrients or substances in food-based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient based recommendations for a healthy diet into food based recommendations intended for the population as a whole.

## TERMS OF REFERENCE AS PROVIDED BY EUROPEAN COMMISSION

In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/2002, the Commission requests EFSA to review the existing advice of the Scientific Committee for Food on population reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

In the first instance the EFSA is asked to provide advice on energy, macronutrients and dietary fibre. Specifically advice is requested on the following dietary components:

- Carbohydrates, including sugars;

---

<sup>5</sup> Scientific Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientific Committee for Food 31<sup>st</sup> series, Office for Official Publication of the European Communities, Luxembourg, 1993.

- Fats, including saturated fatty acids, poly-unsaturated fatty acids and mono-unsaturated fatty acids, *trans* fatty acids;
- Protein;
- Dietary fibre.

Following on from the first part of the task, the EFSA is asked to advise on population reference intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice into guidance, intended for the European population as a whole, on the contribution of different foods or categories of foods to an overall diet that would help to maintain good health through optimal nutrition (food-based dietary guidelines).


## ASSESSMENT

A draft of this Opinion, agreed by the NDA Panel on 2 July 2009, was published on the EFSA website<sup>6</sup> for public consultation between 5 August and 15 October 2009. The draft Opinion was also discussed at a National Expert Meeting with Member States on Dietary Reference Values held in Barcelona on 7 and 8 September 2009. All the public comments received and comments from Member States that related to the remit of EFSA were assessed and the Opinion has been revised taking relevant comments into consideration. The comments received, a report on the outcome of the public consultation, and the minutes of the meeting with Member States have been published on the EFSA website.

### 1. Introduction

Dietary fats or lipids mainly consist of triacylglycerol, which are molecules composed of three fatty acids and glycerol, but phosphatidylcholine and cholesterol are also included. Along with proteins, carbohydrates, and alcohol, fats are a major energy source for the body. The energy produced by one gram of the most common triacylglycerols in the diet is approximately 37 kilojoules (kJ) (9 kilocalories (kcal)) per gram. Fatty acids, however, are also involved in many other vital processes.

Fatty acids can be classified according to their number of double bonds. Saturated fatty acids (SFA) have no double bonds, while monounsaturated fatty acids (MUFA) have one double bond and polyunsaturated fatty acids (PUFA) have two or more double bonds. The position of the double bond can vary along the carbon chain and its position can be indicated in several ways. When counted from the carboxyl-end (-COOH) of the molecule, the so-called “ $\Delta x$ ”-nomenclature is applied, while the “n-x” or “ $\omega x$ ” classification is used when counting starts from the methyl-end (-CH<sub>3</sub>). Thus, “n-9” or “ $\omega 9$ ” means that the double bond is located at the ninth carbon atom from the methyl-end. These double bonds can have either the *cis* or *trans* configuration. *Cis* means that the two carbon (C)-atoms (or hydrogen (H)-atoms) adjacent to the double bond point into the same direction, while in the *trans* configuration the two carbon atoms point into opposite directions. As an example, elaidic acid [*trans*-C18:1(n-9)] and oleic acid [*cis*-C18:1(n-9)] are shown in Figure 1. These two molecules are so-called geometrical isomers.



**Figure 1:** Structure of oleic acid and elaidic acid

<sup>6</sup> [http://www.efsa.europa.eu/EFSA/efsa\\_locale-1178620753812\\_1211902045161.htm](http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902045161.htm)

Most unsaturated fatty acids in the diet have the *cis* configuration, but *trans* fatty acids (TFA) are also present. Both *trans*-MUFA and *trans*-PUFA exist. *Trans*-PUFA have at least one *trans* double bond and may therefore also have double bonds in the *cis* configuration.

In most countries, separate dietary recommendations exist for total fat intake, SFA, MUFA, PUFA, and TFA. For this purpose, PUFA are frequently subdivided into n-6 PUFA, n-3 PUFA, and n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA). This latter class of fatty acids has 20 or more carbon atoms. Except for the n-3 LCPUFA, recommendations are expressed as percentage of total dietary energy (E%) or as milligrams (mg) per day.

Due to its physical properties, cholesterol, a steroid, is also included in dietary fats. It does not provide energy, but plays a central role in many metabolic processes. Recommendations are expressed in mg/day or in mg/megajoule (MJ).

## 2. Categories, structure and function


In foods, fats are represented by several components such as fatty acids and sterols. Fatty acids are generally esterified on the glycerol backbone as triacylglycerols (also referred to as triglycerides, see below), but are also part of the phospholipid molecule. Phospholipids, which generally represent less than 1% of total dietary lipids, are found in cell membranes, milk fat globules, and eggs. A major phospholipid is phosphatidylcholine. Structurally, there are no differences between a fat and oil. Fats, however, are usually solid at room temperature, while oils are liquid.

Triacylglycerols and fatty acids facilitate the absorption of other fat-soluble components such as vitamins. In the body, fatty acids are not only a major source of energy for the body, but also serve many vital functions (e.g. structural components of cell membranes, precursors for bioactive molecules, regulators of enzyme activities (e.g. protein myristoylation), regulation of gene expression).

### 2.1. Triacylglycerols and fatty acids

Triacylglycerols represent the major dietary form of fatty acids. The term “fatty acid” designates any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis of triacylglycerols from fats and oils. In general, fatty acids represent more than 90% by weight of triacylglycerols. Three fatty acids are esterified to a glycerol backbone. Due to the asymmetric structure of substituted glycerol, the esterified fatty acids are distinguished by their position, namely sn-1, sn-2 and sn-3 position. Considering their metabolic fate (action of lipases) in the digestive tract, sn-1 and sn-3-esterified fatty acids are considered as esterified at “external” positions, whereas the sn-2 position is named “internal”.

Pancreatic lipase has a high specificity for the sn-1 and sn-3 position of dietary triacylglycerols so that free fatty acids from the sn-1 and sn-3 position and 2-monoacylglycerol are released and absorbed into the enterocyte where they are reassembled into triacylglycerols thereby conserving the fatty acid at the sn-2 position. Whilst the absorption of saturated fatty acids decreases with increasing chain length because of slow solubilisation into mixed micelles in the intestinal lumen and because of the formation of insoluble soaps with divalent cations like calcium, it can be enhanced by positioning the saturated fatty acid at sn-2 (Carnielli et al., 1996). Mixtures of saturated and unsaturated fatty acids in dietary fat, however, are almost completely absorbed (Bonanome and Grundy, 1989).



**Figure 2:** Structure of a triacylglycerol

The most common fatty acids in the diet are listed in Table 1.

**Table 1:** Main fatty acids in the diet.

Systematic nomenclature	Common name	Abbreviation
<b>Saturated fatty acids (SFA)</b>		
Butanoic acid	Butyric acid	4:0
Hexanoic acid	Caproic acid	6:0
Octanoic acid	Caprylic acid	8:0
Decanoic acid	Capric acid	10:0
Dodecanoic acid	Lauric acid	12:0
Tetradecanoic acid	Myristic acid	14:0
Pentadecanoic acid	Pentadecylic acid	15:0
Hexadecanoic acid	Palmitic acid	16:0
Heptadecanoic acid	Margaric acid	17:0
Octadecanoic acid	Stearic acid	18:0
<b><i>Cis</i>-monounsaturated fatty acids (<i>cis</i>-MUFA)</b>		
Hexadecenoic acid	Palmitoleic acid	16:1 $\Delta$ 9c
Octadecenoic acid	Oleic acid	18:1 $\Delta$ 9c (n-9; $\omega$ 9)
Eicosenoic acid	Gadoleic acid	20:1 $\Delta$ 9c
<b><i>Trans</i>-monounsaturated fatty acids (<i>trans</i>-MUFA)</b>		
Octadecenoic acid	Elaidic acid	18:1 $\Delta$ 9t (n-9; $\omega$ 9)
Octadecenoic acid	<i>Trans</i> -vaccenic acid	18:1 $\Delta$ 11t (n-7; $\omega$ 7)
<b>Polyunsaturated fatty acids (PUFA)</b>		
<b>n-6 Polyunsaturated fatty acids (n-6 PUFA)</b>		
.Octadecadienoic acid	Linoleic acid	18:2 $\Delta$ 9c,12c (n-6; $\omega$ 6)
.Octadecatrienoic acid	$\gamma$ -Linolenic acid	18:3 $\Delta$ 6c,9c,12c (n-6; $\omega$ 6)
.Eicosatetraenoic acid	Arachidonic acid	20:4 $\Delta$ 5c,8c,11c,14c (n-6; $\omega$ 6)
<b>n-3 Polyunsaturated fatty acids (n-3 PUFA)</b>		
.Octadecatrienoic acid	$\alpha$ -Linolenic	18:3 $\Delta$ 9c,12c,15c (n-3; $\omega$ 3)
.Eicosapentaenoic acid	EPA	20:5 $\Delta$ 5c,8c,11c,14c,17c (n-3; $\omega$ 3)
.Docosapentaenoic acid	DPA	22:5 $\Delta$ 7c,10c,13c,16c,19c (n-3; $\omega$ 3)
.Docosahexaenoic acid	DHA	22:6 $\Delta$ 4c,7c,10c,13c,16c,19c (n-3; $\omega$ 3)
<b>Conjugated linoleic acid (CLA)</b>		
Octadecadienoic acid	Rumenic acid	18:2 $\Delta$ 9c,11t
Octadecadienoic acid		18:2 $\Delta$ 10t,12c

### 2.1.1. Saturated fatty acids (SFA)

Although exceptions exist, SFA consist - like all fatty acids - of an even number of carbon atoms. This number usually ranges between 4 and 20. Depending on the number of carbon atoms, SFA are divided into short chain saturated fatty acids (SCFA: less than 6 carbon atoms), medium chain fatty acids (MCFA: 6-10 carbon atoms), or long chain saturated fatty acids (12 to 18 carbon atoms). It should be noted, however, that this division is not stringent, and – that for example lauric acid with 12 carbon atoms is sometimes also denoted as a MCFA. In this Opinion, however, lauric acid is considered as a long chain saturated fatty acid.

The most prevailing SFA in the diet are lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), and stearic acid (18:0). The human body can synthesise SFA, although to a very low extent.

### 2.1.2. Monounsaturated fatty acids (MUFA)

MUFA have one double bond in the fatty-acid chain. The quantitatively most important representative in the diet and in tissue lipids is oleic acid (18:1, n-9) with a double bond at the n-9 ( $\omega$ 9) position. Like other fatty acids, MUFA are almost completely absorbed from the intestine and are oxidised (for energy production), converted into other fatty acids, or incorporated into tissue lipids. Humans can synthesise MUFA and MUFA are therefore not required as such from the diet.

### 2.1.3. Polyunsaturated fatty acids (PUFA)

PUFA have 2 to 6 double bonds. Humans lack the enzymes  $\Delta$ 12- and  $\Delta$ 15-desaturase that can introduce double bonds in the n-6 and n-3 positions, respectively. Two PUFA with methylene-interrupted *cis*-double bonds of the omega-3 (alpha-linolenic acid, 18:3, n-3) and omega-6 series (linoleic acid, 18:2, n-6) are thus essential to humans and must be provided by the diet. They are also the most abundant PUFA in the diet. The n-6 and n-3 PUFA are metabolised (desaturated and elongated) further by the same enzyme systems. PUFA with 20 or more carbon atoms are usually referred to as LCPUFA. Important n-6 and n-3 PUFA occurring in foods are mentioned in Table 1.

The essential PUFA and LCPUFA serve important physiological functions in the organism. Arachidonic acid (ARA) and eicosapentaenoic acid (EPA) can be further transformed to eicosanoids, a group of biologically active substances including prostaglandins, prostacyclins and leukotrienes, which participate in the regulation of blood pressure, renal function, blood coagulation, inflammatory and immunological reactions and other functions in tissues. Furthermore, n-6 and n-3 PUFA, particularly the LCPUFA, are important structural components of cell membranes. They are essential for various membrane functions such as fluidity, permeability, activity of membrane-bound enzymes and receptors, and signal transduction.

Other non-essential *cis*-PUFA can be formed from saturated and monounsaturated fatty acids, e.g. in the n-7 and n-9 series. These are generally found in small amounts in foods.

#### 2.1.3.1. n-6 polyunsaturated fatty acids (n-6 PUFA)

n-6 PUFA mainly include linoleic acid (LA), and to a lesser extent ARA. Strictly speaking, only linoleic acid is essential, as the body can synthesise arachidonic acid from linoleic acid at intakes below 3.8 E% (Angela Liou and Innis, 2009). ARA is the precursor for series 2 prostanoids and series 4 leukotrienes (Kinsella et al., 1990).

Linoleic acid, when incorporated into skin ceramides, is essential for maintaining the water-permeability barrier of the skin thereby avoiding excessive trans-epidermal water loss and the



accompanying energy loss from water evaporation. Linoleic acid is metabolised to, for example, gamma-linolenic acid (18:3, n-6), dihomo-gamma-linolenic acid (20:3, n-6; DHGLA) and arachidonic acid (20:4, n-6; ARA). The conversion of linoleic acid is limited. Emken et al. (1994), for example, estimated that less than 1% of deuterated LA was converted into ARA, possibly due to a low  $\Delta 5$  desaturase activity (El Boustani et al., 1989), which may be even further decreased in elderly women (Babin et al., 1999). Also the activity of  $\Delta$ -6 desaturase decreases with age (Angela Liou and Innis, 2009).

#### 2.1.3.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

n-3 PUFA are polyunsaturated fatty acids with one of the double bonds located at three carbon atoms from the methyl end. The quantitatively most important n-3 PUFA in the diet are: 18:3 (alpha-linolenic acid, ALA), 20:5 (eicosapentaenoic acid, EPA), 22:5 (docosapentaenoic acid, DPA), and 22:6 (docosahexaenoic acid, DHA). EPA is the precursor for series 3 prostanoids and series 5 leukotrienes (Kinsella et al., 1990).

ALA is essential in human nutrition as precursor for the n-3 LCPUFA. EPA, DPA and to a lesser degree DHA are synthesised from ALA through the sequential action of various desaturases and elongases in animal tissues, but not in plants. Estimates for the conversion of ALA into EPA are around 8 to 12%, while the conversion into DHA may be less than 1% (Goyens et al., 2006). Due to this low conversion and the fact that ALA, and EPA and DHA may have different biological function, many authorities have separate recommendations for ALA on the one hand, and for EPA and DHA on the other hand (see section 4).

DHA is a component of membrane structural lipids, especially of phospholipids in nervous tissue and the retina. The developing brain accumulates large amounts of DHA both pre- and postnatally, particularly during the first two years of life, which is predominantly acquired from the mother via placental transfer and breast milk, although the capacity of the brain to synthesise DHA increases with gestational age (Clandinin, 1999; Salem et al., 1996).

Linoleic acid and ALA are converted into their respective LCPUFA by the same enzymes. In fact, the conversion of ALA into EPA and DHA is decreased when the amount of linoleic acid in the diet increases (and vice versa). For this reason, some dietary recommendations also include guidelines for the n-3/n-6 ratio in the diet. Whilst the proportion of dietary ALA converted into n-3 LCPUFA is not influenced by the dietary n-3/n-6 ratio, the amounts of n-3 LCPUFA formed depends on the amount of ALA consumed (Goyens et al., 2006). The ability to convert ALA into n-3 LCPUFA and the levels of n-3 LCPUFA in plasma phospholipids and red blood cells are, moreover, individually related to polymorphisms in the human  $\Delta$ -5 and  $\Delta$ -6 desaturase genes FADS1 and FADS2 (Schaeffer et al., 2006).

#### 2.1.4. *Trans* fatty acids (TFA)

Most unsaturated fatty acids in the diet have the *cis* configuration, but TFA are also present. These fatty acids originate from several sources and *trans*-MUFA are the most common TFA in the diet. *Trans*-PUFA, however, are also present. *Trans*-PUFA have at least one *trans* double bond and may therefore also have double bonds in the *cis* configuration. TFA do not serve any vital functions.

#### 2.1.5. Conjugated linoleic acid (CLA)

CLA refers to a mixture of positional and geometric natural isomers of linoleic acid, whose double bonds can be in either *trans* or *cis* configuration. They differ from most natural PUFA in that the double bonds are not separated by a methylene carbon, but are conjugated.

## 2.2. Sterols

Sterols are mainly represented by cholesterol from animal fat, while phytosterols (sitosterol, campesterol, and stigmasterol) are present in vegetable-derived food items and supplemented products.

Cholesterol is a sterol found in the cell membranes of all body tissues. It is not only derived from the diet, but it is also synthesised by the body. Cholesterol plays a central role in many biochemical processes. For example, cholesterol is a precursor for the synthesis of steroid hormones. In animal fat, sterols are mainly represented by cholesterol, while phytosterols are present in vegetable-derived food items and supplemented products. Trace amounts of cholesterol are also found in plant membranes.

Due to too limited data available at habitual intakes, phytosterols will not be considered further in this Opinion.

## 3. Dietary sources and intake data

### 3.1. Dietary sources

Examples of typical fat and fatty acid compositions of some common edible fats and oils are provided in Table 2, while Table 3 presents examples of the composition of some animal-derived food products.

**Table 2:** Typical fatty acid (g/100 g) and cholesterol (mg/100 g) profiles of some edible oils and fats.

	Milk fat	Coconut oil	Palm kernel oil	Palm oil	Cocoa butter	Olive oil	Low-erucic rapeseed oil	High-linoleic acid sunflower oil	Corn oil	Soybean oil
<b>SFA</b>	63.4	86.5	81.5	49.3	59.7	13.8	7.4	10.3	12.9	15.3
<b>&lt;12:0</b>	11.0	14.1	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>12:0</b>	3.2	44.6	47.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
<b>14:0</b>	9.1	16.8	16.4	1.0	0.1	0.0	0.0	0.0	0.0	0.0
<b>16:0</b>	26.8	8.2	8.1	43.5	25.4	11.3	4.3	5.9	10.6	10.7
<b>18:0</b>	12.3	2.8	2.8	4.3	33.2	2.0	2.1	4.5	1.8	4.0
<b>MUFA</b>	25.9	5.8	11.4	37.0	32.9	73.0	63.3	19.5	27.6	22.7
<b>Cis-18:1(n-9)</b>	21.0	5.8	11.4	36.6	32.6	71.3	61.7	19.5	27.3	22.6
<b>Trans-C18:1</b>	3.7									
<b>PUFA</b>	3.7	1.8	1.6	9.3	3.0	10.5	28.1	65.7	54.7	57.3
<b>18:2, n-6</b>	3.3	1.8	1.6	9.1	2.8	9.8	18.6	65.7	53.2	50.1
<b>18:3, n-3</b>	0.4	0.0	0.0	0.2	0.1	0.8	9.1	NA	1.2	6.5
<b>CLA</b>	0.4	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Cholesterol</b>	265	0	0	0	0	0	0	0	0	0

Values are derived from the U.S. Department of Agriculture, Agricultural Research Service. USDA Nutrient Database for Standard Reference, Release 20. Nutrient Data Laboratory Home Page, <http://www.ars.usda.gov/nutrientdata>, accessed on August 26, 2008.

NA: not available

**Table 3:** Typical fat and fatty acid (g/100 g food) and cholesterol (mg/100 g food) of some animal-derived food products.

	Milk	Butter	Lean Pork (<5 g fat/100 g)	Lean Beef (<5 g fat/100 g)	Lean Lamb (<5 g fat/100 g)	Chicken (white meat)	Fatty Fish (>10 g fat/100 g)	Lean Fish (<2 g fat/100 g)
<b>Total fat</b>	3.2	81.1	3.8	4.0	4.4	1.6	11.1	1.3
<b>SFA</b>	1.86	51.37	1.26	1.46	1.88	0.37	2.42	0.38
<b>&lt;12:0</b>	0.30	8.95	<0.01	0.00	0.01	0.00	0.00	0.00
<b>12:0</b>	0.80	2.95	<0.01	<0.01	0.01	0.00	<0.01	0.00
<b>14:0</b>	0.30	7.44	0.04	0.10	0.09	0.01	0.54	0.03
<b>16:0</b>	0.83	21.70	0.79	0.89	0.90	0.26	1.71	0.26
<b>18:0</b>	0.36	10.0	0.41	0.47	0.73	0.10	0.91	0.09
<b>MUFA</b>	0.81	21.01	1.57	1.66	1.69	0.48	4.60	0.35
<b>Cis 18:1</b>	0.81	16.98	1.36	1.52*	1.60*	0.40*	1.98*	0.23*
<b>Trans-C18:1</b>	NA	2.98	0.02					
<b>PUFA</b>	0.20	3.04	0.45	0.17	0.22	0.40	2.41	0.42
<b>18:2, n-6</b>	0.12	2.17	0.37	0.20	0.13	0.24	0.27	0.06
<b>18:3, n-3</b>	0.08	0.32	0.01	0.01	0.07	0.01	0.25	0.01
<b>20:5, n-3</b>	0.00	0.00	0.00	0.0	NA	0.00	0.57	0.07
<b>22:6, n-3</b>	0.00	0.00	0.00	0.0	NA	0.02	0.86	0.20
<b>CLA</b>	NA	0.27	NA	NA	NA	NA	NA	NA
<b>Cholesterol</b>	10	215	57	45	74	57	78	48

Values are from the U.S. Department of Agriculture, Agricultural Research Service. USDA Nutrient Database for Standard Reference, Release 20. Nutrient Data Laboratory Home Page, <http://www.ars.usda.gov/nutrientdata>, accessed on February 26, 2009.

NA: not available

\* undifferentiated

### 3.1.1. Saturated fatty acids (SFA)

SFA are present in animal- and plant-derived foods. Dairy fat is relatively rich in MCFA. Coconut oil and palm kernel oil also contain appreciable amounts of MCFA. The latter fat sources are also rich in lauric and myristic acids. Palm oil and meat are characterised by high amounts of palmitic (16:0) and stearic acid (18:0), while cocoa butter is relatively rich in stearic acid (18:0).

### 3.1.2. Monounsaturated fatty acids (MUFA)

Like SFA, MUFA originate from both plant and animal-derived foods. Especially olive, high oleic acid sunflower and rapeseed oils are rich sources. Besides, seeds and nuts contain significant amounts. Although the SFA content is in general higher, products rich in SFA are also a source of MUFA. Finally, fish may contain significant amounts of MUFA.

### 3.1.3. Polyunsaturated fatty acids (PUFA)

Vegetable oils and fish oils are important sources of PUFA. In many cereals and vegetables, the proportion of PUFA in the fat can also be high, although the total fat content of these products is relatively low.

### 3.1.3.1. n-6 polyunsaturated fatty acids (n-6 PUFA)

Foods rich in n-6 PUFA include vegetable oils such as corn oil, soybean oil, and sunflower seed oil. Medium-high levels are found in rapeseed oil. Also dressings and fat spreads containing these oils have moderate levels of n-6 PUFA. Linoleic acid is the predominating PUFA in many vegetable oils. Oils derived from bacteria and microalgae and, to a lesser extent, egg yolk and lean meat contain ARA.

### 3.1.3.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

Alpha-Linolenic acid (18:3, n-3), a plant-derived n-3 PUFA, is found in some vegetable foods, e.g. linseeds, rapeseed oil and walnuts. Fish is a unique rich source of n-3 LCPUFA (EPA and DHA). Other natural sources are human milk and cultivated marine algae (single cell oils). EPA and DHA may also be provided by foods and supplements enriched with the LCPUFA.

### 3.1.4. *Trans* fatty acids (TFA)

A large number of TFA isomers of MUFA and PUFA, including positional isomers of individual fatty acids, occurs in foods. These TFA originate from several sources:

- Bacterial transformation of unsaturated fatty acids in the rumen of ruminant animals.
- Industrial hydrogenation (used to produce semi-liquid and solid fats that can be used for the production of foods such as margarine, shortenings and biscuits).
- Deodorisation (a necessary step in refining) of unsaturated vegetable oils (or occasionally fish oils) high in polyunsaturated fatty acids.
- Heating and frying of oils at too high temperatures (> 220°C). These modifications are time-dependent with about 5% of isomerisation of n-3 18:3 after 2 hours and 25% after 12 hours of heating (Henon et al., 1999).

Dairy and beef fat typically contain around 3 to 6% TFA (as % weight (wt%) of total fatty acids), while levels in lamb and mutton can be somewhat higher. In fat of milk and meat products from ruminant animals the main TFA are isomers of the monounsaturated fatty acid oleic acid, with *trans*-vaccenic acid (18:1t, n-7) predominating (about 30 to 50% of total *trans*-18:1 isomers in milk fat).

The TFA content in margarine and fat spreads may vary, depending on the proportion of partially hydrogenated oils used. In foods containing partially hydrogenated vegetable oil, the main TFA are also isomers of oleic acid with elaidic acid (18:1t n-9) accounting for 20 to 30% of total *trans*-18:1 isomers. The TFA profiles of ruminant fat and hydrogenated vegetable oil show considerable overlap for many TFA isomers, although present in different proportions (Table 4). Except for *trans*-C18:1 isomers, *trans* isomers of other MUFA (e.g. 14:1 and 16:1) as well as of polyunsaturated fatty acids also occur. Partially hydrogenated fish oil also contains *trans* 20:1 and 22:1 isomers. Dietary TFA are secreted into human milk.

**Table 4:** Typical proportions (% of total *trans* 18:1 isomers) of positional 18:1 *trans*-isomers in ruminant and industrially hydrogenated fats from conventional foods

<i>Trans</i> 18:1 isomer n-x position of double bond	$\Delta$ -position of double bond	Milk fat, goat	Milk fat, ewe	Milk fat, cow	Industrially hydrogenated fats
n-2	16	10	8	6-8	1
n-3	15	6	6	4-6	2
n-4	14	9	8	8	<sup>a</sup>
n-5	13	8	7	6-7	9-12 <sup>a</sup>
n-6	12	9	7	6-10	8-13
n-7 (vaccenic acid)	11	37	47	30-50	10-20
n-8	10	10	9	6-13	10-20
n-9 (elaidic acid)	9	6	5	5-10	20-30
n-10 to n-12	6-8	3	2	2-9	14-18
n-13	5	< 1	< 1	< 1	2
n-14	4	< 1	< 1	< 1	1

Data compiled from Precht et al., 2001; Wolff et al., 2000; and Seppänen-Laakso et al., 1996.

<sup>a</sup> Sum of n-4 and n-5 isomers

### 3.1.5. Conjugated linoleic acid (CLA)

*Cis*-9, *trans*-11 CLA (rumenic acid) is present in small amounts in ruminant fats and produced by bacteria. Mammals can also synthesise rumenic acid from *trans*-vaccenic acid (*trans*-18:1, n-7) through the action of  $\Delta$ 9 desaturases. *Trans*-10, *cis*-12 CLA in combination with rumenic acid (50/50) is found in supplements and produced by industrial processing. Human milk contains small quantities of rumenic acid and *trans*-10, *cis*-12 CLA.

### 3.1.6. Cholesterol

Cholesterol is present in animal-derived food items. Eggs in particular are a rich source of cholesterol. However, also dairy products and meats substantially contribute to the intake of cholesterol.

## 3.2. Intake data

Typical intakes of total fat and fatty acids are presented for children and adolescents in 15 countries (Annexes 1a and 1b) and adults in 22 countries in Europe (Annexes 2a and 2b). The data refer to individual based food consumption surveys, conducted from 1994 onwards. Most studies comprise national representative population samples. The data were derived from national reports and from a recently published overview (Elmadfa, 2009).

As demonstrated in the Annexes there is a large diversity in the methodology used to assess the individual intakes of children, adolescents and adults. Because the different methods apply to different time frames, this inevitably resulted in variance in both the quality and quantity of available data, which make direct comparisons difficult. Moreover, age classifications are in general not uniform. Comparability might also be hampered by differences in food composition tables used for the conversion of food consumption data to estimated nutrient intakes. For fat, fatty acids and cholesterol, however, values might be considered as reasonably comparable (Deharveng et al., 1999). It should also be kept in mind that food consumption data is prone to reporting errors and there might be a varying degree of underreporting in different surveys.

Although these differences may have an impact on the accuracy of between-country comparisons and the results should be interpreted with caution, the presented data still give a good overview of the fat intake in a number of European countries. Most studies reported mean intakes and standard deviations (SD) or mean intakes and intake distributions. The number of studies that assessed the intake of n-3 and n-6 polyunsaturated fatty acids and *trans* fatty acids appeared to be small. Dietary supplements were generally not taken into account in the calculation of intake estimates.

### 3.2.1. Total fat

Apart from infants till 18 months of age, available data show that average total fat intakes in children and adolescents in European countries varied between 28 and 42 E%, with 60% of the average intakes between 31 and 35 E%. Within population ranges varied from 22 to 29 E% (5<sup>th</sup> percentile) to 38 to 46% E% (95<sup>th</sup> percentile). In infants in the second half of the first year of life average intakes varied between approximately 26 and 29 E%.

In adults average total fat intakes ranged from less than 30 E% to 47 E%. With the exception of adults aged 19 to 34 years, about one third of the reported average data were between 30 and 35 E%; approximately 15% were 40 E% or higher. In young adults these proportions were 50% and 8%, respectively. Within population ranges varied between 22 and 25 E% at the lower (5<sup>th</sup> percentile) and 38 to 48 E% at the upper end (95<sup>th</sup> percentile) of the distributions.

In general, mean intakes were lowest in Norway and Portugal and highest in Latvia, Lithuania and Greece.

### 3.2.2. Saturated fatty acids (SFA)

In infants average intakes were between 11 and 13 E%. In Italian and Hungarian children mean SFA intakes of 10 to 11 E% were found. In other countries most average intakes ranged between 13 and 15 E%, whereas in some age groups in Belgium, Denmark and the UK mean intakes were 15 E% and higher. The lower (5<sup>th</sup> percentile) and upper (95<sup>th</sup> percentile) end of the intake distributions varied between 8 and 9 E% and between 15 and 19 E%.

In adults average SFA intakes varied between less than 9 and 26 E%, with lowest values mostly in South European countries and highest values in Romania. In adults aged 35 to 64 years and 65 and over approximately 35% of the reported average intakes were 15 E% or higher (7% in individuals aged 19 to 35 years). Within population ranges varied between 7 and 11 E% at the lowest (5<sup>th</sup> percentile) and between 17 and 22 E% at the highest (95<sup>th</sup> percentile).

### 3.2.3. Monounsaturated fatty acids (MUFA)

Average MUFA intakes ranged between 8 and 11 E% in infants and in children and adolescents mostly between 10 and 13 E% (range approximately 9 and 18 E%). In Portugal and Spain the highest average intakes were observed. Intake distributions varied between 6 and 9 E% (5<sup>th</sup> percentile) and between 13 and 17 E% (95<sup>th</sup> percentile).

In adults the highest mean intake was found in Greece (22 to 23 E%); in other European countries average intakes varied between 11 and 18 E%. When intake distributions were available, within population ranges varied between 6 and 8 E% and between 14 and 17 E% at the 5<sup>th</sup> and 95<sup>th</sup> percentiles, respectively.

### 3.2.4. Polyunsaturated fatty acids (PUFA)

In infants PUFA contributed on average 4 to 5% to total energy intake. In children and adolescents this contribution ranged from approximately 4% to 9%, with the highest intake in Hungary. Intake distributions ranged between 2.4 and 4.7 E% (5<sup>th</sup> percentile) and between 5.7 and 12.9 E% (95<sup>th</sup> percentile).

In adult populations average PUFA intakes varied between 4 and 8 E%, with highest intakes in Lithuania and Hungary. The lower and upper end of the intake distributions varied between 2.7 and 4.1 E% (5<sup>th</sup> percentile) and between 4.7 and 11 E% (95<sup>th</sup> percentile).

#### 3.2.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)

Some countries reported data for *cis* n-6 PUFA and/or linoleic acid. For children, average *cis* n-6 PUFA intakes in absolute amounts varied between approximately 5 and 17 g per day and as percentage of energy between 2.9 E% (Sweden) and 6.9 E% (the Netherlands). Within population ranges varied between 2.7 to 7.7 g per day and 4.2 to 11.6 g per day and between 1.8 to 3.7 E% and 4.2 to 11.6 E% at the 5<sup>th</sup> and 95<sup>th</sup> percentiles, respectively.

For adults, average intake of *cis* n-6 PUFA ranged between 3.8 E% and nearly 6 E%. Distribution of intakes were only available for the Netherlands, ranging from 2.6 to 9.8 E% at the 5<sup>th</sup> and the 95<sup>th</sup> percentile respectively, and for the UK, ranging from 1.9 to 10.5 E% at the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile, respectively.

#### 3.2.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

Some countries reported data for *cis* n-3 PUFA and/or ALA, EPA and DHA.

For children average *cis* n-3 PUFA varied between 1.1 and 2.2 g per day (0.6 E% and 1.4 E%). At the 5<sup>th</sup> percentile average intakes ranged from 0.5 to 0.8 g per day (0.3 to 0.5 E%); at the 95<sup>th</sup> percentile average intakes ranged from 1.9 to 3.8 g/day (0.6 to 1.7 E%). Mean ALA intake was around 0.8 g per day (0.5 E%) for young children and 0.5 to 1.1 g per day (0.5 to 0.6 E%) for children and for adolescents. The intake of EPA and DHA varied between 0.02 and 0.04 g per day (0.01 to 0.02 E%) and less than 0.1 to 0.13 g per day (0.03 to 0.06 E%), respectively.

In adults average intakes of *cis* n-3 PUFA ranged from approximately 1.5 to 2.6 g/day (0.7 to 1.3 E%). Distribution of intakes ranged in the Netherlands from 0.4 to 4.2 g per day (0.3 to 1.3 E%) at the 5<sup>th</sup> and the 95<sup>th</sup> percentile, and in the UK from 0.4 to 5.2 g per day (0.3 to 1.8 E%) at the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile, respectively. For ALA mean intakes varied between 0.7 g per day and approximately 2.3 g per day (~0.4 to 0.8 E%). For EPA and DHA the mean intakes were between 0.03 and 0.15 g/d (0.01 and 0.06 E%) and between 0.05 and 0.27 g per day (0.02 and 0.12 E%), respectively.

### 3.2.5. Trans fatty acids (TFA)

Data of the intake of TFA in children were available for Denmark, the Netherlands, Sweden and the UK. Average intakes varied between 0.6 and 1.7 E%. Within population ranges varied between 0.2 and 0.4 E% and 0.8 to 3.3 E% (5<sup>th</sup> and 95<sup>th</sup> percentiles, respectively).

TFA intake data for adults referred to Denmark, Finland, the Netherlands and the UK. Average intakes varied between 0.5 and 1.6 E%. Distribution of intakes ranged 0.2 to 0.7 E% (5<sup>th</sup> percentile) and from 0.9 to 1.7 E% (95<sup>th</sup> percentile).



Evidence from a number of countries indicates that the intake of TFA in the EU has decreased considerably over recent years, owing to reformulation of food products, e.g. fat spreads, sweet bakery products and fast food. More recent reported intakes in some EU Member States are close to 1 to 2 E% (EFSA, 2004). For example, in the UK the average intake of TFA has been halved to less than 1 E% (SACN, 2007). In France, intake data from 4079 individuals 3 to 79 years of age collected with 7-day food diaries and calculated with tables of TFA content of foods from 2008 show that TFA intakes have decreased by 40 % and are, on average, 1 E% in adults (1.4 E% at the 95th percentile), including 0.6 % for TFA from ruminant sources and 0.4 % for TFA from other sources (AFSSA, 2009). Average intakes of TFA in Denmark, Finland, Norway and Sweden have decreased to around 0.5 to 0.6 E% (Johansson et al., 2006; Lyhne et al., 2005; Männistö et al., 2003; Becker et al., 2005).

### 3.2.6. Cholesterol

In children below 15 years of age average intakes of cholesterol varied between approximately 100 mg per day and more than 400 mg per day. In adolescents aged 15 to 18 years average intakes were between nearly 180 and 600 mg per day. At the 95th percentile the highest values were observed in Germany.

Except for Romania, average intakes in adults ranged from nearly 200 mg per day to 550 mg per day. Mean daily intakes of about 800 and 700 mg per day were reported for Romanian men and women.

## 4. Overview of Dietary Reference Values and recommendations

Several national and international organisations and authorities have formulated Dietary Reference Values or recommendations for the intakes of total fat, fatty acids, and cholesterol. The German Society for Nutrition has published in 2006 a guideline on fat consumption based on an assessment of the strength for the evidence for the relationship between fat in the diet and certain dietary-related diseases (DGE, 2006).

In general, recommendations are expressed as E%. For the long chain n-3 PUFA and cholesterol, recommendations may be expressed in mg. An overview of some dietary recommendations as set by different organisations is presented in Annex III and summarised in this paragraph.

Most organisations have formulated a lower consumption level for total fat, because it was reasoned that at too low intakes adequate consumption of fat-soluble vitamins and essential fatty acids (EFA) could not be ensured. Upper limits for total fat intake have also been formulated because of possible relationships between total fat intake with energy intake and the risk to develop type 2 diabetes mellitus. In view of in particular their detrimental effects on dyslipoproteinaemia and cardiovascular risk, upper consumption levels for SFA and TFA were formulated. For linoleic acid and alpha-linolenic acid lower consumption levels were formulated to prevent essential fatty acid deficiency. In addition, it was acknowledged that PUFA intake might protect against cardiovascular disease. However, upper limits were also formulated, mainly because of lack of data of extreme life-long high PUFA intakes on human health. Finally, only a limited number of organisations have formulated guidelines for dietary cholesterol. For those who did not, it was generally reasoned that guidelines for total fat and SFA would already result in a decreased intake of cholesterol.

## 4.1. Adults

### 4.1.1. Total fat

Based on epidemiological and intervention studies in humans indicating a reduction in the risk of cardiovascular disease and obesity if a balanced diet with a maximum of 30 E% of fat is consumed in conjunction with physical activity, the German-Austrian-Swiss recommendations (D-A-CH, 2008) set a reference value for fat intake of 30 E%. During pregnancy and lactation this can be increased to 35 E%.

The Nordic Nutrition Recommendations (NNR, 2004) recommend a total fat intake of 25 to 35 E% calculated as triglycerides from the age of 2 years onwards with a population goal of 30 E% of total fat for planning purposes. It is stated that a reduction of fat intake below 25 E% does not provide any additional benefits, since very low fat diets tend to reduce HDL cholesterol and increase triglycerides in blood and impair glucose tolerance in susceptible individuals.

The UK Committee on Medical Aspects of Food Policy (COMA) (DoH, 1991) concludes that DRVs for fat should be calculated from the summation of reference values for individual classes of fatty acids (saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, *trans* fatty acids) and glycerol. Total fatty acid intake should therefore average 30 E% and total fat including glycerol 33 E% including alcohol or 35 E% excluding alcohol.

The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend limiting total fat intake to 30–35 % of energy intake given the increasing prevalence of obesity, despite the empirical nature of this value. In addition, below 30 E%, a well-balanced intake of various fatty acids, especially polyunsaturated fatty acids, is more difficult to reach using the current food supply.

The Health Council of the Netherlands (GR, 2001) recommends an amount of fat equivalent to 20 to 40 E% for individuals with an ideal bodyweight. Overweight individuals or individuals with undesirable weight gain should limit their fat intake to 20–35 E%. The lower level of 20 E% was set as a diet with a fat content of less than 20 E% has an adverse effect on HDL cholesterol and triglycerides concentrations. An amount of 20 E% was also considered to be sufficient for an adequate linoleic acid intake. The upper bound of 40 E% was chosen because higher intakes could have adverse effects on the postprandial concentration of lipids in the blood and on the concentration of blood coagulation factor VII. It also reflects the average fat consumption in the Netherlands.

The US Institute of Medicine (IoM, 2005) did not set an AI, an estimated average requirement (EAR) or a recommended dietary allowance (RDA) for adults as insufficient data were available to identify a defined intake level for fat based on maintaining fat balance or on the prevention of chronic diseases. The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend keeping fat intake between 20 E% and 35 E%

The WHO/FAO (2003) recommendations for total fat are formulated to include countries where the usual fat intake is typically above 30 E% as well as those where the usual intake may be very low, for example less than 15 E%. The WHO considers that total fat energy of at least 20 E% is consistent with good health. For countries where the usual fat intake is between 15 E% and 20 E%, there is no direct evidence that raising fat intake to 20 E% will be beneficial for men. WHO/FAO therefore sets a population nutrient intake goal of 15-30 E%. For women of reproductive age at least 20 E% has been recommended by the Joint FAO/WHO Expert Consultation on Fats and Oils in Human Nutrition that met in 1993 (FAO/WHO, 1994).

#### 4.1.2. Saturated fatty acids (SFA)

The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend a maximum saturated fatty acid intake of 10 E% in order to prevent a rise in blood cholesterol concentrations.

The Nordic Nutrition Recommendations (NNR, 2004) set a maximum intake of 10 E% of saturated fatty acids and *trans* fatty acids (calculated as fatty acids) based on the assumption that a reduction in the intake of SFA and TFA would reduce the risk of coronary heart disease (CHD).

The UK COMA Committee (DoH, 1991) recommends that saturated fatty acids should provide an average of 10% of total dietary energy (including alcohol). A reduction of SFA in the diet to 10 E% in the UK would be expected to result in a decrease of blood cholesterol concentrations of about 0.4 mmol/L.

The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend limiting the intake of saturated fatty acids to about 8 E% or 25 % of total fatty acids based on epidemiological data which associate excess intake of SFA with coronary heart disease as well as on the knowledge of the effect of different SFA. It is also recommended to consider the different SFA independently.

The Health Council of the Netherlands (GR, 2001) states that SFA increase the risk of coronary heart disease. Therefore, SFA intake should be as low as possible. A UL for SFA has been set at 10 E% for adults and children of 4 years and older and is based on the lowest percentage of intakes currently observed in the Netherlands.

The US Institute of Medicine (IoM, 2005) did not set an AI, EAR or RDA as there was no evidence to indicate that saturated fatty acids are essential in the diet or have a beneficial role in the prevention of chronic diseases. The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend consuming less than 10 E% of saturated fatty acids.

The WHO/FAO (2003) set population nutrient intake goals for SFA at <10 E%.

#### 4.1.3. Monounsaturated fatty acids (MUFA)

The German-Austrian-Swiss recommendations (D-A-CH, 2008) state that monounsaturated fatty acids can be consumed up to 10 E%. With higher fat intakes >10 E% of MUFA are acceptable.

The Nordic Nutrition Recommendations (NNR, 2004) state that the intake of *cis*-unsaturated fatty acids of adults and children from 2 years of age should be at about 20 E% with MUFA making up around 10 to 15 E% of it and PUFA around 5 to 10 E%.

The UK COMA Committee (DoH, 1991) recommends that *cis* monounsaturated fatty acids (principally oleic acid) should provide an average of 12% of total dietary energy (including alcohol) for the population.

The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend an intake of monounsaturated fatty acids of 20 E% in adults including pregnant and lactating women. It was concluded that the neutrality of oleic acid was an advantage and that its consumption was justified.

The Health Council of the Netherlands (GR, 2001) did not formulate AI for monounsaturated fatty acids alone but formulated AI ranges for monounsaturated fatty acids together with polyunsaturated fatty acids. They have been calculated on the basis of DRVs for fats, saturated fatty acids and *trans* fatty acids. Given a total fat consumption of 20 E%, the intake of monounsaturated fatty acids plus polyunsaturated fatty acids equals not less than 8 E% and no more than 19 E%. At a fat consumption of 35 E%, the optimum intake of monounsaturated fatty acids plus polyunsaturated fatty acids is

between 22 E% and 33 E%. Since the intake of polyunsaturated fatty acids should be between 3 E% and 12 E%, it is also possible to calculate upper and lower bounds for the intake of monounsaturated fatty acids. When total fat consumption is 35 E% and there is low intake of polyunsaturated fatty acids (3 E%), the optimum intake of monounsaturated fatty acids varies from 19–30 E%. Where there is a high intake of polyunsaturated fatty acids (12 E%), the optimum intake of monounsaturated fatty acids varies from 10 to 21 E%.

The US Institute of Medicine (IoM, 2005) did not set an AI, EAR or RDA as there was no evidence to indicate that monosaturated fatty acids are essential in the diet and they have no known role in preventing chronic diseases.

The WHO/FAO (2003) calculated the population nutrient intake goals for MUFA as “total fat minus (saturated fatty acids + polyunsaturated fatty acids + *trans* fatty acids)” and did not set a definitive value.

#### 4.1.4. Polyunsaturated fatty acids (PUFA)

##### 4.1.4.1. n-6 Polyunsaturated fatty acids (n-6 PUFA)

The German-Austrian-Swiss recommendations (DGE, 2006; D-A-CH, 2008) advise that both n-6 and n-3 fatty acids should contribute between 7 and 10% of total energy intake. Recommended intakes for LA are based on the mean LA requirement of young adults (2 E%, CV of 15%) and are set at 2.5 E% for adults and children of 4 years and older.

The Nordic Nutrition Recommendations (NNR, 2004) recommend an intake of *cis*-unsaturated fatty acids of about 20 E% for adults and children from 2 years of age with MUFA making up around 10 to 15 E% and PUFA around 5 to 10 E% including 1 E% n-3 PUFA. Minimum requirements on which the recommendations are based are derived from threshold intake data from children. A ratio of n-6 to n-3 PUFA between 3 and 9 is considered to be adequate.

The SCF (1992) calculated a PRI of 2 E% of linoleic acid based on rough estimations from infant feeding studies. It is recommended that total PUFA intake should not exceed 15 E%. The same PRI is applied for pregnant or lactating women.

The UK COMA (DoH, 1991) recommends that *cis* polyunsaturated fatty acids should provide an average of 6% of total dietary energy (including alcohol) for the population. They should be derived from a mixture of n-6 and n-3 fatty acids. Dietary intake of total PUFA should not exceed 10 E%. For infants, children and adults, linoleic acid should provide at least 1 E%.

The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend an intake of linoleic acid of 4 E% in adults and 4.4 E% in pregnant and lactating women with a n-6/n-3 ratio of 5:1. This recommendation is based on outcomes of studies of the effect of PUFA on cardiovascular disease and cancer. Concerning long-chain PUFAs, values are proposed after observation of usual consumption in dietary surveys around 500 mg per day corresponding to 0.2 E%. The recommendation is doubled to 0.4 E% for long-chain PUFA in pregnant and lactating women.

The Health Council of the Netherlands (GR, 2001) has set an AI for linoleic acid of 2 E% in adults which is considered to be sufficient to prevent deficiency and reach a triene/tetraene ratio in plasma (eicosatrienoic acid:arachidonic acid) ratio below 0.2. Adults having a triene/tetraene ratio of less than 0.2 are considered to have an adequate fatty acid status. In pregnancy and lactation the recommendation is raised to 2.5 E%. In pregnancy an average amount of 525 g of linoleic acid is deposited in the foetus. Breastfeeding women secrete on average 3.2 g per day of linoleic acid.

The US Institute of Medicine (IoM, 2005) states that studies in adult patients receiving total parental nutrition have shown to reverse n-6 fatty acid deficiency symptoms with as little as 7.4 to 8 g per day of linoleic acid. However, these data were considered insufficient to set an EAR and the AI is calculated based on the median intake of linoleic acid in the United States in the respective age group. In the US, the presence of an n-6 fatty acid deficiency is basically nonexistent in the free-living population. The AI for the age groups of 19 to 30 years and 31 to 50 years is 17g per day of linoleic acid for men and 12 g per day for women. From 51 years onwards the AI for linoleic acid is reduced to 14 g per day in men and 11 g per day in women due to the lower energy expenditure in comparison to the younger age groups. The AI for pregnant and lactating women has been set at 13 g per day using the same calculation method as for non-pregnant and non-lactating women.

The WHO/FAO (2003) set the population nutrient intake goals for n-6 PUFA at 5 to 8 E% with a total intake of PUFA of 6 to 10 E%.

#### 4.1.4.2. n-3 Polyunsaturated fatty acids (n-3 PUFA)

The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend that n-6 and n-3 fatty acids together should contribute 7 to 10% of total energy intake with a ratio of linoleic acid (n-6) to alpha-linolenic acid (n-3) of 5:1. The estimated value for n-3 fatty acid intake is 0.5 E% for all age groups including infants, children, pregnant and lactating women and is based on the recommendations for n-6 PUFA taking into account the desirable ratio. For primary and secondary prevention of coronary heart disease 0.25 and 1 g per day of n-3 LCPUFA, respectively, are deemed to be adequate, whilst up to 3 g per day are considered to be safe. DHA intake during pregnancy and lactation is to be at least 200 mg per day.

The Nordic Nutrition Recommendations (NNR, 2004) recommend an intake of *cis*-unsaturated fatty acids of about 20 E% for adults and children from 2 years of age with MUFA making up around 10 to 15 E% of it and PUFA around 5 to 10 E% including 1 E% n-3 PUFA. Minimum requirements on which the recommendations are based were derived from threshold intake data from children. A ratio of n-6 to n-3 PUFA between 3 and 9 is considered to be adequate.

The SCF (1992) calculated a PRI of 0.5 E% of n-3 PUFA based on data from current dietary habits in Europe. It is recommended that habitual intakes of total PUFA should not exceed 15 E% and total n-3 PUFA intake should not exceed 5 E%. The same PRI is applied for pregnant or lactating women.

The UK COMA (DoH, 1991) recommends that *cis*-polyunsaturated fatty acids should provide an average of 6% of total dietary energy (including alcohol) for the population. They should be derived from a mixture of n-6 and n-3 fatty acids. Dietary intake of PUFA should not exceed 10 E%. For infants, children and adults alpha-linolenic acid should provide at least 0.2 E%. The Scientific Advisory Committee on Nutrition (SACN) recommended an intake of 450 mg of n-3 LCPUFA for the population including pregnant women (SACN, 2004).

The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend an intake of alpha-linolenic acid of 0.8 E% in adults and 0.9 E% in pregnant and lactating women with a n-6/n-3 ratio of 5:1. This recommendation is based on the outcome of studies of the effect of PUFA on cardiovascular disease and cancer. Concerning LCPUFAs, values are proposed after observation of usual consumption in dietary surveys around 500 mg per day corresponding to 0.2 E%, including 120 mg per day DHA, corresponding to 0.05 E%. The recommendation is doubled to 0.4 E% for LCPUFA and 0.1 E% for DHA in pregnant and lactating women.

The Health Council of the Netherlands (GR, 2001) has set an AI for alpha-linolenic acid of 1 E% in adults, which is based on the protective effect of alpha-linolenic acid in relation to CHD. In pregnancy an average amount of 75 g of alpha-linolenic acid is deposited in the foetus. Breastfeeding women



secrete on average 0.5 g per day of alpha-linolenic acid. The recommendations are the same for pregnant and lactating women (GR, 2001). An AI for n-3 fatty acids from fish has been set at 0.45 g per day for adults and pregnant and lactating women (GR, 2006).

The US Institute of Medicine (IoM, 2005) states that studies in adult patients who were fed by gastric tube showed a alpha-linolenic acid deficiency with intakes ranging from 0.015 to 0.095 g per day whereas intakes of 0.3 g per day prevented symptoms of deficiency. However, these data were considered insufficient to set an EAR and the AI is calculated based on the median intake of alpha-linolenic acid in the United States where the presence of n-3 fatty acid deficiency is basically nonexistent in the free-living population. Small amounts of EPA and DHA can contribute towards reversing an n-3 fatty acid deficiency and can therefore contribute towards the AI for alpha-linolenic acid. For men the AI of alpha-linolenic acid has been set at 1.6 g per day and for women at 1.1 g per day. The AI for pregnant (1.4 g per day) and lactating women (1.3 g per day) has been set using the same calculation method as for non-pregnant and non-lactating women.

The WHO/FAO (2003) set the population nutrient intake goals for n-3 PUFA at 1 to 2 E% with a total intake of PUFA of 6 to 10 E%.

#### **4.1.5. *Trans* fatty acids (TFA)**

The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend limiting the intake of *trans* fatty acids to <1 E% based on the fact that *trans* fatty acids increase LDL and decrease HDL cholesterol concentrations and increase the risk for coronary heart disease.

The Nordic Nutrition Recommendations (NNR, 2004) recommend a maximum intake of 10 E% of saturated fatty acids and *trans* fatty acids (calculated as fatty acids) from the age of 12 months onwards based on the assumption that a reduction in the intake of SFA and TFA would reduce the risk of CHD.

The UK COMA (DoH, 1991) states that *trans* fatty acid intake in the population should not increase further than the current estimated average of 5 g per day or 2 % of dietary energy (including alcohol). In 2007, the UK SACN endorsed the recommendation set by COMA, that the average *trans* fatty acid intake should not exceed 2 E%. It states that there is consistent evidence to support a moderate effect of *trans* fatty acids on increasing the risk of CHD. The primary mechanism for this effect appears to be via changes in the blood lipoprotein profile, although inflammatory responses and endothelial function may also be negatively affected by dietary *trans* fatty acids (SACN, 2007).

In its report on health risks and benefits of *trans* fatty acids in food the French AFSSA states that daily consumption of total *trans* fatty acids higher than 2 E% gives rise to a significant increase in the risk of cardiovascular disease. Therefore it is recommended to consider this value a consumption level that should not be exceeded (AFSSA, 2005).

The Health Council of the Netherlands (GR, 2001) states that *trans* fatty acids increase the risk of coronary heart disease and may have adverse effects on the metabolism of EFA. The Health Council of the Netherlands therefore recommends keeping intake levels as low as possible.

The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend keeping *trans* fatty acid intake as low as possible.

The WHO/FAO (2003) set the population nutrient intake goals for *trans* fatty acids at below 1 E%.

#### **4.1.6. Cholesterol**

Only the German-Austrian-Swiss recommendations (D-A-CH, 2008) and the WHO/FAO (2003) have set recommendations for a maximum intake of cholesterol. Both recommend not exceeding a cholesterol intake of 300 mg per day in the adult population.

### **4.2. Infants and children**

#### **4.2.1. Total fat**

The German-Austrian-Swiss recommendations (D-A-CH, 2008) for total fat intake are 35 to 45 E% for infants from 4 to <12 months old. For children from 1 to <4 years old 30 to 40 E% are recommended, thereafter up to the age of 15 years 30 to 35 E%.

The Nordic Nutrition Recommendations (NNR, 2004) do not set recommendations for total fat intake for infants aged 0 to 6 months. For infants between 6 and 11 months of age the proportion of total fat should be kept between 30 and 45 E% and between 30 and 35 E% in infants between 12 and 23 months of age.

The Health Council of the Netherlands (GR, 2001) has set an AI for total fat for infants from 0 to 5 months at the average fat content of human milk (40 to 45 E%). For infants aged 6 to 11 months it has endorsed the recommendation of the European Society of Paediatric Gastroenterology, which sets an AI at 40 E%.

The recommended intakes of the US Institute of Medicine (IoM, 2005) for total fat for infants from 0 to 6 months are based on an AI that reflects the observed mean intake of infants fed human milk. This corresponds to 31 g fat per day and 55% of total energy intake of infants from 0 to 6 months, assuming that the energy requirements of the infants are being met. The proportion of energy from dietary fat decreases during the second 6 months of life. The AI for older infants aged 7 to 12 months is based on the average intake of fat ingested from human milk and complementary foods. This corresponds to 30 g fat per day and 40% of total energy. No AI, EAR or RDA has been set by IoM for children and adolescents aged 1 to 18 years, as data generally show that there is no effect of fat intake on growth when consumed at levels as low as 21 E% and insufficient evidence exists to identify a defined intake level of fat to prevent obesity and chronic disease. The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend a total fat intake of 30 to 35 E% for children 2 to 3 years of age and between 25 E% and 30 E% for children and adolescents 4 to 18 years of age.

#### **4.2.2. Saturated fatty acids (SFA)**

The German-Austrian-Swiss recommendations (D-A-CH, 2008) for SFA intake in children are less than 10 E%.

The Health Council of the Netherlands (GR, 2001) set an AI for SFA for infants at 25 E% based on SFA equivalents in human milk. The maximum intake for children of 6–11 months should be 20 E% and 15 E% for children of 1–3 years of age.

#### **4.2.3. Monounsaturated fatty acids (MUFA)**

No recommendations for children were set.



#### 4.2.4. Polyunsaturated fatty acids (PUFA)

##### 4.2.4.1. n-6 Polyunsaturated fatty acids (n-6 PUFA)

The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend a linoleic acid intake of 4 E% for children 0 to 4 months, 3.5 E% in children aged 4–12 months, 3 E% in children from 1–3 years, decreasing to 2.5 E% thereafter.

The Nordic Nutrition Recommendations (NNR, 2004) recommend that from 6–23 months of age the total amount of PUFA should constitute 5–10% of the total energy intake, including at least 1% of n-3 fatty acids. From 6 to 11 months of age it is recommended that the initial n-6/n-3 ratio of 5 to 15:1 (in infant and follow-on formulae) should gradually approach the ratio for adults 3 to 9:1.

The SCF (1992) defined for n-6 PUFA a PRI of 4.5 E% of for infants 6–11 months and of 3 E% for infants 1–3 years. PRIs for children above 4 years should be the same as those for adults.

The Health Council of the Netherlands (GR, 2001) concluded that the AI for linoleic acid for infants from 0 to 5 months is 0.6 g/kg bodyweight per day based on breast milk composition. An AI for arachidonic acid for children from 0 to 5 months has been set at 0.04 g/kg bodyweight per day.

The US Institute of Medicine (IoM, 2005) based the AI for n-6 PUFA for infants from 0 to 6 months on the observed mean intakes of infants fed human milk. This corresponds to 4.4 g per day of n-6 PUFA and around 8% of daily energy intake. The AI for older infants aged 7 to 12 months is based on the average intake of n-6 PUFA ingested from human milk and complementary foods. This corresponds to 4.6 g per day of n-6 PUFA and around 6% of daily energy intake. For children and adolescents an AI for linoleic acid is set based on the median intake of linoleic acid consumed in the United States where the presence of an n-6 fatty acid deficiency is basically nonexistent in the free-living population. For children aged 1 to 3 years the AI is set at 7g per day of linoleic acid, for children from 4 to 8 years of age the AI is 10 g per day. For 9 to 13 year old boys it is 12 g per day and for girls 10 g per day of linoleic acid. In the age group of 14 to 18 years the AI for boys is 16 g per day and for girls 11 g per day of linoleic acid.

##### 4.2.4.2. n-3 Polyunsaturated fatty acids (n-3 PUFA)

The recommendations from Germany, Austria and Switzerland (D-A-CH, 2000) for alpha-linolenic acid intake for children do not differ from the recommendations for adults (0.5 E%).

The Nordic Nutrition Recommendations (NNR, 2004) recommend that from 6–23 months of age the total amount of PUFA should constitute 5–10% of the total energy intake, including at least 1% of n-3 fatty acids. From 6 to 11 months of age it is recommended that the n-6/n-3 ratio of 5 to 15:1 (in infant and follow-on formula) should gradually approach the ratio for adults of 3 to 9:1.

The SCF (1992) defined a PRI of 0.5 E% of n-3 PUFA for infants 6 months to 3 years of age.

The Health Council of the Netherlands (GR, 2001) concluded that the AI for alpha-linolenic acid for infants from 0 to 5 months is 0.08 g/kg bodyweight per day based on breast milk composition. The AI for n-3 fatty acids from fish has been set for children and adolescence from 6 months to 18 years at 0.15 to 0.2 g per day. An AI for DHA has been set for children from 0 to 5 months at 0.02 g/kg per day.

The US Institute of Medicine (IoM, 2005) based the AI for n-3 PUFA for infants aged 0 to 6 months on the amount of n-3 fatty acids, total fat, and energy provided by human milk. This results in an AI of 0.5 g per day and 1% of energy intake. The AI for older infants aged 7 to 12 months is based on the

average intake of n-3 PUFA ingested from human milk and complementary foods. This corresponds to 0.5 g per day of n-3 PUFA and around 0.67% of daily energy intake. For children and adolescents an AI for alpha-linolenic acid is set based on the median intake of alpha-linolenic acid consumed in the United States where the presence of n-3 fatty acid deficiency is basically nonexistent in the free-living population. Small amounts of EPA and DHA can contribute towards reversing n-3 fatty acid deficiency and can therefore contribute towards the AI for alpha-linolenic acid. The AI is set at 0.7 g per day for children between 1 and 3 years and for children between 4 and 8 years at 0.9 g per day. For boys between the age of 9 and 13 years the AI is 1.2 g per day of alpha-linolenic acid and for girls 1.0 g per day. This is increased in the age group of boys from 14 to 18 years to 1.6 g per day and in girls to 1.1 g per day of alpha-linolenic acid.

#### **4.2.5. Cholesterol**

Only the German-Austrian-Swiss recommendations (D-A-CH, 2000) and Eurodiet (2000) have set guidance values for children. Cholesterol intake in children should not exceed 80 mg/1000 kcal.

**Table 5:** Overview of dietary recommendations for the intakes of total fat and fatty acids intakes for adults as set by different organisations.

Countries / Organisation	Year	Total fat	SFA	TFA	<i>cis</i> -MUFA	PUFA	Cholesterol
United Kingdom	1991	33 E%	<10 E%	< 2 E%	12 E%	6 E% with at least 1 E% LA and 0.2 E% ALA	
Germany, Austria, Switzerland	2000	30 E%	<10 E%	< 1 E%		Total PUFA: 7-10 E%, n-6 PUFA 2.5 E%, n-3 PUFA: 0.5 E%	< 300 mg per day
France	2001 2005	30-35 E%	<8 E%	< 2 E%	20 E%	4 E% of which 4 % LA, 0.8 E% ALA, 0.20 E% LCPUFA, and 0.05 E% DHA	
The Netherlands	2001 2006	20-40 E%	< 10 E%	alap		<12 E% of which at least 2 E% LA, 1.0 E% ALA, 450 mg EPA + DHA	
USA	2002 2005	20-35 E%	< 10 E%	alap		5-10 E% LA, 0.6-1.2 E% ALA	
WHO/FAO	2003	15-30 E%	< 10 E%	< 1 E%		6-10 E%, of which 5-8 E% n-6 PUFA and 1-2 E% n-3 PUFA	< 300 mg per day
Nordic Countries	2004	25-35 E%	<10 E% (includes TFA)		10-15 E%	5-10%, of which 1 E% n-3 fatty acids	

SFA: Saturated fatty acids; TFA: *Trans* fatty acids; *cis*-MUFA: *cis*-monounsaturated fatty acids; PUFA: Polyunsaturated fatty acids; LA: Linoleic acid; ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; alap = as low as possible; E%: percent of energy.

## 5. Criteria (endpoints) on which to base Dietary Reference Values

The amount and type of fat in the diet affects a wide variety of metabolic responses. As fat provides energy, changes in fat intake will usually be accompanied by changes in the intake of other energy providing food constituents, namely carbohydrates and/or protein. Therefore, these effects cannot be discussed in isolation. In general, responses are discussed relative to those of another nutrient that delivers energy. This can complicate comparisons between studies, as in one study – for example – carbohydrates are taken as point of reference, while in another study oleic acid is the point of reference. It is also possible that studies have been carried out under non-isocaloric conditions. These latter studies will however not be considered, except for the outcome of body weight control. In addition, in view of the large number of studies in this field, emphasis will be on recent meta-analyses of data from randomised intervention trials or prospective cohort studies.

### 5.1. Dietary requirements

There are insufficient data to determine the absolute amounts of fat and individual fatty acids which are needed for metabolic integrity and human health. Observed intakes in healthy population groups in combination with observed intakes associated with deficiency symptoms and amounts needed to alleviate such symptoms are useful to provide estimates of nutritionally sufficient and, therefore, desirable intake levels.

During pregnancy and lactation an estimate of the additional needs for both the increase in maternal body tissues and the growth and development of the foetus and the production of breast milk need to be taken into account.

For infants in the first half of the first year of life requirements are assumed to be covered by the nutrients provided with exclusive breastfeeding by a well nourished mother.

#### 5.1.1. Total fat

Fat is an important source of energy and facilitates the absorption of fat soluble vitamins and carotenoids. Despite this important role of fat and despite the indispensability of the two fatty acids LA and ALA, it is not possible to define a quantitative requirement for total fat.

##### 5.1.1.1. Adults

Within the European adult population, intake ranges varied from 22 to 26 E% at the lower end (2.5 to 10<sup>th</sup> percentile) to 38 to 48 E% at the upper end (90 to 97.5<sup>th</sup> percentile) of the distributions. Very low fat diets may increase the risk of an insufficient intake of PUFA, can impair the absorption of fat-soluble vitamins and be associated with insufficiency of other essential nutrients like zinc and B vitamins. The addition of 5 g fat to a diet providing only 5 g fat per day (total of 10g fat per day) was shown to significantly improve blood vitamin A concentrations and improve vitamin K availability (Jayarajan et al., 1980; Uematsu et al., 1996). Such low fat intakes are highly unlikely in European countries and no signs of deficiency have been observed at the lowest observed intakes in the European population including pregnant and lactating women.

##### 5.1.1.2. Pregnancy

Pregnancy leads to an additional energy requirement of 375, 1200, 1950 kJ per day during the first, second and third trimesters, respectively (Prentice and Goldberg, 2000; Butte and King, 2005). There

are no data which would suggest that the fat intake as percentage of the total energy should differ from that of the diet in non-pregnant women.

#### 5.1.1.3. Lactation

Lactating women have an increase in energy expenditure consistent with the energy cost of milk synthesis. Part of this energy can be mobilised from subcutaneous fat particularly but the major part has to be provided by the diet. An additional energy requirement of 1380 to 1900 kJ per day has been estimated (Butte and King, 2005; IoM, 2005). There are no data which would suggest that the fat intake as percentage of the total energy should differ from that of the diet in non-lactating women.

#### 5.1.1.4. Infants and children

The observed mean intake of fat of infants from 0 to 6 months fed human milk averages 50 to 55% of total energy intake. Fat intake usually decreases thereafter to reach adult values by the end of the third year of life (Aggett et al., 1994; Agostoni et al., 2008). Within the European child and adolescent population, fat intake ranges varied from 22 to 29 E% (5 to 10<sup>th</sup> percentile) to 38 to 46 E% (90 to 97.5<sup>th</sup> percentile).

If the diet provides an adequate supply of energy and essential nutrients, there is no evidence that a dietary fat intake of 30 E% adversely affects the growth and development of healthy children in European countries. A review of studies from Europe and North America found little evidence of adverse effects of low dietary fat on growth of young children aged 6 to 36 months. The percentage of dietary fat was not correlated with growth velocity or energy density of the diet between ages 6 and 12 months, whereas energy density of the diet was positively associated with energy intake and weight gain (Fjeld et al., 1989, Butte, 1996, Nicklas et al., 1992, Shea et al., 1993). No association between fat intake and growth was detected in infants aged 7 to 13 months or children aged 2 to 5 years or 3 to 5 years (Friedman and Goldberg, 1976; Lapinleimu et al., 1995, Michaelsen and Jorgensen, 1995).

In the Special Turku Coronary Risk Factor Intervention Project (STRIP) trial, a moderately restricted fat intake (25 to 30E%) was not associated with compromised growth or impaired neurological development in 1062 infants between 7 and 36 months and followed-up until the age of 18 years (Niinikoski et al., 1996). A similar intervention with a dietary fat intake of 30 to 35 E% in Danish infants also did not result in impaired growth between ages 7 and 13 months (Michaelsen, 1997).

Some investigators have reported lower vitamin and mineral intakes in association with low-fat diets (Jayarajan et al., 1980). A cohort of 500 Canadian preschoolers was stratified according to fat intake: <30%, 30 to 40% or >40% of energy from fat between the ages of 3 and 6 years. Low-fat intake was associated with inadequate intake of fat-soluble vitamins. For children habitually on low-fat diets, the odds ratio for underweight for the age of 6 years was 2.3 (Gibson et al., 1993). The effect of dietary fat intake on growth of 140 children in New Zealand was examined at the age of 2, 4, 6 and 8 years (Boulton and Magarey, 1995). The median dietary fat intake (in percent of energy) fell from 44% at 3 months to 36% at 6 months at which level it remained until 8 years. At each age interval no differences were observed in height, weight or skinfold thickness among children consuming <30%, 30 to 34.9% and >34.9% of dietary energy as fat.

In conclusion, older infants and children can grow normally with total fat intakes as low as about 25 E% provided the energy intake and the intake of micronutrients is appropriate. Because of the higher energy requirement of infants and children per kilogram of body weight, such a low-fat diet may bear an increased risk of an overall too low energy intake.

### 5.1.2. *cis*-Polyunsaturated fatty acids (PUFA)

There are only two fatty acids that are essential to maintain metabolic integrity: linoleic acid and alpha-linolenic acid (see sections 2.1.3.1 and 2.1.3.2). Case reports of deficiency of the n-6 fatty acid linoleic acid and of the n-3 fatty acid alpha-linolenic acid do not allow defining the precise requirements for these essential fatty acids (Bjerve et al., 1987; 1989; Bjerve, 1989; Holman et al., 1982).

Mean dietary PUFA intakes in Europe range between 3.6 and 8 to 9 E% in both children and adults (see Annex 1a and b).

At the lowest observed intake of *cis* n-3 PUFA and *cis* n-6 PUFA in children, adolescents and adults in Europe (see section 3.2.4.1 and 3.2.4.2), no overt sign of deficiencies were observed. There are also no indications of overt deficiencies in pregnant and lactating women.

Human milk supplies 10 to 18% of fats as PUFA depending on maternal dietary habits. Therefore, at early ages up to 10 E% may be represented by polyunsaturated fatty acids, possibly decreasing to 5 to 10 E% once total fat intake is reduced to 30 E%.

#### 5.1.2.1. *cis* n-6 Polyunsaturated fatty acids (n-6 PUFA)

Cases of LA deficiency were reported in patients on (total) parenteral nutrition (e.g. Jeppesen et al., 1998) and in infants fed skim-milk formula providing between 10 and 800 mg of LA/kg bodyweight per day. A LA intake of less than 0.1 E% resulted in dry squamous skin lesions, susceptibility to staphylococcal infections and retarded growth. Symptoms disappeared with a LA intake of 1 E% and did not occur in infants consuming 1.3 to 7.3 E% in the form of LA (Hansen et al., 1963). LA deficiency was associated with an elevated ratio of eicosatrienoic acid to arachidonic acid (>0.4 to 0.2) (Holman, 1960; Jeppesen et al., 1998).

No data are available to establish desirable tissue LA levels or to conclude on the LA requirement of healthy individuals.

The habitual dietary intake in European countries varies considerably (see Section 3.2.4.1 and Annex 1) and does not lead to signs of LA deficiency. There is no indication for the necessity of an increase of LA intake during pregnancy and lactation, because the absolute amount consumed will increase in proportion to the increased energy intake.

Human milk supplies 10 to 18% of total fatty acids as n-6 PUFA, mostly LA, depending on maternal dietary habits. Therefore, at early ages up to 5 to 8 E% may be represented by n-6 PUFA, later to decrease to 3 to 6 E% once total fat intake is reduced to 30 E%.

The synthesis of long-chain n-6 derivatives, whose main compound in the n-6 series is arachidonic acid (ARA, 20:4, n-6), seems in conjunction with dietary intake to cover the need of healthy (non-vegetarian) subjects, given the present lifestyle and dietary habits, and no requirement for preformed arachidonic acid can be defined for infants, adults and children, despite a low rate of conversion of LA into ARA in LA-deficient subjects (Plourde and Cunnane, 2007) and in infants (Demmelmaier et al., 2001).

Pregnant women with an adequate intake of LA do provide sufficient ARA for the foetus. The ARA content in human milk is similar over the world (0.35 to 0.7 weight % of total fatty acids) (Yuhás et al., 2006).



### 5.1.2.2. *cis* n-3 Polyunsaturated fatty acids (n-3 PUFA)

The essentiality of ALA consists of its role as a precursor for EPA and DHA. From the few cases of n-3 PUFA deficiency reported in the literature it was concluded that 0.2 E% of ALA were sufficient to increase deficient plasma levels of EPA, DPA and DHA, but not of ALA, and that this intake stimulated growth in growth-deficient children. From the same case reports “minimal” and “optimal” intakes of n-3 LCPUFA were calculated, 100 to 200 mg per day and 350 to 400 mg per day, respectively (Bjerve et al., 1987 and 1989). However, the plasma and tissue levels of DHA below which visual or neural functions are impaired are not known.

Mean ALA intakes in the European population of 0.7 to 0.9 g per day (0.5 E%) of young children, 1.0 to 1.2 g per day (0.4 to 0.6 E%) in children and adolescents and 0.7 to 2.3 g per day (0.4 to 0.8 E%) in adults have been reported and were not associated with signs of deficiency. Human milk supplies 0.5 to 1% of total fatty acids as n-3 PUFA depending on maternal dietary habits. The same content is requested by European law in infant formulae intended for non-breastfed infants.

Studies in normal healthy adults consuming western diets, which are rich in linoleic acid (LA), show that supplemental ALA raises EPA and DPA status in the blood and in breast milk (Brenna et al., 2009). The conversion of the essential fatty acid ALA to LCPUFA, particularly to DHA is low in humans and is estimated to be approximately 5% to EPA and <0.5% to DHA both in studies performed with stable isotopes and in supplementation studies where the increase of EPA and/or DHA in blood lipids in response to physiological and supraphysiological amounts of ALA was measured (Plourde and Cunnane, 2007). Whilst EPA increased significantly in most instances, the response of DHA was much smaller or not measurable and not related to the dose of ALA, except in vegetarians or in ALA deficiency. Possible explanations for this non-response are low endogenous synthesis, homeostatic regulation of DHA levels in tissues and influences of the individual diet. However, women convert twice as much ALA to DHA than men (Burdge and Wootton, 2002) and this conversion is increased by estrogens, which may explain the increase in maternal DHA status measured as DHA content in plasma and red blood cell phospholipids during pregnancy (Otto et al., 1997 and 2001). Maternal DHA status, more than maternal ALA status or actual dietary intake, has a positive effect on placental DHA transfer to the foetus and on DHA content in human milk.

The foetal brain is rich in fat, especially in DHA and ARA. First ARA and later DHA accumulate rapidly during the third trimester of pregnancy and after birth (Clandinin et al., 1980a and b). The growth spurt of the brain starts in the 28<sup>th</sup> week of gestation and continues to 1 year whilst the demand for DHA and ARA continues to 2 years of age (Martinez, 1992; 1994) and DHA content of the brain continues to increase in adolescence (Carver et al., 2001). In the normal term infant total DHA content of the body is about 3.8 g (Cunnane et al., 2000) and n-3 PUFA accretion during the last trimester has been estimated to be 34.1 mg/kg body weight per day of which most is DHA (Lapillonne and Jensen, 2009). Whole body and brain DHA accumulation may be limited by DHA availability due to a low maternal DHA status. In addition, recent data indicate that there is inter-individual variation in the ability to convert the precursor ALA to n-3 LCPUFA and, particularly to DHA, which is related to common polymorphisms in the human  $\Delta$ -5 and  $\Delta$ -6 desaturase genes FADS1 and FADS2 (Schaeffer et al., 2006). DHA is preferentially transferred across the human placenta to the foetus mediated by specific transfer proteins (Larque et al., 2003 and 2006).

Estimates of the DHA amount a woman needs to accumulate to accommodate the needs of her infant for deposition of DHA in the brain and retina during the last trimester of pregnancy (about 10 g) and during six months of lactation (12 to 14 g) add up to an additional requirement of 22 to 25 g equivalent to 90 to 100 mg per day over her basic DHA requirement (SACN, 2004) satisfied by limited endogenous synthesis from ALA and her habitual dietary DHA intake which may be low in many women in Europe who do not regularly consume fatty fish (or fish oil). Oxidative losses of maternal dietary DHA and accumulation of DHA in body fat of the foetus/infant should be taken into



account when estimating adequate dietary DHA intakes for pregnant women (SACN, 2004). A recent consensus among several research projects and scientific societies recommends a dietary intake of at least 200 mg of DHA per day for both pregnant and lactating women (Koletzko et al., 2007 and 2008).

Intakes of fish, fish oils or n-3 LCPUFA from other sources during pregnancy are positively associated with slightly longer gestation, slightly higher birth weight and a reduced risk of preterm delivery (Koletzko et al., 2008). Moreover, a higher intake predicted a lower prevalence of postpartum depression (Hibbeln, 2002).

The main n-3 compound supplied by human milk is docosahexaenoic acid, DHA, 22:6n-3, averaging 7 to 8 mg/dL (means of DHA range from 0.17% to 1.0% of total fatty acids (Yuhas et al., 2006)). The DHA content of human milk is mainly a reflection of the variability in maternal DHA intake. However, even in the milk of vegans who consume no DHA containing food, some DHA (0.05 % of total fatty acids) (Sanders et al., 1978) is present. A dose dependent relationship between habitual maternal DHA consumption and DHA levels in human milk was demonstrated (Gibson et al., 1997). However, ALA or EPA dietary supplements have little effect on blood or breast milk DHA levels (Brenna et al., 2009).

The DHA amount contained in breast milk can be considered to provide an estimate of the amount of DHA which is added to infant formulae since it has been shown that 2 to 6 months old infants who were fed a formula which contained ALA only and no EPA and DHA accumulated less DHA in brain than breast-fed infants (Farquharson et al., 1992; Makrides et al., 1994): 2.5 mg per day compared to 5.0 mg per day (Cunnane et al., 2000). Addition of ALA to the diets of formula-fed infants does raise DHA, but no level of ALA tested raises DHA to levels achievable with preformed DHA at intakes similar to typical human milk DHA supply (Brenna et al., 2009). Hoffman et al. (2004) investigated the effects of solid baby food supplementation with DHA on visual maturation at one year of age in term infants exclusively breastfed from birth until four months and likely to have breast milk as the only source of milk until one year of age. Infants were randomly assigned at six months of age to consume daily one jar of either standard commercial solid baby foods (controls, n = 26) or baby foods containing DHA-enriched egg yolk (intervention, n = 25) until the age of one year. Breast-feeding continued in both groups up to an age of about nine months. Thus, for the entire 6-months trial period, the intervention group received an average of 108 mg DHA per day (13 mg/kg body weight per day) from baby foods and breast milk compared with 38 mg DHA per day (4.5 mg/kg body weight per day) in control infants from breast milk only. In DHA-supplemented infants, visual evoked potential (VEP) acuity was significantly more mature at 12 months of age than in controls. Both red blood cell-DHA levels and DHA intake were significantly correlated with VEP acuity at 12 months.

Such small amounts of DHA may be needed for optimal growth and development of infants and children: approximately 20 to 50 mg per day of DHA in the 0 to 6 months period (estimated from the DHA content and the daily breast milk volume: 7 to 8 mg/dL and 500 to 750 mL) and 100 mg per day in the 6 to 24 months period (estimated from RCT with DHA) (e.g. Hoffman et al., 2004).

## **5.2. Blood lipids and lipoproteins**

Numerous studies have dealt with the effects of fatty acids on blood lipid and lipoprotein concentrations. In addition to the many individual studies, also several meta-analyses have been published (Gardner and Kraemer, 1995; Clarke et al., 1997; Howell et al., 1997; Kris-Etherton and Yu, 1997; Mensink et al., 2003; Mozaffarian et al., 2006). Although quantitative estimates of the effects varied slightly, conclusions were essentially similar.

Although certain genetic dispositions have been shown to influence the levels of blood lipid levels and explain part of the variability in the effects of nutrient consumption on risk factors for example cardiovascular diseases, the Panel considers that the present knowledge on interactions between

environment and human genome is at present insufficient to determine Dietary Reference Values with a view on preventive dietary measures early in life (Ordovas, 2009).

### 5.2.1. Total fat

When SFA are kept constant, varying total fat has no significant effects on LDL cholesterol (IoM, 2005). Data from intervention studies consistently show that, at low intakes of SFA (<10%E), decreasing total fat intake increases the total/HDL cholesterol ratio and TG concentrations and decreases blood concentrations of HDL cholesterol, particularly in sedentary populations which are overweight or obese. This is supported by observational studies and provides a basis to set a lower bound (about 20 E%) for total fat intake (IoM, 2005).

### 5.2.2. Saturated fatty acids (SFA)

There is wide consensus that a mixture of SFA increases blood total, LDL and HDL cholesterol concentrations (Annex IV) relative to carbohydrates. As a consequence, the total to HDL cholesterol ratio does not change. A mixture of dietary SFA also decreased fasting triacylglycerol concentrations. SFA, however, differ in their potency to change blood lipid and lipoprotein concentrations. While lauric, myristic and palmitic acid raise blood total and LDL cholesterol concentrations, effects of stearic acid are more similar to those of carbohydrates. Effects of SFA on blood HDL cholesterol concentrations are in the opposite direction: lauric acid strongly increases blood HDL cholesterol concentrations, an effect that decreases with increasing chain length. Thus, stearic acid had the smallest effects on blood HDL cholesterol concentrations. For the total to HDL cholesterol ratio, effects of lauric acid are more favourable than carbohydrates. Stearic acid also slightly decreased this ratio, but effects did not differ significantly from those of carbohydrates. Effects of myristic and palmitic acids were very similar to those of carbohydrates. No differences between the effects of the different SFA on fasting blood triacylglycerol concentrations were detected.

### 5.2.3. *Cis*-monounsaturated fatty acids (*cis*-MUFA)

*Cis*-MUFA had a modest blood total and LDL cholesterol-lowering effect relative to carbohydrates. HDL cholesterol concentrations increased and consequently the blood total to HDL cholesterol ratio decreased. Fasting blood triacylglycerol concentrations also decreased. This effect was comparable to that of SFA. In these studies, *cis*-MUFA was mainly provided by oleic acid.

Palmitoleic acid (C16:1(n-7)) is a minor *cis*-MUFA in the human diet and in blood plasma. One well-controlled study in slightly hypercholesterolaemic men showed that the effects of palmitoleic acid on blood LDL cholesterol concentrations are comparable to those of palmitic acid (16:0). HDL cholesterol concentrations were significantly lower with palmitoleic than with palmitic acid. In view of the low levels of palmitoleic acid in the diet, the practical relevance of these findings is however limited (Nestel et al., 1994).

### 5.2.4. *cis*-Polyunsaturated fatty acids (*cis*-PUFA)

#### 5.2.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)

*cis* n-6 PUFA lowered blood total and LDL cholesterol concentrations relative to carbohydrates. These effects were slightly stronger than those for *cis*-MUFA. Blood HDL cholesterol concentrations also increased, but this effect was slightly less than with SFA and *cis*-MUFA. Consequently, the blood total to HDL cholesterol ratio decreased. Changes in blood triacylglycerol were comparable to those of SFA and *cis*-MUFA. In these analyses, *cis* n-6 PUFA refers to linoleic acid. Increasing the

daily intake of ARA (20:4, n-6) from 210 mg to 1700 mg for 50 days did not influence the blood lipid and lipoprotein levels (Nelson et al., 1997).

#### 5.2.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

Effects of alpha-linolenic acid on the blood lipoprotein profile are comparable to those of linoleic acid. EPA and DHA, on the other hand, lower blood triacylglycerol concentrations compared to carbohydrates and other fatty acids. This effect is in particular evident in patients with increased blood triacylglycerol levels. In addition, these fatty acids may slightly increase blood LDL and HDL cholesterol concentrations. However, it should be noted that at daily intakes below <1 g, effects of n-3 LCPUFA on the blood lipoprotein profile are small (Balk et al., 2006).

#### 5.2.5. *Trans* fatty acids (TFA)

Evidence from many controlled human intervention studies indicates that consumption of diets containing *trans*-MUFA, like diets containing mixtures of SFA, consistently results in increased blood total and LDL cholesterol concentrations, compared with consumption of diets containing *cis*-MUFA or *cis*-PUFA (EFSA, 2004; Mozaffarian and Clarke 2009). The effect shows a linear dose response relationship with blood LDL cholesterol concentrations, indicating that effects are proportional to the amounts of TFA consumed. While the blood LDL cholesterol concentration increasing effect of *trans*-MUFA was very similar to that of palmitic acid (C16:0) and slightly less than that of myristic acid (C14:0), the available evidence does not provide a definitive answer to the question of whether TFA have an effect on blood LDL cholesterol concentrations different from that of SFA on a gram-for-gram basis. Consumption of diets containing *trans*-MUFA also results in reduced blood HDL cholesterol concentrations compared with consumption of diets containing SFA, *cis*-MUFA or *cis*-PUFA. Therefore, *trans*-MUFA, in comparison with other fatty acids, increase the total cholesterol to HDL cholesterol ratio.

Evidence from controlled human intervention studies also indicates that, relative to diets containing SFA, *cis*-MUFA or *cis*-PUFA, consumption of diets containing TFA results in increased concentrations of fasting TG. The relationship shows a linear dose response.

In most of the human intervention studies reviewed above, the effects of *trans*-MUFA from hydrogenated vegetable oils were assessed. Two recent studies have evaluated effects of *trans*-MUFA from ruminants on the blood lipoprotein profile. A controlled human intervention study indicates that, compared with a low total TFA diet (0.8% of energy), a diet with 3.7% of energy from TFA, whether from ruminant or industrial sources, had similar adverse effects on blood lipids and lipoproteins, including increases in blood LDL cholesterol concentrations, decreases in blood HDL cholesterol concentrations, and increases in the ratio of total to HDL cholesterol (Motard-Bélanger et al., 2008). The outcome from a second study was equivocal - compared with a diet containing ~5% TFA from dairy products, a diet containing industrially produced TFA lowered blood LDL cholesterol and HDL cholesterol concentrations in women but not in men while the ratio of total to HDL cholesterol was not affected (Chardigny et al., 2008).

In conclusion, available evidence indicates that consumption of diets containing *trans*-MUFA, like diets containing mixtures of SFA, increases blood total and LDL cholesterol concentrations in a dose-dependent manner compared with consumption of diets containing *cis*-MUFA or *cis*-PUFA. Consumption of diets containing *trans*-MUFA also results in reduced blood HDL cholesterol concentrations and increased total cholesterol to HDL cholesterol ratio. The available evidence indicates that TFA from ruminant sources have similar adverse effects on blood lipids and lipoproteins to those from industrial sources.

### 5.2.6. Conjugated linoleic acid (CLA)

From an extensive review of the literature, it was concluded that a mixture of CLA isomers has no major effects on plasma lipids (Terpstra, 2004; Salas-Salvadó et al., 2006). Studies have also been carried out to address the specific effects of the two major CLA isomers on the plasma lipoprotein profile. Tricon et al. (2004) found in healthy humans that *cis*-9, *trans*-11 CLA decreased blood LDL cholesterol and triacylglycerol concentrations, and the LDL to HDL cholesterol ratio as compared with *trans*-10, *cis*-12 CLA. The isomers were studied at three different daily intakes: approximately 0.6 g, 1.2 g, and 2.4 g. A dose-response relationship was however not evident. In contrast, Naumann et al. (2006) did not observe in humans with LDL phenotype B differential effects of a daily consumption of 3 g of *cis*-9, *trans*-11 CLA or *trans*-10, *cis*-12 CLA on the blood lipoprotein profile. Thus, these intervention studies do not provide evidence that a mixture of CLA isomers, *cis*-9, *trans*-11 CLA, or *trans*-10, *cis*-12 CLA have a clinically significant impact on the blood lipoprotein profile.

### 5.2.7. Cholesterol

Weggemans et al. (2001) have reviewed the effects of dietary cholesterol on blood lipids and lipoproteins. Based on the results of 17 well-controlled studies involving 556 subjects, it was found that the addition of 100 mg dietary cholesterol per day increased total cholesterol concentrations by 0.056 mmol/L (95% CI: 0.046, 0.065 mmol/L), LDL cholesterol concentrations by 0.050 mmol/L (95% CI: 0.042, 0.058 mmol/L), and HDL cholesterol concentrations by 0.008 mmol/L (95% CI: 0.005, 0.010 mmol/L). The ratio of total to HDL cholesterol increased by 0.020 units (95% CI: 0.010, 0.030). When studies were divided into two groups based on the polyunsaturated-to-saturated fat ratio (P/S-ratio), the response in LDL cholesterol was 0.036 mmol/L for studies with a background diet characterised by a low P/S ratio (<0.7) and 0.061 mmol/L for studies with a high P/S ratio (>0.7). The fatty acid composition of the background diet did not affect responses of blood HDL cholesterol concentrations or the ratios of total to HDL cholesterol.

### 5.2.8. Conclusion

Under iso-energetic conditions, the most favourable lipoprotein profile to lower atherosclerotic risk is achieved when a mixture of SFA and TFA is replaced by a mixture of oleic acid, linoleic acid and n-3 LCPUFA. These effects are dose-dependent. The various SFA may also differ in their effects on the blood lipoprotein profile. In particular, the effects of stearic acid may be less disadvantageous than those of myristic and palmitic acids. However the available data are insufficient to set different DRVs for different SFA.

## 5.3. Haemostatic function

Haemostatic function is a complex interplay of many processes such as endothelial function, platelet aggregation, coagulation and fibrinolysis. Each of these processes is determined by many different factors. This complex interplay illustrates that haemostatic function cannot be described by one single factor, which complicates dietary studies in this area. A further complication is that many different approaches exist to measure these factors and no single method exists to evaluate all aspects of haemostatic function.

### 5.3.1. Total fat

The effects of total fat intake on haemostatic profiles are conflicting. Overall, however, it appears that high-fat diets increase factor VII activity or levels, which are positively related to cardiovascular risk (Vorster et al., 1997; Thijssen and Mensink, 2005). Due to the different methods to measure factor VII, it is not possible to quantify these effects.

### 5.3.2. Saturated fatty acids (SFA)

From an extensive review of the literature, it was concluded that SFA with 12 to 16 carbon atoms might increase factor VII levels as compared to stearic acid. It was emphasised however that studies were far from consistent. For other factors involved in the coagulation or fibrinolytic pathway, or in platelet aggregation, no consistent patterns have emerged (Miller, 2005; Thijssen and Mensink, 2005).

### 5.3.3. *Cis*-monounsaturated fatty acids (*cis*-MUFA)

In two studies, Berry et al. (2007a, 2007b) compared the acute effects of a sunflower oil high in oleic acid with those of palm oil and shea butter - rich in the SFA stearic acid - on postprandial factor VII levels. It was found that both oils rich in saturated fatty acids resulted in lower postprandial factor VII concentrations. For oleic acid, no consistent effects on fasting coagulation or fibrinolytic factors or on platelet aggregation have been found (Thijssen and Mensink, 2005).

### 5.3.4. Polyunsaturated fatty acids (PUFA)

#### 5.3.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)

For linoleic acid, no consistent effects on fasting coagulation or fibrinolytic factors or on platelet aggregation have been found (Thijssen and Mensink, 2005).

#### 5.3.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

For fish oils, no consistent effects on fasting coagulation or fibrinolytic factors have been found (Thijssen and Mensink, 2005). For platelet aggregation, results are more consistent. Using various outcome parameters, such as *ex vivo* and *in vitro* platelet aggregation tests, it has been demonstrated that consumption of fish oils reduces the tendency of platelets to aggregate. Effects, however, are only consistent at fish oil intakes of more than 1 g per day (Knapp, 1997; Wensing et al., 1999; Thijssen and Mensink, 2005). For alpha-linolenic acid, no effects have been reported compared to linoleic acid, oleic acid or SFA (Thijssen and Mensink, 2005; Goyens and Mensink, 2006).

### 5.3.5. *Trans* fatty acids (TFA)

The effects of TFA from hydrogenated sources on haemostatic function have recently been reviewed (EFSA, 2004). It was concluded that intervention studies do not provide evidence that TFA from hydrogenated oils have an impact on haemostatic function.

### 5.3.6. Conjugated linoleic acid (CLA)

Effects of CLA on haemostatic function have hardly been studied. In one study with 17 healthy female volunteers, consumption for 63 days of a diet enriched with a mixture of 3.9 g of CLA isomers did not affect *in vivo* bleeding time, *in vitro* platelet aggregation, the prothrombin time, activated partial thromboplastin time, and the antithrombin III levels when compared with sunflower oil. The four major isomers in the mixture used were: *cis*-9, *trans*-11 CLA (17.5% of total CLA), *trans*-8, *cis*-10 CLA (16.6%), *cis*-11, *trans*-13 CLA (23.5%), *trans*-10, *cis*-12 CLA (22.6%) (Benito et al., 2001).



### 5.3.7. Conclusion

No consistent picture has emerged of the effects of SFA, MUFA, TFA, and n-6 PUFA on haemostatic function. An exception may be the n-3 LCPUFA, which may decrease platelet aggregation in particular at daily intakes above 1 g. Dose-response relationships, however, cannot be ascertained.

## 5.4. Inflammation and immune function

Like haemostatic function, inflammation and immune function include numerous processes and many different cell types, which make it impossible to identify one single marker that describes the inflammatory or immune status of the human body.

### 5.4.1. Saturated fatty acids (SFA), *cis*-monounsaturated fatty acids (*cis*-MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA)

Based on prospective cohort studies and intervention studies, Kontogianni et al. (2006) concluded that SFA might increase plasma concentrations of inflammatory markers, but that results are far from consistent. For *cis*-MUFA, results were also not consistent.

#### 5.4.1.1. n-3 polyunsaturated fatty acids (n-3 PUFA)

The effects of n-3 PUFA on blood markers of low-grade systemic inflammation and immune function have been the focus of many reviews. Balk et al. (2006) concluded that the evidence regarding the effects of n-3 PUFA from both animal and vegetable origin on high-sensitivity C-reactive protein (hs-CRP) are inconclusive. Calder (2006) also concluded that ALA did not exert anti-inflammatory effects at realistic dietary intakes (up to 10g/day) in contrast to Giugliano et al. (2006). For fish oil it was concluded that n-3 LCPUFA are potentially potent anti-inflammatory agents. Many studies however have been carried out at intakes exceeding >1 up to 2 g per day, which limits the practical implications of these findings. Also, it was emphasised that larger trials are required to assess the therapeutic potential of n-3 LCPUFA in inflammatory diseases. Finally, Fritsche (2006) concluded that most studies – possibly because they were underpowered - failed to demonstrate an effect of n-3 LCPUFA on the production of pro-inflammatory cytokines.

### 5.4.2. *Trans* fatty acids (TFA)

Reviews of epidemiologic studies have suggested that adverse effects of TFA from hydrogenated sources were related with some - but not all - inflammatory markers (Mozaffarian et al., 2006; Gebauer et al., 2007). Results from dietary intervention studies have inconsistently revealed similar effects (Lichtenstein et al., 2003).

### 5.4.3. Conjugated linoleic acid (CLA)

There is no evidence from human studies that at habitual intakes CLA has beneficial or detrimental effects on inflammation or immune function. At extreme high intakes (>3 g per day), *trans*-10, *cis*-12 CLA may have unwanted effects in obese men on plasma pro-inflammatory markers (Risérus et al., 2002).

### 5.4.4. Conclusion

No consistent picture has emerged on the effects SFA, MUFA, CLA and n-6 PUFA on parameters related to inflammation and immune function. There are indications that n-3 LCPUFA from fish oil



may have beneficial effects, but results between studies are not consistent. In contrast, TFA from hydrogenated sources may have adverse effects on the inflammatory profile. Clear dose-response relationships have, however, not been established.

## **5.5. Blood pressure**

### **5.5.1. Total fat**

According to a meta-analysis of studies carried out in subjects with a body mass index of at least 25 kg/m<sup>2</sup>, it appeared that after 12 months total fat intake did not affect blood pressure (Nordmann et al., 2006).

### **5.5.2. Saturated fatty acids (SFA)**

Effects of SFA on blood pressure have been mainly studied in comparison with those of linoleic acid. In these studies, however, no specific effects of linoleic acid were identified (Pietinen, 1994).

### **5.5.3. *Cis*-monounsaturated fatty acids (*cis*-MUFA)**

Shah et al. (2007) published the results of a meta-analysis of ten intervention studies comparing high-carbohydrate and high-*cis*-MUFA diets on blood pressure. It was reported that the diets rich in carbohydrate resulted in significantly higher systolic blood pressure (2.6 mm Hg, 95% CI: 0.4, 4.7 mm Hg) and diastolic blood pressure (1.8 mm Hg, 95% CI: 0.0, 3.6 mm Hg). When the analysis was limited to the six randomised crossover studies, differences between the diets no longer reached statistical significance. It was, therefore, concluded that diets rich in carbohydrate might be associated with slightly higher blood pressure than diets rich in *cis*-monounsaturated fat. However, the difference – if any – is small and does not justify recommendations to increase the intake of *cis*-MUFA at the expense of carbohydrates to manage blood pressure.

### **5.5.4. Polyunsaturated fatty acids**

#### **5.5.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)**

There is no convincing evidence that linoleic acid positively influences blood pressure (see also SFA).

#### **5.5.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA)**

In a recent meta-analysis (Geleijnse et al., 2002), the effects of fish oil on reducing blood pressure were estimated from randomised trials. The median intake of fish oil (mainly EPA and DHA) was 3.7 g per day. It was found that fish oil reduced systolic blood pressure on average by 2.1 mmHg and diastolic blood pressure by 1.6 mmHg. When the analyses were limited to double-blind trials, reductions of 1.7 mmHg and 1.5 mmHg were reported. Effects appeared to be larger in populations that were older (> 45 years) or hypertensive, while no dose response relationship of fish oil intake with change in blood pressure was observed. It was further mentioned that the antihypertensive effect of lower doses of fish oil (< 0.5 g per day) remained to be established.

### **5.5.5. *Trans* fatty acids (TFA)**

Effects of TFA from hydrogenated oils on blood pressure have been examined in only a few trials with normotensive, healthy subjects. When compared with SFA, oleic acid or linoleic acid, no effects

of *trans*-MUFA on systolic or diastolic blood pressure were found (EFSA, 2004). Recently, it was also reported that a daily intake of 3.6 g of TFA from milk fat for 5 weeks did not change blood pressure and isobaric arterial elasticity (Raff et al., 2006).

#### **5.5.6. Conjugated linoleic acid (CLA)**

Effects of CLA on blood pressure have hardly been studied. In one study with healthy young men, it was however shown that a daily intake of 4.7 g of a mixture containing equal amounts of *cis*-9, *trans*-11- and *trans*-10, *cis*-12 CLA isomers for 5 weeks did not affect blood pressure and isobaric arterial elasticity (Raff et al., 2006).

#### **5.5.7. Conclusion**

n-3 LCPUFA from fish oil and other sources may have a slight beneficial effect on blood pressure, especially at higher intakes (>0.5 g per day). For other fatty acids, there is no convincing evidence that they affect blood pressure.

### **5.6. Glucose tolerance and insulin sensitivity**

#### **5.6.1. Total fat**

There is some evidence that high-fat diets decrease insulin sensitivity, although the available data are not consistent (IoM, 2005). In the KANWU-study, for example, the adverse effect of SFA on insulin sensitivity was not evident when total fat intake exceeded 37 E% (Vessby et al., 2001). This may suggest that at these intakes total fat intake overruled effects of SFA on insulin sensitivity. Westerbacka et al. (2005) found in 10 obese women that increasing total fat intake from 16 to 56 E% for 2 weeks decreased insulin sensitivity.

#### **5.6.2. Saturated fatty acids (SFA), *cis*-monounsaturated fatty acids (*cis*-MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA)**

In 2004, Riccardi et al. (2004) have published a review on the effects of dietary fatty acids in relation to insulin sensitivity. It was concluded that in most intervention studies no effects were found of SFA versus unsaturated fatty acids. It was emphasised, however, that most studies were performed in very small groups of subjects and for a short period of time. In fact, in one of the largest trials in this field (the KANWU study), it was found that SFA might impair insulin-sensitivity when compared with *cis*-MUFA, but only when total fat intake was below 37 E% (Vessby et al., 2001). Noteworthy, Lichtenstein et al. (2003) did not observe a consistent pattern between fatty acid intake with fasting glucose or insulin concentrations or with the HOMA-index, a marker for insulin resistance.

#### **5.6.3. n-3 polyunsaturated fatty acids (n-3 PUFA)**

In the KANWU study, fish oil had no effect on insulin-sensitivity (Vessby et al., 2001). Griffin et al. (2006) also found no effects of four different diets providing 6% of energy as PUFAs with an n-6:n-3 ratio between 5:1 and 3:1 as compared with a control diet with a n-6:n-3 ratio of 10:1. The diets were enriched with alpha-linolenic acid, EPA, or DHA, or all three fatty acids. The diets were provided for six months. Insulin sensitivity was assessed with the homeostatic model assessment of insulin resistance and the revised quantitative insulin sensitivity test. Brady et al. (2004) did also not observe any effects of a daily supplement of 4 g of fish oil for six weeks on insulin sensitivity in Indian Asians. Insulin sensitivity was assessed by using the frequently sampled intravenous glucose tolerance

test with minimal model analyses. In contrast, another study suggested that in overweight women a daily supplement of 5 g of fish oil for 12 weeks improved insulin sensitivity as measured by an OGTT, but only in females with a high inflammatory status at baseline (Browning et al., 2007).

#### **5.6.4. Trans fatty acids (TFA)**

Effects of TFA from hydrogenated sources on insulin-sensitivity have been recently reviewed. It was concluded that intervention studies may suggest that - at extreme high intakes - TFA may have the same effects on postprandial insulinaemia in obese subject with type 2 diabetes as do SFA. At lower intakes, TFA did not adversely affect insulin sensitivity of healthy volunteers (EFSA, 2004; Risérus, 2008).

#### **5.6.5. Conjugated linoleic acid (CLA)**

Several studies have examined the effects of CLA on plasma glucose and insulin concentrations. In only a few studies, insulin resistance was measured using the gold standard euglycaemic-hyperinsulinaemic clamp technique.

Using a euglycaemic-hyperinsulinaemic clamp, Risérus et al. (2002) concluded that a daily supplement of 3.4 g *trans*-10, *cis*-12 CLA increased insulin-resistance by 19% in obese men with signs of the metabolic syndrome. In another study with abdominally obese men (Risérus et al., 2004), daily consumption of 3 g *cis*-9, *trans*-11 CLA increased insulin resistance by 15%. On the other hand, Syvertsen et al. (2007) reported no effects on insulin resistance in overweight and obese men and women of a daily consumption of 3.4 g of a mixture of CLA isomers, composed of 37.5% *cis*-9, *trans*-11 and 38% *trans*-10, *cis*-12 CLA. Risérus et al. (2004) also found no effect on insulin resistance of a CLA mixture, composed of *cis*-9, *trans*-11 and *trans*-10, *cis*-12 CLA in similar proportions. Also, results of studies that measured fasting glucose and insulin concentrations or used an OGTT to assess insulin-sensitivity are conflicting. Tricon et al. (2004) found no effects of dairy products naturally enriched with *cis*-9, *trans*-11 CLA (1.4 g per day for six weeks) on fasting glucose and insulin concentrations. Naumann et al. (2006) also concluded that consumption for 13 weeks of 3 g per day of either *cis*-9, *trans*-11 or *trans*-10, *cis*-12 CLA did not affect fasting glucose or insulin concentration in volunteers with LDL phenotype B. In contrast, Lambert et al. (2007) recently reported that supplementation for 12 weeks of 3.9 g per day of a mixture of CLA isomers, mainly *cis*-9, *trans*-11 and *trans*-10, *cis*-12 CLA in similar proportions, improved insulin sensitivity as measured with an OGTT in non-obese, regularly exercising women. A sunflower oil high in oleic acid was used as control.

#### **5.6.6. Conclusion**

The limited number of human intervention studies in non-diabetic subjects does not provide consistent evidence that fatty acids change insulin sensitivity. If anything, SFA intake may impair and n-3 PUFA intake may improve insulin sensitivity. In addition, total fat intake may decrease insulin sensitivity. Clear dose-response relationships have, however, not been established.

### **5.7. Body weight control and energy balance**

#### **5.7.1. Total fat**

The impact of manipulation of the macronutrient content on body weight in the context of weight management in overweight and obese subjects may be different from the effects on prevention of

weight gain in leaner persons and may depend on whether diets are administered *ad libitum* or under isocaloric conditions.

In intervention trials with tightly controlled energy intakes and fat intakes ranging from 10 to 78 E%, energy expenditure, weight loss and weight maintenance are a function of energy intake rather than of the macronutrient composition of the diet (IoM, 2005; van Dam and Seidell, 2007; Nordman et al., 2006; Sacks et al., 2009). However, even in such studies, reduced fat diets (<35 E%) tend to be hypocaloric when compared to reduced carbohydrate diets (<50 E%) and enhance compliance with energy restriction, leading to slightly greater weight loss (IoM, 2005; van Dam and Seidell, 2007).

Several randomised intervention studies suggest that reduced-fat (< 25 to 30 E%) diets consumed *ad libitum* have the potential to prevent weight gain in normal weight subjects and produce weight loss in overweight (BMI >25kg/m<sup>2</sup>) individuals as compared to higher fat diets (> 35 E%) (IoM, 2005). In some long-term (>1 year) intervention studies, dietary modifications with a shift from a habitual Western-type, high fat (35 to 40 E%), to fat-reduced (<30 E%) diets consumed *ad libitum* were associated with a reduced risk of weight gain or a moderate weight loss in various population groups including normal, overweight and obese subjects (IoM, 2005; Howard et al., 2006a; Lanza et al., 2001).

Foods containing high amounts of fat tend to be energy dense, and evidence suggests that consuming diets of high energy density can undermine normal appetite regulation leading to increased overall energy intake through 'passive overconsumption' of food and can result in weight gain (WHO/FAO, 2003; IoM, 2005).

Overall, diets with <35 E% fat may provide some advantages over diets with >35 E% fat in medium-term weight reduction and long-term prevention of weight gain.

### **5.7.2. Saturated fatty acids (SFA), *cis*-monounsaturated fatty acids (*cis*-MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA)**

Increasing the intake of oleic acid from 13.1 E% to 31.4 E% while decreasing the intake of palmitic acid from 8.4 E% to 1.7 E% for four weeks in a group of healthy non-obese adults resulted in a 223 kcal higher daily energy expenditure than a change from 8.4 E% to 16.8 E% palmitic acid plus a change from 13.1 E% to 16.4 E% oleic acid in another group for the same duration (Kien et al., 2005). Piers et al. (2003) also concluded that increasing the intake of *cis*-MUFA and *cis*-PUFA by 13 E% at the expense of SFA for four weeks had a beneficial effect on body mass in overweight and obese men. Schirmer and Phinney (2007) reported that a daily intake of 890 mg per day of  $\gamma$ -linolenic acid (provided by 5 g borage oil) for 1 year reduced weight regain in formerly obese subject. Olive oil was used as control.

### **5.7.3. n-3 polyunsaturated fatty acids (n-3 PUFA)**

Hill et al. (2007) have studied the individual and combined effects of n-3 PUFA supplements in addition to the usual diet and regular exercise on body composition. Overweight volunteers consumed daily for 12 weeks 6 g tuna oil (approximately 1.9 g n-3 LCPUFA) or 6 g sunflower oil, with or without an exercise intervention. It was concluded that fish oil reduced body fat mass when compared with sunflower oil. Couet et al. (1997) have reported similar results for lean subjects when daily fish oil intake was increased for three weeks by 6 g at the expense of visible fats in the usual diet.

#### 5.7.4. *Trans* fatty acids (TFA)

In a prospective cohort study in 16,587 men, Koh-Banerjee et al. (2003) found that each 2 E% increase in TFA intake was associated with a 0.77 cm waist gain over 9 years, when isocalorically substituted for either PUFA or carbohydrates.

#### 5.7.5. Conjugated linoleic acid (CLA)

CLA isomers have been extensively studied as potential modulators of body composition and body fat mass. In a recent meta-analysis of 18 clinical studies, Whigham et al. (2007) reported that the effect of CLA supplementation on the loss of fat mass is modest. It was estimated that supplementation with 3.2 g CLA reduced fat mass by 0.09 kg per week. In a 1-year study, it was found that a daily consumption of 3.5 g CLA isomers containing equal amounts of *cis*-9, *trans*-11- and *trans*-10, *cis*-12 CLA isomers decreased fat mass by approximately 2 kg. This effect was already achieved after six months (Gaullier et al., 2004). The reduction in fat mass appears to be located mainly in the legs (Gaullier et al., 2007), which is not considered as the metabolically active fat region. Although animal studies have suggested that *trans*-10, *cis*-12 CLA is the most active CLA isomer, this conclusion cannot be drawn from the limited number of human studies that have been carried out with single isomers (Whigham et al., 2007). It needs to be emphasised that CLA intakes in these studies exceed by far those that can be achieved with normal diets.

#### 5.7.6. Conclusion

Short to medium-term (up to 1 year) and long-term intervention studies provide evidence that a moderate fat intake (<35 E%) is associated with reduced energy intake and therefore moderate weight reduction or prevention of weight gain.

Some studies may suggest that SFA decreases energy expenditure as compared with *cis*-unsaturated fatty acids, but more studies - especially at lower intakes - are needed to extend these observations. From human studies, there is no evidence that, at habitual intakes n-3 PUFA, TFA, and CLA have a discernable impact on energy balance.

### 5.8. Cardiovascular disease

#### 5.8.1. Total fat, saturated fatty acids (SFA), *cis*-monounsaturated fatty acids (*cis*-MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA)

A review of three dietary intervention studies has shown that decreasing the intakes of products rich in SFA plus cholesterol at the expense of products rich in linoleic acid and alpha-linolenic acid, and low in cholesterol, decreased the number of cardiovascular deaths (Sacks and Katan, 2002). No such effects were seen in a fourth study. Overall, these intervention trials strongly suggest that diet-induced changes in blood total cholesterol concentrations are causally related to changes in cardiovascular risk. Noteworthy, in these studies, total fat intake was hardly changed. In three other intervention trials, the reduction of total fat intake, in particular of saturated fat, and the increase in the consumption of carbohydrate-rich foods, did not significantly reduce the risk of cardiovascular disease. However, it cannot be excluded that the duration, compliance, and sample sizes may have been insufficient to demonstrate a reduction in coronary events. In the Health Professional follow up study, no relationships between total fat intake or intake of SFA, *cis*-MUFA, and n-6 PUFA with risk of stroke have been reported (He et al., 2003). Also, in the Women's Health Initiative Dietary Modification Trial a dietary intervention that reduced total fat intake and increased intakes of vegetables, fruits, and grains did not significantly reduce the risk of cardiovascular disease (Howard et al., 2006b).



### 5.8.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

He et al. (2004a) carried out a meta-analysis of cohort studies to examine the association between fish intake and CHD mortality. Results indicated that fish consumption was inversely associated with fatal CHD. Compared with subjects who never consumed fish or consumed fish less than once per month, the multivariate relative risk (RR) for CHD mortality were 0.89 (95% CI, 0.79 to 1.01) for fish intake 1 to 3 times per month, 0.85 (95% CI, 0.76 to 0.96) for once per week, 0.77 (95% CI, 0.66 to 0.89) for 2 to 4 times per week, and 0.62 (95% CI, 0.46 to 0.82) for 5 or more times per week. Each daily increase in fish intake of 20 g was related to a 7% lower risk of CHD mortality. Comparable conclusions were drawn when stroke was considered as endpoint (He et al., 2004b). It should be noted that in these two studies, relationships with fish intake were examined and not with n-3 LCPUFA.

Bucher et al. (2002) explored the relationship between the intake of dietary (from fish) and supplemental n-3 LCPUFA on CHD using data from randomised controlled trials. The risk ratio in patients who were on n-3 LCPUFA-enriched diets was 0.8 (95% CI, 0.5 to 1.2) for nonfatal myocardial infarction, 0.7 (95% CI, 0.6 to 0.8) for fatal myocardial infarction, 0.7 (95% CI, 0.6 to 0.9) for sudden death, and 0.8 (95% CI, 0.7 to 0.9) for overall mortality compared to those on control diets or placebo. Results did not differ between dietary and supplemental interventions. No dose-response relationships were reported.

Based on a meta-analysis of randomised trials and large prospective studies, Mozaffarian and Rimm (2006) reported that the intake of EPA plus DHA is negatively related to cardiovascular risk in a dose-dependent way. Intakes of 250 mg per day of EPA and DHA appeared to be sufficient for primary prevention in healthy adults. Recently, Harris et al. (2008) also conducted a meta-analysis based on six epidemiological studies in the United States. Results showed a continuous significant dose-response relationship between the intake of EPA plus DHA up to 500 mg per day and the risk of death from CHD. In addition, observational studies, randomised clinical trials and experimental studies provide evidence that modest consumption of fish or fish oil (1–2 servings/wk of oily fish, or approx. 250 mg per day of EPA plus DHA) reduces the risk of coronary heart disease and sudden cardiac death (Mozaffarian, 2008).

Wang et al. (2006) also concluded from a systematic review of the literature that increased consumption of n-3 LCPUFA from fish or fish-oil supplements, but not of alpha-linolenic acid, reduces the rates of all-cause mortality, cardiac and sudden death, and possibly stroke. Effects appeared to be stronger in secondary than in primary prevention settings. Adverse effects were minor. In contrast, based on a meta-analysis that included both randomised controlled trials and cohort studies, Hooper et al. (2006) concluded that dietary or supplemental n-3 PUFA had no effect on cardiovascular events in subjects at risk or in the general population. For many reasons, however, their approach has been criticised by other authors (Twisselmann, 2006). Virtanen et al. (2008) also reported that fish consumption was associated with a lower risk of total cardiovascular disease, a relationship that was not modified by the intake of n-6 PUFA.

Mozaffarian et al. (2005) reported that fish oil significantly reduced heart rate, particularly in those with higher baseline heart rate or longer intervention duration. This conclusion was based on a meta-analysis of thirty randomised controlled trials in humans. No evidence was present for a dose-response effect. Brouwer et al. (2006) did not observe any beneficial effects of a daily supplement of 2 g of fish oil on ventricular tachyarrhythmia or death in patients with implantable cardioverter-defibrillators and prior documented malignant ventricular tachycardia or ventricular fibrillation.

Results for alpha-linolenic acid are less consistent. Brouwer et al. (2004) reported that increasing intake of alpha-linolenic acid by 1.2 g per day decreased the risk of fatal coronary heart disease by at least 20%. Wang et al. (2006), however, found no evidence that alpha-linolenic acid reduced the rates of all-cause mortality, cardiac and sudden death, and possibly stroke.



### 5.8.3. *Trans* fatty acids (TFA)

As already reviewed (EFSA, 2004; Mozaffarian and Clarke, 2009), results from a number of prospective cohort studies consistently support the findings from intervention studies for an association between higher intakes of TFA and increased risk of CHD. The available evidence is insufficient to establish whether there is any difference between ruminant and industrially produced TFA consumed in equivalent amounts and risk of CHD.

### 5.8.4. Cholesterol

In 2003, Hu and Willett (2002) reviewed the literature and concluded that there was no strong evidence that dietary cholesterol and modest egg consumption (1 egg per day) were related with either CHD or stroke. However, it was estimated that the relative risk for cardiovascular disease for each increase in the intake of dietary cholesterol of 200 mg / 1000 kcal was 1.37 (95% CI: 1.12 to 1.68) (Tanasescu et al., 2004). Djousse and Gaziano (2008) reported that in the 21,275 participants from the Physicians' Health Study I, the hazard ratio for incident heart failure was 1.28 (95% CI: 1.02 to 1.61) for men who consumed daily one egg and 1.64 (95% CI: 1.08 to 2.49) for those who consumed 2 or more eggs a day. Below these intakes, no associations were reported. In the Nurses' Health Study cohort, however, cholesterol intake was not related to intraparenchymal hemorrhages (Iso et al., 2001). For stroke, no relationship with cholesterol intake was found in male US healthcare professionals (He et al., 2003).

### 5.8.5. Conclusion

From intervention and epidemiological prospective cohort studies, it can be concluded that the fatty-acid composition of the diet is an important determinant of cardiovascular risk. Decreasing the intake of SFA and TFA, and increasing the intake of fish oil, lower cardiovascular risk. Alpha-linolenic acid may also have a specific beneficial effect, but more intervention studies, specifically designed to look at the cardioprotective effects of this fatty acid, are needed. Available data on the relationship between cholesterol intake and risk of cardiovascular disease are inconsistent at current levels of intake.

## 5.9. Type 2 diabetes mellitus

### 5.9.1. Total fat, saturated fatty acids (SFA), *cis*-monounsaturated fatty acids (*cis*-MUFA), and n-6 polyunsaturated fatty acids (n-6 PUFA)

In the Nurses Health Study, no effects were found of total fat, SFA, and *cis*-MUFA intakes vs. those of an isocaloric amount of energy from carbohydrates on the risk to develop type 2 diabetes mellitus. However, for a 5 E% increase of linoleic acid intake, the RR was 0.63 (95% CI, 0.53 to 0.76) (Salmerón et al., 2001). In contrast, the Iowa Women's Health Study only found some suggestions for an inverse relationship between PUFA and vegetable fat intake with the incidence of type 2 diabetes, but not with any type of fatty acids or with animal fat (Meyer et al., 2001). In the Health Professionals Follow-up Study, no relationships were observed for men between total fat or fatty acid intake and the risk of type 2 diabetes. Relationships with vegetable or animal fat intake were also not statistically significant (Van Dam et al., 2002).

### 5.9.2. n-3 polyunsaturated fatty acids (n-3 PUFA)

Salmeron et al. (2001) reported that in the Nurses Health Study EPA plus DHA intake was inversely related to the risk to develop type 2 diabetes mellitus. In two other studies, however, no effects of n-3 PUFA were reported (Meyer et al., 2001; Van Dam et al., 2002).

### 5.9.3. *Trans* fatty acids (TFA)

In the Nurses Health Study a positive relationship was observed between the intake of TFA and the risk of development of type 2 diabetes. These effects were primarily observed in obese women, which may be explained by the fact that these women were already more insulin resistant at the start of the study compared with non-obese women (Salmeron et al., 2001). In other studies, however, such relationships were not reported (Meyer et al., 2001; van Dam et al., 2002).

### 5.9.4. Cholesterol

Meyer et al. (2001) found a positive relationship between the intake of cholesterol and the incidence of type 2 diabetes mellitus. At a median daily intake of 382 mg, the RR was 1.17 (95% CI, 1.01 to 1.37). Results were not corrected for intakes of fatty acids. Salmeron et al. (2001) reported that each increase of 100 mg dietary cholesterol/1000 kcal was associated with a 12% increased risk of type 2 diabetes mellitus, when results were adjusted for differences in the intakes of fatty acids.

### 5.9.5. Conclusion

Epidemiological prospective cohort studies have not found consistent relationships between total fat intake, the intake of specific fatty acids or cholesterol with the risk to develop type 2 diabetes mellitus.

## 5.10. Cancer

A large number of studies have examined the link between total fat, SFA, MUFA, n-3 and n-6 LCPUFA, TFA and other specific fatty acid intakes and the occurrence of cancers. In its last report, the World Cancer Research Foundation (WCRF/AICR, 2007) found however that only few suggestive relationships could be established between the intake of total fat and/or fat-containing foods and the risk of cancer.

There is limited evidence suggesting that high total fat intakes may increase the risk of breast (postmenopausal) cancer. Schulz et al. (2008) confirmed the positive association between total fat intake and incidence of breast cancer in the EPIC-Potsdam study (HR 2.34, 95% CI 1.45-3.79, *p* for trend 0.0004 for the highest compared to the lowest tertile of a simplified food pattern score. This score is positively associated with total dietary fat and all fatty acid fractions. Total fat intake was 31.15 E% for the first tertile and 39.2 E% for the highest tertile, after adjustment for confounders). Similar conclusions were reached in other studies (Prentice et al., 2006; Chlebowski et al., 2006; Borugian et al., 2004; McEligot et al., 2006). Total fat intake has also been associated with higher risk of lung cancer.

Saturated fat intakes appear to be positively associated with breast cancer risk (Boyd et al., 2003; Bingham et al., 2003; Cho et al., 2003; Thiebaut et al., 2007; Sieri et al., 2008). Results from the EPIC cohort in Cambridge show that, using dietary data from diaries, a daily intake of around 35 g SFA doubles the risk of breast cancer in comparison to daily intakes of 10 g or less (Gonzalez, 2006). No significant association was found between the intake of either SFA, total fat or any subtype of fat and the risk of prostate cancer (Crowe et al., 2008).

*Trans* fatty acids (Maillard et al., 2002) and more specifically *trans*-MUFA (Chajès et al., 2008) have been also strongly associated with an increased risk of breast cancer.

Finally, the consumption of certain food items has also been associated with cancer risk. For example, butter consumption is associated with an increased risk of lung cancer, whereas the consumption of foods containing animal fat has been associated with an increased risk of colorectal cancer (WCRF/AICR, 2007). Conversely, consumption of fish (WCRF/AICR, 2007; Geelen et al., 2007; Hall et al., 2008) and olive oil (Stoneham et al., 2000; Rouillier et al., 2005; Galeone et al., 2007) appear to decrease the risk of colorectal cancer. However, these associations cannot be attributed to specific fatty acids.

#### **5.10.1. Conclusion**

For many specific fatty acids, results from prospective cohort studies are still too limited, and sometimes contradictory, to conclude on clear associations between their intakes and the risk of a particular type of cancer. The Panel concludes that at present the evidence is not sufficient to define a DRVs for total fat or specific fatty acids based on cancer outcomes.

#### **5.11. Nervous system function**

In the first months of life, lipids, besides energy, also supply structural components for the anatomical and functional development of the brain and the nervous system. DHA in functional areas of the brain is higher in breastfed infants than in infants fed formulas devoid of DHA (Farquharson et al., 1992; Makrides et al., 1994). The DHA content of tissues and brain has been associated with higher developmental scores observed in breastfed compared to formula-fed infants and this effect may be modulated by the individual genetic polymorphisms leading to DHA synthesis (Caspi et al., 2007).

Within breastfed infants, DHA status at birth and maternal DHA intake in pregnancy are interconnected and are associated with the infants' developmental performance (Helland et al., 2003; Dunstan et al., 2008; Innis, 2007). Results from trials in formula fed infants are more divergent, and could be partly related to un-investigated covariates such as infants' DHA status at birth and the individual genetic background (Simmer et al., 2008).

DHA supplementation through the complementary feeding period seems still effective in improving the neuro-functional and visual performance (Birch et al., 2007; Agostoni et al., 2009). Section 5.1.2.2 reports indications on the levels of preformed DHA in the diet of infants. While 20 mg per day seem to represent the lowest limit of intake in the first six months through human milk (Marangoni et al., 2000) and may partly affect the timing of developmental milestones in the first 12 months (Agostoni et al., 2009), 50 to 100 mg per day have been found effective for the visual function during the subsequent complementary feeding period (Birch et al., 2007; EFSA 2009).

#### **5.12. Cognitive decline and dementia**

There is some evidence from cross-sectional and prospective observational studies for an inverse association between dietary and supplemental intake of n-3 LCPUFA and the risk of cognitive decline, dementia, and Alzheimer disease (Lim et al., 2006; Issa et al., 2006). Available observational studies are more consistent in reporting benefits of n-3 LCPUFA on cognitive decline in elderly individuals without dementia than in the incidence of dementia or Alzheimer disease (Fothui et al., 2009). The few clinical trials available do not provide convincing evidence for an effect of n-3 LCPUFA in the prevention or treatment of any form of dementia (Fothui et al., 2009) and most recent systematic reviews agree that available data are insufficient to draw firm conclusions on the role of n-

3 LCPUFA on cognitive function in normal aging or on the incidence of dementia, including Alzheimer disease (Cederholm and Palmblad, 2010; Cole et al., 2009).

The Panel concludes that the evidence available is not sufficient to define a DRV for n-3 LCPUFA based on cognitive decline or dementia outcomes.

## **6. Key data on which to base Dietary Reference Values**

It should be emphasised that Dietary Reference Values for macronutrients - which are expressed as E% - are mutually dependent, because the sum of the separate recommendations is 100%. Thus, a change in the recommendation for one of the macronutrients is necessarily accompanied by a change in the recommendation of at least one of the other energy-providing macronutrients. Similarly, reference values for the separate classes of fatty acids are mutually dependent, as the sum equals total fat intake. An exception may be the n-3 LCPUFA and cholesterol for which reference intakes are usually expressed in mg per day. Recommendations for dietary cholesterol – if any – are also expressed in mg/MJ or mg per day.

### **6.1. Total fat**

Fat is an important dense source of energy and facilitates the absorption of fat-soluble dietary components such as vitamins. Fats and oils are in themselves important sources of these components and of EFA. High-fat diets may decrease insulin-sensitivity. Also, fat intake is positively associated with changes in fasting and postprandial factor VII, which may increase cardiovascular risk. However, no unequivocal conclusions can be drawn and effects cannot be quantified. Short to medium-term (up to one year) and long-term intervention studies provide evidence that a moderate fat intake (<35 E%) is accompanied by a reduced energy intake and therefore moderate weight reduction or prevention of weight gain. The available data do not permit to establish dose-response relationships. The Panel, therefore, comes to the conclusion that only a Reference Intake range can be given for total fat intake, partly based on practical considerations (e.g. current levels of intake, achievable dietary patterns). At the lowest observed intake of total fat in European countries (20 E%) no overt signs of deficiencies have been observed neither adverse effects on blood lipids. Total fat intakes > 35 E% may be compatible with both good health and normal body weight depending on dietary patterns and the level of physical activity. The Panel proposes to set for adults a lower bound of the Reference Intake range of 20 E% and an upper bound of 35 E%.

Fat intake in infants can gradually be reduced in the second half of the first year of life, from the start of the complementary feeding period up to three years of age: 40 E% in the 6 to 12 month period and 35 to 40 E% in the 2<sup>nd</sup> and 3<sup>rd</sup> year of life. Fat intakes below 25 E% have been associated with low vitamin levels in some young children. For children above the age of three years the RI for adults applies.

### **6.2. Saturated fatty acids (SFA)**

SFA are synthesised by the body and are not required in the diet. Therefore, no PRI, AR, LTI or AI is set.

There is a positive, dose-dependent relationship between the intake of a mixture of SFA and blood LDL cholesterol concentrations when compared to carbohydrates. There is also evidence from dietary intervention studies that decreasing the intakes of products rich in SFA by replacement with products rich in n-6 PUFA (without changing total fat intake) decreases the number of cardiovascular events. As the relationship between SFA intake and the increase in blood LDL cholesterol concentrations is continuous, no threshold of SFA intake can be defined below which there is no adverse effect. Also

no UL can be set as any increase in the intake of a mixture of SFA adversely affects blood LDL cholesterol concentrations.

The four major SFA in the diet (lauric acid, myristic acid, palmitic acid, and stearic acid) may have different effects on the blood lipoprotein profile. However, the data available are not sufficient for the establishment of DRVs for individual SFA.

Dietary SFA are provided by all fats and oils, which are also important sources of essential fatty acids. Furthermore, a significant proportion of dietary SFA is obtained from animal foods that are important sources of vitamins and essential minerals. Thus, there is a limit to which the intake of SFA can be lowered without compromising adequacy of intake of essential nutrients and this will vary between populations depending on prevailing patterns of food intake. Therefore, the Panel concludes that SFA intake should be as low as possible within the context of a nutritionally adequate diet. Limiting the intake of SFA should be considered when establishing nutrient goals and recommendations.

The Panel notes that a number of authorities have established nutrient recommendations of SFA for individuals below 8 to 10 E% (see Section 4). Typically, these nutrient recommendations reflect a judgement of what level of SFA intake is practically achievable within the context of a nutritionally adequate diet based on known patterns of intake of foods and nutrients in specific populations. It is also noted that the average intake of SFA in adults in many EU Member States exceeds these recommendations (see Section 3).

### **6.3. *Cis*-monounsaturated fatty acids (*cis*-MUFA)**

*Cis*-MUFA are not nutritionally essential as they can be synthesised from other (saturated) fatty acids and from carbohydrates and have no known specific role in preventing or promoting diet-related diseases, and are, therefore, not required in the diet. The Panel proposes not to set any DRV for *cis*-MUFA.

### **6.4. *Cis*-polyunsaturated fatty acids (*cis*-PUFA)**

In view of the different metabolic effects of the various dietary *cis*-PUFA, the Panel proposes not to formulate a DRV for the intake of total *cis*-PUFA. Also, the Panel proposes not to set specific values for the n-3/n-6 ratio as there are insufficient data on clinical and biochemical endpoints in humans to recommend a ratio independent of absolute levels of intake.

#### **6.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)**

Linoleic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is therefore an EFA. However, there are not sufficient scientific data to derive an AR, PRI or LTI.

There is a negative (beneficial), dose-dependent relationship between the intake of linoleic acid and blood LDL cholesterol concentrations, while this relationship is positive for HDL cholesterol concentrations. In addition, linoleic acid lowers fasting blood triacylglycerol concentrations, when compared to carbohydrates. There is also evidence from dietary intervention studies that decreasing the intakes of products rich in SFA by a replacement of products rich in n-6 PUFA (without changing total fat intake) reduces the number of cardiovascular events. As the relationship between linoleic acid intake and the blood lipid profile is continuous, no threshold value of linoleic acid intake can be identified below which the risk for cardiovascular events increases.

The Panel proposes to set an AI for linoleic acid of 4 E%, based on the lowest estimated mean intakes of the various population groups from a number of European countries, where overt linoleic deficiency symptoms are not present.

Arachidonic acid is synthesised by the body from linoleic acid and is therefore not an EFA. Though it plays an important role to maintain metabolic integrity, there is no need to define a DRV for preformed arachidonic acid. The Panel, therefore, proposes not to set any DRV for arachidonic acid.

Finally, there is at present no consistent evidence that the intake of any of the n-6 PUFA has detrimental effects on health (e.g. in promoting diet-related diseases). The Panel therefore proposes not to set an UL for total or any of the n-6 PUFA.

#### **6.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA)**

Alpha-linolenic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is therefore an EFA. However, there are not sufficient scientific data to derive an AR. The Panel therefore proposes to set an AI for alpha-linolenic acid of 0.5 E%, based on the lowest estimated mean intakes of the various population groups from a number of European countries, where overt alpha-linolenic acid deficiency symptoms are not present. There is no convincing evidence for a further positive or negative unique role for alpha-linolenic acid in diet-related diseases.

The human body can synthesise EPA and DHA from alpha-linolenic acid. Intervention studies have demonstrated beneficial effects of preformed n-3 LCPUFA on recognised cardiovascular risk factors, such as a reduction of plasma triacylglycerol concentrations, platelet aggregation, and blood pressure. These effects were mainly observed at intakes  $\geq 1$ g per day, well above levels that were associated with lower CVD risk in epidemiological studies. With respect to cardiovascular diseases, prospective epidemiological and dietary intervention studies indicate that oily fish consumption or n-3 LCPUFA dietary supplements (equivalent to a range of 250 to 500 mg of EPA plus DHA daily) decrease the risk of mortality from CHD and sudden cardiac death. An intake of 250 mg per day of EPA plus DHA appears to be sufficient for primary prevention in healthy subjects. Therefore, and because available data are insufficient to derive an AR, the Panel proposes to set an AI of 250 mg for EPA plus DHA based on considerations of cardiovascular health.

In infants, DHA intakes at levels of 50 to 100 mg per day have been found effective for visual function during the complementary feeding period. The Panel proposes an AI of 100 mg for the age >6 months to 24 months.

The currently available data do not permit to define an age specific quantitative estimate of an adequate dietary intake of EPA and DHA for children aged 2 to 18 years. However dietary advice for children should be consistent with advice (food and nutrient based dietary guidelines, respectively) for the adult population (which is 1 to 2 fatty fish meals per wk or ~250 mg of EPA plus DHA per day). This intake should also be compatible with an adequate n-3 LCPUFA supply during pregnancy and lactation, when 100 to 200 mg additional preformed DHA should be added to the habitual diet to compensate for oxidative losses of maternal dietary DHA and accumulation of DHA in body fat of the foetus/infant.

#### **6.5. Trans fatty acids (TFA)**

TFA are not synthesised in the human body to a significant extent, but are also not required in the diet. Therefore, no PRI, AR, or AI is set.



Consumption of diets containing *trans*-MUFA, like diets containing mixtures of SFA, increases blood total and LDL cholesterol concentrations in a dose-dependent manner, compared with consumption of diets containing *cis*-MUFA or *cis*-PUFA. Consumption of diets containing *trans*-MUFA also results in reduced blood HDL cholesterol concentrations and increases the total cholesterol to HDL cholesterol ratio. The available evidence indicates that TFA from ruminant sources have adverse effects on blood lipids and lipoproteins similar to those from industrial sources. Prospective cohort studies show a consistent relationship between higher intakes of TFA and increased risk of CHD. The available evidence is insufficient to establish whether there is a difference between equivalent amounts of ruminant and industrially produced TFA on the risk of CHD.

Dietary TFA are provided by several fats and oils that are also important sources of essential fatty acids and other nutrients. Thus, there is a limit to which the intake of TFA can be lowered without compromising the adequacy of intake of essential nutrients. Therefore, the Panel concludes that TFA intake should be as low as possible within the context of a nutritionally adequate diet. Limiting the intake of TFA should be considered when establishing nutrient goals and recommendations.

The Panel notes that a number of authorities have established nutrient recommendations of TFA for individuals below 1 to 2 E% (see Section 4). Typically, these recommendations reflect a judgement of what maximum level of TFA intake is practically achievable within the context of a nutritionally adequate diet based on known patterns of intake of foods and nutrients in specific populations. The Panel also notes that the average intake of TFA in adults in the EU has decreased considerably over recent years (see Section 3).

#### **6.6. Conjugated linoleic acid (CLA)**

There is no convincing evidence that any of the CLA isomers in the diet play a role in prevention or promotion of diet-related diseases. The Panel, therefore, proposes not to set any DRV for CLA.

#### **6.7. Cholesterol**

Cholesterol is sufficiently synthesised by the body and is not required in the diet. Therefore, no PRI, AR, or AI is set.

Although there is a positive dose-dependent relationship between the intake of dietary cholesterol and blood LDL cholesterol concentrations, the main dietary determinant of blood levels of LDL cholesterol is saturated fat intake. Furthermore, most dietary cholesterol is obtained from foods which are also significant sources of dietary SFA, e.g. dairy and meat products. Therefore the Panel decided not to propose a reference value for cholesterol intake beside its conclusion on the intake of SFA.

### **CONCLUSIONS AND RECOMMENDATIONS**

#### **Total fat**

Available data are insufficient to define a Lower Threshold Intake or Tolerable Upper Intake Level for total fat intake. The Panel concludes that only a Reference Intake range can be established for total fat intake, partly based on practical considerations (e.g. current levels of intake, achievable dietary patterns in healthy populations). At the lowest observed intake of total fat (20 E%), no overt signs of deficiencies have been observed neither adverse effects on blood lipids. Total fat intakes > 35 E% may be compatible with both good health and normal body weight depending on dietary patterns and the level of physical activity.

The Panel proposes to set a lower bound of the Reference Intake Range of 20 E% and an upper bound of 35 E% for adults.

In the second half of the first year of life, from the start of the complementary feeding period up to three years of age fat intake in infants and young children can be, gradually reduced: 40 E% in the 6 to 12 month period and 35 to 40 E% in the 2<sup>nd</sup> and 3<sup>rd</sup> year of life. For children above the age of three years the Reference Intake Range for adults applies.

Fat intakes below 25 E% have been associated with low vitamin levels in some infants and young children.

### **Saturated fatty acids**

Saturated fatty acids are synthesised by the body and are not required in the diet. Therefore, no Population Reference Intake, Average Requirement, or Adequate Intake is set.

As the relationship between saturated fatty acids intake and the effects on the blood lipid profile is continuous, there is no threshold of saturated fatty acids intake below which no adverse effects are observed. Thus, no Tolerable Upper Intake Level can be set.

The Panel concludes that saturated fatty acids intake should be as low as possible within the context of a nutritionally adequate diet. Limiting the intake of saturated fatty acids should be considered when establishing nutrient goals and recommendations.

### ***Cis*-monounsaturated fatty acids (*cis*-MUFA)**

*Cis*- monounsaturated fatty acids are not nutritionally essential, are synthesised by the body, have no known specific role in preventing or promoting diet-related diseases, and are not required in the diet. The Panel, therefore, proposes not to set any Dietary Reference Value for *cis*- monounsaturated fatty acids.

### ***Cis*-polyunsaturated fatty acids (*cis*-PUFA)**

In view of the different metabolic effects of the various dietary *cis*- polyunsaturated fatty acids, the Panel proposes not to formulate any Dietary Reference Value for the intake of total *cis*-polyunsaturated fatty acids. Also, the Panel proposes not to set specific values for the n-3/n-6 ratio as available data are insufficient to recommend a ratio independent of absolute levels of intake which should be the subject of nutrient and/or food based dietary guidelines.

### **n-6 polyunsaturated fatty acids (n-6 PUFA)**

Linoleic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is therefore an essential fatty acid. However, there is not sufficient scientific evidence to derive a Lower Threshold Intake, Average Requirement or Population Reference Intake.

As the relationship between linoleic acid intake and the blood lipid profile is continuous, there is no threshold of linoleic acid intake to establish a Lower Threshold Intake.

The Panel proposes to set an Adequate Intake for linoleic acid of 4 E%, based on the lowest estimated mean intakes of the various population groups from various European countries, where overt linoleic acid deficiency symptoms are not present.

Arachidonic acid is synthesised by the body from linoleic acid and is, therefore, not an essential fatty acid. The Panel proposes not to set any Dietary Reference Value for arachidonic acid.

Finally, there is at present no consistent evidence that intake of any of the n-6 polyunsaturated fatty acids has any detrimental effects on health (e.g. in promoting diet-related diseases). The Panel, therefore, proposes not to set an Tolerable Upper Intake Level for total or any of the n-6 polyunsaturated fatty acids.

### **n-3 polyunsaturated fatty acids (n-3 PUFA)**

Alpha-linolenic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is therefore an EFA. However, there are not sufficient scientific data to derive an Average Requirement, a Lower Threshold Intake or a Population Reference Intake.. The Panel proposes to set an AI for alpha-linolenic acid of 0.5 E%, based on the lowest estimated mean intakes of the various population groups from the various European countries, where overt alpha-linolenic acid deficiency symptoms are not present.

The human body can synthesise eicosapentaenoic acid and docosahexaenoic acid from alpha-linolenic acid. Scientific evidence indicates that oily fish consumption or dietary supplements containing eicosapentaenoic acid plus docosahexaenoic acid decrease the risk of mortality from coronary heart disease. Taking into account that available data are insufficient to derive an Average Requirement, the Panel proposes to set an Adequate Intake for adults of 250 mg for eicosapentaenoic acid plus docosahexaenoic acid based on considerations of cardiovascular health.

The Panel proposes an Adequate Intake of 100 mg docosahexaenoic acid for older infants (>6 months of age) and young children below the age of 24 months.

For the age period 2 to 18 years, the Panel proposes no Adequate Intake for docosahexaenoic acid plus eicosapentaenoic acid. However dietary advice for children should be consistent with advice for the adult population.

The Panel considers that during pregnancy and lactation an adequate n-3 long-chain polyunsaturated fatty acids supply consists of the Adequate Intake for adults (250 mg docosahexaenoic acid plus eicosapentaenoic acid) and 100 to 200 mg additional preformed docosahexaenoic acid.

### ***Trans* fatty acids (TFA)**

*Trans* fatty acids are not synthesised by the human body, but are also not required in the diet. Therefore, no Population Reference Intake, Average Requirement, or Adequate Intake is set.

Higher intakes of *trans* fatty acids have consistently been found to be associated with an increased risk of coronary heart disease.

There is a limit to which the intake of *trans* fatty acids can be lowered without compromising the adequacy of intake of essential nutrients. Therefore, the Panel concludes that *trans* fatty acids intake should be as low as possible within the context of a nutritionally adequate diet. Limiting the intake of *trans* fatty acids should be considered when establishing nutrient goals and recommendations.

### **Conjugated linoleic acids (CLA)**

There is no convincing evidence that any of the conjugated linoleic acids isomers in the diet play a role in prevention or promotion of diet-related diseases. The Panel therefore proposes not to set any Dietary Reference Value for conjugated linoleic acids.

## **Cholesterol**

Cholesterol is synthesised by the body and is not required in the diet. Therefore, no Population Reference Intake, Average Requirement, or Adequate Intake is set.

Although there is a positive dose-dependent relationship between the intake of dietary cholesterol with blood LDL cholesterol concentrations, the main dietary determinant of blood LDL cholesterol concentrations is saturated fat intake.

Therefore the Panel decided not to propose a reference value for cholesterol intake beside its conclusion on the intake of saturated fatty acids.

**SUMMARY OF DRV FOR FATS**

	<b>Adults</b>	<b>Children<sup>1</sup></b>	<b>Pregnancy and lactation<sup>1</sup></b>
<b>Total fat</b>	RI = 20-35E%	>6-12 months, AI <sup>2</sup> = 40 E% 1-3 years, RI = 35-40 E% > 4 years, RI = 20-35 E%	RI = 20-35E%
<b>SFA</b>	As low as possible	As low as possible	As low as possible
<b>Cis-MUFA</b>	No DRV	No DRV	No DRV
<b>Cis-PUFA</b>	No DRV	No DRV	No DRV
<b>.n-3/n-6 ratio</b>	No recommendation	No recommendation	No recommendation
<b>.n-6 PUFA</b>	No DRV	No DRV	No DRV
<b>..LA</b>	AI <sup>3</sup> = 4 E%,	AI <sup>3</sup> = 4 E%,	AI <sup>3</sup> = 4 E%,
<b>..ARA</b>	No DRV	No DRV	No DRV
<b>.n-3 PUFA</b>	No DRV	No DRV	No DRV
<b>..ALA</b>	AI <sup>3</sup> = 0.5 E%	AI <sup>3</sup> = 0.5 E%	AI <sup>3</sup> = 0.5 E%
<b>..EPA+DHA</b>	AI = 250mg per day	AI 7-24 mths, DHA = 100 mg per day	RI: DHA+EPA = 250mg per day plus 100-200mg per day DHA
<b>TFA</b>	As low as possible	As low as possible	As low as possible
<b>CLA</b>	No DRV	No DRV	No DRV
<b>Cholesterol</b>	No reference value besides the limitation on the intake of SFA	No reference value besides the limitation on the intake of SFA	No reference value besides the limitation on the intake of SFA

<sup>1</sup> Dietary Reference Values are as for adults unless otherwise noted.

<sup>2</sup> Based upon experimentally derived estimates of adequate nutrient intake/ consensus reports (Aggett et al., 1994, Agostoni et al., 2008)

<sup>3</sup> Based on lowest estimated mean intakes in EU where overt deficiency symptoms are not present

## REFERENCES

- AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris, 605 pp.
- AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2005. Risques et bénéfices pour la santé des acides gras trans apportés par les aliments. Recommandations.
- AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2009. Avis de l'Agence française de sécurité sanitaire des aliments sur l'estimation des apports en acides gras trans de la population française. Request 2007-SA-220.
- Aggett PJ, Haschke F, Heine W, Hernell O, Koletzko B, Lafeber H, Ormission A, Rey J and Tormo R, 1994. Committee report: childhood diet and prevention of coronary heart disease. ESPGAN Committee on Nutrition. European Society of Pediatric Gastroenterology and Nutrition. *Journal of Pediatric Gastroenterology and Nutrition*, 19, 261-269.
- Agostoni C, Decsi T, Fewtrell M, Goulet O, Kolacek S, Koletzko B, Michaelsen KF, Moreno L, Puntis J, Rigo J, Shamir R, Szajewska H, Turck D and van Goudoever J, 2008. Complementary feeding: a commentary by the ESPGHAN Committee on Nutrition. *Journal of Pediatric Gastroenterology and Nutrition*, 46, 99-110.
- Agostoni C, Zuccotti GV, Radaelli G, Besana R, Podesta A, Sterpa A, Rottoli A, Riva E and Giovannini M, 2009. Docosahexaenoic acid supplementation and time at achievement of gross motor milestones in healthy infants: a randomized, prospective, double-blind, placebo-controlled trial. *American Journal of Clinical Nutrition*, 89, 64-70.
- Andersen N, Fagt S, Groth M, Hartkopp H, Møller A, Ovesen L and Warming D, 1996. Danskernes kostvaner (1995). Hovedresultater. Levnedsmiddelstyrelsen, Søborg.
- Angela Liou Y and Innis SM, 2009. Dietary linoleic acid has no effect on arachidonic acid, but increases n-6 eicosadienoic acid, and lowers dihomo-gamma-linolenic and eicosapentaenoic acid in plasma of adult men. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 80, 201-206.
- Anonymous, 2008. National Verzehrs Studie II. Ergebnisbericht, Teil 2. Max Rubner Institut. Bundesforschungsinstitut für Ernährung und Lebensmittel. Karlsruhe.
- Ascherio A, Hennekens CH, Buring JE, Master C, Stampfer MJ and Willett WC, 1994. Trans-fatty acids intake and risk of myocardial infarction. *Circulation*, 89, 94-101.
- Astorg P, 2004. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. *Cancer Causes and Control*, 15, 367-386.
- Babin F, Abderrazik M, Favier F, Cristol JP, Leger CL, Papoz L and Descomps B, 1999. Differences between polyunsaturated fatty acid status of non-institutionalised elderly women and younger controls: a bioconversion defect can be suspected. *European Journal of Clinical Nutrition*, 53, 591-596.
- Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P and Lau J, 2006. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. *Atherosclerosis*, 189, 19-30.
- Becker, Haglund M and Wretling S, 2008. Fat and fatty acids in the Swedish diet. Analysis of market baskets 2005. National Food Administration. Report No 17.
- Becker W and Pearson M, 2002. Riksmaten 1997-1998. Befolkningens kostvanor och näringsintag. Metod- och resultatanalys. Livsmedelsverket, Uppsala.



- Benito P, Nelson GJ, Kelley DS, Bartolini G, Schmidt PC and Simon V, 2001. The effect of conjugated linoleic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. *Lipids*, 36, 221-227.
- Berry SE, Miller GJ and Sanders TA, 2007a. The solid fat content of stearic acid-rich fats determines their postprandial effects. *American Journal of Clinical Nutrition*, 85, 1486-1494.
- Berry SE, Woodward R, Yeoh C, Miller GJ and Sanders TA, 2007b. Effect of interesterification of palmitic acid-rich triacylglycerol on postprandial lipid and factor VII response. *Lipids*, 42, 315-323.
- Bingham SA, Luben R, Welch A, Wareham N, Khaw KT and Day N, 2003. Are imprecise methods obscuring a relation between fat and breast cancer? *Lancet*, 362, 212-214.
- Birch EE, Garfield S, Castaneda Y, Hughbanks-Wheaton D, Uauy R and Hoffman D, 2007. Visual acuity and cognitive outcomes at 4 years of age in a double-blind, randomized trial of long-chain polyunsaturated fatty acid-supplemented infant formula. *Early Human Development*, 83, 279-284.
- Biró L, Regöly-Mérei A, Nagy K, Pintér B, Beretvás E, Morava E and Antal M, 2007. Dietary habits of schoolchildren: representative survey in metropolitan elementary schools: Part 2. *Annals of Nutrition and Metabolism*, 51, 454.
- Bjerve KS, 1989. n-3 fatty acid deficiency in man. *Journal of Internal Medicine*. Supplement, 731, 171-175.
- Bjerve KS, Fischer S, Wammer F and Egeland T, 1989. alpha-Linolenic acid and long-chain omega-3 fatty acid supplementation in three patients with omega-3 fatty acid deficiency: effect on lymphocyte function, plasma and red cell lipids, and prostanoid formation. *American Journal of Clinical Nutrition*, 49, 290-300.
- Bjerve KS, Mostad IL and Thoresen L, 1987. Alpha-linolenic acid deficiency in patients on long-term gastric-tube feeding: estimation of linolenic acid and long-chain unsaturated n-3 fatty acid requirement in man. *American Journal of Clinical Nutrition*, 45, 66-77.
- Boer EJ, Hulshof KFAM and ter Doest D, 2006. Voedselconsumptie bij jonge peuters. Report Nr. 6269. TNO, Zeist.
- Bonanome A and Grundy SM, 1989. Intestinal absorption of stearic acid after consumption of high fat meals in humans. *Journal of Nutrition*, 119, 1556-1560.
- Borugian MJ, Sheps SB, Kim-Sing C, Van Patten C, Potter JD, Dunn B, Gallagher RP and Hislop TG, 2004. Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? *Cancer Epidemiology, Biomarkers and Prevention*, 13, 1163-1172.
- Boulton TJ and Magarey AM, 1995. Effects of differences in dietary fat on growth, energy and nutrient intake from infancy to eight years of age. *Acta Paediatrica*, 84, 146-150.
- Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ and Minkin S, 2003. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. *British Journal of Cancer*, 89, 1672-1685.
- Brady LM, Lovegrove SS, Lesauvage SV, Gower BA, Minihaue AM, Williams CM and Lovegrove JA, 2004. Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians. *American Journal of Clinical Nutrition*, 79, 983-991.
- Brenna JT, Salem N, Jr., Sinclair AJ and Cunnane SC, 2009. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 80, 85-91.

- Brouwer IA, Katan MB and Zock PL, 2004. Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. *Journal of Nutrition*, 134, 919-922.
- Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A, Buschler H and Schouten EG, 2006. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. *JAMA*, 295, 2613-2619.
- Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA and Jebb SA, 2007. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. *Diabetes, Obesity and Metabolism*, 9, 70-80.
- Bucher HC, Hengstler P, Schindler C and Meier G, 2002. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. *American Journal of Medicine*, 112, 298-304.
- Burdge GC and Wootton SA, 2002. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. *British Journal of Nutrition*, 88, 411-420.
- Butte NF, 1996. Energy requirements of infants. *European Journal of Clinical Nutrition*, 50 Suppl 1, S24-36.
- Butte NF and King JC, 2005. Energy requirements during pregnancy and lactation. *Public Health Nutrition*, 8, 1010-1027.
- Calder PC, 2006. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *American Journal of Clinical Nutrition*, 83, 1505S-1519S.
- Carnielli VP, Luijendijk IH, Van Goudoever JB, Sulkers EJ, Boerlage AA, Degenhart HJ and Sauer PJ, 1996. Structural position and amount of palmitic acid in infant formulas: effects on fat, fatty acid, and mineral balance. *Journal of Pediatric Gastroenterology and Nutrition*, 23, 553-560.
- Carver JD, Benford VJ, Han B and Cantor AB, 2001. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. *Brain Research Bulletin*, 56, 79-85.
- Caspi A, Williams B, Kim-Cohen J, Craig IW, Milne BJ, Poulton R, Schalkwyk LC, Taylor A, Werts H and Moffitt TE, 2007. Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, 104, 18860-18865.
- Castetbon K, Vernay M, Malon A, Salanave B, Deschamps V, Roudier C, Oleko A, Szego E and Hercberg S, 2009. Dietary intake, physical activity and nutritional status in adults: the French nutrition and health survey (ENNS, 2006-2007). *British Journal of Nutrition*, 102, 733-743.
- Cederholm T and Palmblad J, 2010. Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? *Current Opinions in Clinical Nutrition Metabolic Care*, 13, 150-5.
- Chajes V, Thiebaut AC, Rotival M, Gauthier E, Maillard V, Boutron-Ruault MC, Joulin V, Lenoir GM and Clavel-Chapelon F, 2008. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. *American Journal of Epidemiology*, 167, 1312-1320.
- Chardigny JM, Destailats F, Malpuech-Brugère C, Moulin J, Bauman DE, Lock AL, Barbano DM, Mensink RP, Bezelgues JB, Chaumont P, Combe N, Cristiani I, Joffre F, German B, Dionisi F, Boirie Y and Sébédio JL, 2008. Do trans fatty acids from industrially produced sources and from

- natural sources have the same effect on cardiovascular diseases risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study. *American Journal of Clinical Nutrition*, 87, 558-566.
- Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL and Elashoff RM, 2006. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. *Journal of the National Cancer Institute*, 98, 1767-1776.
- Cho E, Spiegelman D, Hunter DJ, Chen WY, Stampfer MJ, Colditz GA and Willett WC, 2003. Premenopausal fat intake and risk of breast cancer. *Journal of the National Cancer Institute*, 95, 1079-1085.
- Cifkova R and Skodova Z, 2004. [Longitudinal trends in major cardiovascular disease risk factors in the Czech population]. *Casopis Lekarů Ceskych*, 143, 219-226.
- Clandinin MT, 1999. Brain development and assessing the supply of polyunsaturated fatty acid. *Lipids*, 34, 131-137.
- Clandinin MT, Chappell JE, Leong S, Heim T, Swyer PR and Chance GW, 1980a. Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. *Early Human Development*, 4, 121-129.
- Clandinin MT, Chappell JE, Leong S, Heim T, Swyer PR and Chance GW, 1980b. Extrauterine fatty acid accretion in infant brain: implications for fatty acid requirements. *Early Human Development*, 4, 131-138.
- Clarke R, Frost C, Collins R, Appleby P and Peto R, 1997. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. *BMJ (Clinical Research Ed.)*, 314, 112-117.
- Cole GM, Ma QL and Frautschy SA, 2009. Omega-3 fatty acids and dementia. *Prostaglandins Leukotriens and Essential Fatty Acids*, 81, 213-21.
- Couet C, Delarue J, Ritz P, Antoine JM and Lamisse F, 1997. Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. *International Journal of Obesity and Related Metabolic Disorders*, 21, 637-643.
- Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, Jakobsen MU, Johnsen NF, Tjønneland A, Linseisen J, Rohrmann S, Boeing H, Pischon T, Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Krogh V, Bueno-de-Mesquita HB, Kiemeneij LA, Chirlaque MD, Ardanaz E, Sanchez MJ, Larranaga N, Gonzalez CA, Quiros JR, Manjer J, Wirfalt E, Stattin P, Hallmans G, Khaw KT, Bingham S, Ferrari P, Slimani N, Jenab M and Riboli E, 2008. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *American Journal of Clinical Nutrition*, 87, 1405-1413.
- Cunnane SC, Francescutti V, Brenna JT and Crawford MA, 2000. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. *Lipids*, 35, 105-111.
- D'Amicis A, 2000. Il quadro nutrizionale della popolazione in Italia. *La Rivista di Scienza dell'Alimentazione*, 3, 7-11.
- D-A-CH (Deutsche Gesellschaft für Ernährung - Österreichische Gesellschaft für Ernährung - Schweizerische Gesellschaft für Ernährungsforschung - Schweizerische Vereinigung für Ernährung), 2000. Referenzwerte für die Nährstoffzufuhr. Umschau Braus Verlag, Frankfurt am Main.
- D-A-CH (Deutsche Gesellschaft für Ernährung - Österreichische Gesellschaft für Ernährung - Schweizerische Gesellschaft für Ernährungsforschung - Schweizerische Vereinigung für

- Ernährung), 2008. Referenzwerte für die Nährstoffzufuhr. Umschau Braus Verlag, Frankfurt am Main.
- De Vriese S, Huybrechts I, Moreau M and Van Oyen H, 2006. De Belgische Voedselconsumptiepeiling 1 - 2004. Brussel: Wetenschappelijk Instituut Volksgezondheid. [WIV/EPI Reports Nr. 2006-016].
- Deharveng G, Charrondiere UR, Slimani N, Southgate DA and Riboli E, 1999. Comparison of nutrients in the food composition tables available in the nine European countries participating in EPIC. European Prospective Investigation into Cancer and Nutrition. European Journal of Clinical Nutrition, 53, 60-79.
- Demmelmair H, Feldl F, Horvath I, Niederland T, Ruzinko V, Raederstorff D, De Min C, Muggli R and Koletzko B, 2001. Influence of formulas with borage oil or borage oil plus fish oil on the arachidonic acid status in premature infants. Lipids, 36, 555-566.
- DGE (Deutsche Gesellschaft für Ernährung), 2006. Evidenzbasierte Leitlinie Fettkonsum und Prävention ausgewählter ernährungsmitbedingter Krankheiten. Deutsche Gesellschaft für Ernährung, Bonn.
- Djousse L and Gaziano JM, 2008. Egg consumption and risk of heart failure in the Physicians' Health Study. Circulation, 117, 512-516.
- DoH (Department of Health), 1991. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy. HMSO, London.
- Dunstan JA, Simmer K, Dixon G and Prescott SL, 2008. Cognitive assessment of children at age 2.5 years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch. Dis. Child Fetal Neonatal 93, 45-50.
- EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the presence of trans fatty acids in foods and the effect on human health of the consumption of trans fatty acids. The EFSA Journal, 81, 1-49.
- EFSA (European Food Safety Authority), 2009. Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies on a request from Mead Johnson Nutritionals on DHA and ARA and visual development. The EFSA Journal, 94, 1-14.
- el Boustani S, Causse JE, Descomps B, Monnier L, Mendy F and Crastes de Paulet A, 1989. Direct in vivo characterization of delta 5 desaturase activity in humans by deuterium labeling: effect of insulin. Metabolism: Clinical and Experimental, 38, 315-321.
- Elmadfa I, ed 2009. European Nutrition and Health Report 2009. Forum of Nutrition Vol. 62. Karger, Basel, 426 pp.
- Elmadfa I, Freisling H, Nowak V, Hofstädter D, Hasenegger V, Ferge M, Fröhler M, Fritz K, Meyer AL, Putz P, Rust P, Grossgut R, Mischek D, Kiefer I, Schätzer M, Spanblöchel J, Sturtzel B, Wagner K-H, Zilberszac A, Vojir F and Plsek K, 2009. Österreichischer Ernährungsbericht 2008.
- Emken EA, Adlof RO and Gulley RM, 1994. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochimica et Biophysica Acta, 1213, 277-288.
- Enghardt-Barbieri H, Pearson M and Becker W, 2006. Riksmaten – Barn 2003. Livsmedels – och näringsintag bland barn i Sveige. Livsmedelsverket, Uppsala.

- Eurodiet, 2000. Eurodiet core report: Nutrition and diet for healthy lifestyles in Europe. Science and policy implications. Available from: [http://ec.europa.eu/health/ph\\_determinants/life\\_style/nutrition/report01\\_en.pdf](http://ec.europa.eu/health/ph_determinants/life_style/nutrition/report01_en.pdf)
- FAO/WHO (Food and Agriculture Organization/World Health Organization), 1994. Fats and oils in human nutrition. Report of a joint expert consultation, Rome, 19-26 October 1993. FAO Food and Nutrition Papers 57.
- Farquharson J, Cockburn F, Patrick WA, Jamieson EC and Logan RW, 1992. Infant cerebral cortex phospholipid fatty-acid composition and diet. *Lancet*, 340, 810-813.
- Finch S, Doyle W, Lowe C, Bates CJ, Prentice A, Smithers G and Clarke PC, 1998. National Diet and Nutrition Survey: people aged 65 years and over. TSO, London.
- Fjeld CR, Schoeller DA and Brown KH, 1989. A new model for predicting energy requirements of children during catch-up growth developed using doubly labeled water. *Pediatric Research*, 25, 503-508.
- Fotuhi M, Mohassel P and Yaffe K, 2009. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. *Nature Clinical Practice in Neurology*, 5, 140-52.
- Friedman G and Goldberg SJ, 1976. An evaluation of the safety of a low-saturated-fat, low-cholesterol diet beginning in infancy. *Pediatrics*, 58, 655-657.
- Fritsche K, 2006. Fatty acids as modulators of the immune response. *Annual Review of Nutrition*, 26, 45-73.
- Galeone C, Talamini R, Levi F, Pelucchi C, Negri E, Giacosa A, Montella M, Franceschi S and La Vecchia C, 2007. Fried foods, olive oil and colorectal cancer. *Annals of Oncology*, 18, 36-39.
- Gardner CD and Kraemer HC, 1995. Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 15, 1917-1927.
- Gaullier JM, Halse J, Hoivik HO, Høy K, Syvertsen C, Nurminiemi M, Hassfeldt C, Einerhand A, O'Shea M and Gudmundsen O, 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. *British Journal of Nutrition*, 97, 550-560.
- Gaullier JM, Halse J, Høy K, Kristiansen K, Fagertun H, Vik H and Gudmundsen O, 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. *American Journal of Clinical Nutrition*, 79, 1118-1125.
- Gebauer SK, Psota TL and Kris-Etherton PM, 2007. The diversity of health effects of individual trans fatty acid isomers. *Lipids*, 42, 787-799.
- Geelen A, Schouten JM, Kamphuis C, Stam BE, Burema J, Renkema JM, Bakker EJ, van't Veer P and Kampman E, 2007. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. *American Journal of Epidemiology*, 166, 1116-1125.
- Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR and Kok FJ, 2002. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. *Journal of Hypertension*, 20, 1493-1499.
- Gibson RA, Neumann MA and Makrides M, 1997. Effect of increasing breast milk docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural indices of exclusively breast fed infants. *European Journal of Clinical Nutrition*, 51, 578-584.
- Gibson RS, MacDonald CA, Smit Vanderkooy PD, McLennan CE and Mercer NJ, 1993. Dietary fat patterns of some Canadian preschool children in relation to indices of growth, iron, zinc, and dietary status. *Journal of the Canadian Dietetic Association*, 54, 33-37.



- Giugliano D, Ceriello A and Esposito K, 2006. The effects of diet on inflammation: emphasis on the metabolic syndrome. *Journal of the American College of Cardiology*, 48, 677-685.
- Gonzalez CA, 2006. The European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutrition*, 9, 124-126.
- Goyens PL and Mensink RP, 2006. Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects. *European Journal of Clinical Nutrition*, 60, 978-984.
- Goyens PL, Spilker ME, Zock PL, Katan MB and Mensink RP, 2006. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. *American Journal of Clinical Nutrition*, 84, 44-53.
- GR (Gezondheidsraad), 2001. Dietary Reference Intakes: energy, proteins, fats and digestible carbohydrates. Publication no. 2001/19R. Health Council of the Netherlands, The Hague.
- GR (Gezondheidsraad), 2006. Guidelines for healthy nutrition 2006. Publication no. 2006/21E. Health Council of the Netherlands, The Hague, 110 pp.
- Gregory J, Lowe S, Bates CJ, Prentice A, Jackson LV, Smithers G, Wenlock R and Farron M, 2000. National Diet and Nutrition Survey: young people aged 4 to 18 years. TSO, London.
- Griffin MD, Sanders TA, Davies IG, Morgan LM, Millward DJ, Lewis F, Slaughter S, Cooper JA, Miller GJ and Griffin BA, 2006. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study. *American Journal of Clinical Nutrition*, 84, 1290-1298.
- Hall MN, Chavarro JE, Lee IM, Willett WC and Ma J, 2008. A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. *Cancer Epidemiology, Biomarkers and Prevention*, 17, 1136-1143.
- Hansen AE, Wiese HF, Boelsche AN, Haggard ME, Adam DJD and Davis H, 1963. Role of linoleic acid in infant nutrition: clinical and chemical study of 428 infants fed on milk mixtures varying in kind and amount of fat. *Pediatrics*, 31, 171-192.
- Harris WS, Kris-Etherton PM and Harris KA, 2008. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. *Current Atherosclerosis Reports*, 10, 503-509.
- He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC and Ascherio A, 2003. Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. *BMJ (Clinical Research Ed.)*, 327, 777-782.
- He K, Song Y, Daviglius ML, Liu K, Van Horn L, Dyer AR, Goldbourt U and Greenland P, 2004b. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. *Stroke*, 35, 1538-1542.
- He K, Song Y, Daviglius ML, Liu K, Van Horn L, Dyer AR and Greenland P, 2004a. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. *Circulation*, 109, 2705-2711.
- Helland IB, Smith L, Saarem K, Saugstad OD and Drevon CA, 2003. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Pediatrics*, 111, e39-44.
- Henderson L, Gregory J, Irving K and Swan G, 2003. The National Diet & Nutrition Survey: adults aged 19 to 64 years. Volume 2. Energy, protein, carbohydrate, fat and alcohol intake. TSO, London.



- Henon G, Kemeny Z, Recseg K, Zwobada F and Kovari K, 1999. Deodorization of vegetable oils. Part I: Modelling the geometrical isomerization of polyunsaturated fatty acids. *Journal of the American Oil Chemists Society*, 76, 73-81.
- HHS/USDA (US Department of Health and Human Services/US Department of Agriculture), 2005. *Dietary Guidelines for Americans*.
- Hibbeln JR, 2002. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. *Journal of Affective Disorders*, 69, 15-29.
- Hilbig A and Kersting M, 2006. Effect of Age and time on energy and macronutrient intake in German infants and young children: Results of the DONALD study. *Journal of Pediatric Gastroenterology and Nutrition*, 43, 518-524.
- Hill AM, Buckley JD, Murphy KJ and Howe PR, 2007. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. *American Journal of Clinical Nutrition*, 85, 1267-1274.
- Hoffman DR, Theuer RC, Castaneda YS, Wheaton DH, Bosworth RG, O'Connor AR, Morale SE, Wiedemann LE and Birch EE, 2004. Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk. *Journal of Nutrition*, 134, 2307-2313.
- Holman RT, 1960. The ratio of trienoic: tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. *Journal of Nutrition*, 70, 405-410.
- Holman RT, Johnson SB and Hatch TF, 1982. A case of human linolenic acid deficiency involving neurological abnormalities. *American Journal of Clinical Nutrition*, 35, 617-623.
- Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB and Davey Smith G, 2006. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. *BMJ (Clinical Research Ed.)*, 332, 752-760.
- Howard BV, Manson JE, Stefanick ML, Beresford SA, Frank G, Jones B, Rodabough RJ, Snetselaar L, Thomson C, Tinker L, Vitolins M and Prentice R, 2006a. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. *JAMA*, 295, 39-49.
- Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC and Kotchen JM, 2006b. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*, 295, 655-666.
- Howell WH, McNamara DJ, Tosca MA, Smith BT and Gaines JA, 1997. Plasma lipid and lipoprotein responses to dietary fat and cholesterol: a meta-analysis. *American Journal of Clinical Nutrition*, 65, 1747-1764.
- Hu FB and Willett WC, 2002. Optimal diets for prevention of coronary heart disease. *JAMA*, 288, 2569-2578.
- Hulshof K, Kistemaker C and Bouman M, 1998. De inname van energie en voedingsstoffen door Nederlandse bevolkingsgroepen – Voedselconsumptiepeiling 1997-1998. TNO report V98.805, Zeist.

- Hulshof K and Ocké MC, 2005. Voedselconsumptiepeiling 2003: onderzoek bij jongvolwassen Nederlanders. Focus op macrovoedingsstoffen. *Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde*, 185-191.
- Hulshof KFAM, Jansen van der Vliet M, Westenbrink S and ter Doest D, 2004. De inneming van vetzuren en vetzuurclusters. (Voedselconsumptiepeiling 1997-1998). Report Nr. 5896, TNO, Zeist.
- Huybrechts I and De Henauw S, 2007. Energy and nutrient intakes by pre-school children in Flanders-Belgium. *British Journal of Nutrition*, 98, 600-610.
- Innis SM, 2007. Dietary (n-3) fatty acids and brain development. *Journal of Nutrition*, 137, 855-859.
- IoM (Institute of Medicine), 2005. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. National Academies Press, Washington DC.
- Issa AM, Mojica WA, Morton SC, Traina S, Newberry SJ, Hilton LG, Garland RH and Maclean CH, 2006. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review. *Dementia and Geriatric Cognitive Disorders*, 21, 88-96.
- Irish Universities Nutrition Alliance, Irish National Children's Food Survey. Available from: [www.iuna.net](http://www.iuna.net)
- Irish Universities Nutrition Alliance, North/South Ireland Food Consumption Survey. Available from: [www.iuna.net](http://www.iuna.net)
- Iso H, Stampfer MJ, Manson JE, Rexrode K, Hu F, Hennekens CH, Colditz GA, Speizer FE and Willett WC, 2001. Prospective study of fat and protein intake and risk of intraparenchymal hemorrhage in women. *Circulation*, 103, 856-863.
- Jayarajan P, Reddy V and Mohanram M, 1980. Effect of dietary fat on absorption of beta carotene from green leafy vegetables in children. *Indian Journal of Medical Research*, 71, 53-56.
- Jeppesen PB, Hoy CE and Mortensen PB, 1998. Essential fatty acid deficiency in patients receiving home parenteral nutrition. *American Journal of Clinical Nutrition*, 68, 126-133.
- Johansson L, Borgejordet A and Pedersen JI, 2006. [Trans fatty acids in the Norwegian diet]. *Tidsskrift for Den Norske Laegeforening*, 126, 760-763.
- Johansson L and Sovoll K, 1999. Norkost, 1997. Landsomfattende kostholdundersøkelse blant menn og kvinner i alderen 16-79 år. Statens råd för ernæring og fysisk aktivitet. Rapport nr. 2/1999.
- Kien CL, Bunn JY and Ugrasbul F, 2005. Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. *American Journal of Clinical Nutrition*, 82, 320-326.
- Kinsella JE, Lokesh B, Broughton S and Whelan J, 1990. Dietary polyunsaturated fatty acids and eicosanoids: potential effects on the modulation of inflammatory and immune cells: an overview. *Nutrition*, 6, 24-44; discussion 59-62.
- Knapp HR, 1997. Dietary fatty acids in human thrombosis and hemostasis. *American Journal of Clinical Nutrition*, 65, 1687S-1698S.
- Koh-Banerjee P, Chu NF, Spiegelman D, Rosner B, Colditz G, Willett W and Rimm E, 2003. Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. *American Journal of Clinical Nutrition*, 78, 719-727.
- Koletzko B, Cetin I and Brenna JT, 2007. Dietary fat intakes for pregnant and lactating women. *British Journal of Nutrition*, 98, 873-877.
- Koletzko B, Lien E, Agostoni C, Bohles H, Campoy C, Cetin I, Decsi T, Dudenhausen JW, Dupont C, Forsyth S, Hoesli I, Holzgreve W, Lapillonne A, Putet G, Secher NJ, Symonds M, Szajewska H, Willatts P and Uauy R, 2008. The roles of long-chain polyunsaturated fatty acids in pregnancy,

- lactation and infancy: review of current knowledge and consensus recommendations. *Journal of Perinatal Medicine*, 36, 5-14.
- Kontogianni MD, Zampelas A and Tsigos C, 2006. Nutrition and inflammatory load. *Annals of the New York Academy of Sciences*, 1083, 214-238.
- Kris-Etherton PM and Yu S, 1997. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. *American Journal of Clinical Nutrition*, 65, 1628S-1644S.
- Kruizinga AG, Westenbrink S, van den Bosch LMC and Jansen MCJF, 2007. De inneming van Omega-3 and -6 vetzuren en van vitamines A, D en E bij jongvolwassenen. Aanvullende berekeningen op basis van Voedselconsumptiepeiling 2003. NO rapport V7451. TNO, Zeist.
- Kyttälä P, Ovaskainen M, Kronberg-Kippilä C, Erkkola M, Tapanainen H, Tuokkola J, Veijola R, Simell O, Knap M and Virtanen SM, 2008. The Diet of Finnish Preschoolers. B32/2008. National Public Health Institute, Helsinki.
- Lagstrom H, Seppanen R, Jokinen E, Niinikoski H, Ronnema T, Viikari J and Simell O, 1999. Influence of dietary fat on the nutrient intake and growth of children from 1 to 5 y of age: the Special Turku Coronary Risk Factor Intervention Project. *American Journal of Clinical Nutrition*, 69, 516-523.
- Lambert EV, Goedecke JH, Bluett K, Heggie K, Claassen A, Rae DE, West S, Dugas J, Dugas L, Meltzer S, Charlton K and Mohede I, 2007. Conjugated linoleic acid versus high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. *British Journal of Nutrition*, 97, 1001-1011.
- Lande B and Andersen LF, 2005. Kosthold blant 2-åringer. Landsomfattende kostholdundersøkelse - Småbarnskost. Rapport nr. IS-1299. Sosial -og helsedirektorat, Oslo.
- Lanza E, Schatzkin A, Daston C, Corle D, Freedman L, Ballard-Barbash R, Caan B, Lance P, Marshall J, Iber F, Shike M, Weissfeld J, Slattery M, Paskett E, Mateski D and Albert P, 2001. Implementation of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial. *American Journal of Clinical Nutrition*, 74, 387-401.
- Lapillonne A and Jensen CL, 2009. Reevaluation of the DHA requirement for the premature infant. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 81, 143-150.
- Lapinleimu H, Viikari J, Jokinen E, Salo P, Routi T, Leino A, Ronnema T, Seppanen R, Valimaki I and Simell O, 1995. Prospective randomised trial in 1062 infants of diet low in saturated fat and cholesterol. *Lancet*, 345, 471-476.
- Larque E, Demmelmair H, Berger B, Hasbargen U and Koletzko B, 2003. In vivo investigation of the placental transfer of (13)C-labeled fatty acids in humans. *Journal of Lipid Research*, 44, 49-55.
- Larque E, Krauss-Etschmann S, Campoy C, Hartl D, Linde J, Klingler M, Demmelmair H, Cano A, Gil A, Bondy B and Koletzko B, 2006. Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins. *American Journal of Clinical Nutrition*, 84, 853-861.
- Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM and Ausman LM, 2003. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. *Atherosclerosis*, 171, 97-107.
- Linseisen J, Schulze MB, Saadatian-Elahi M, Kroke A, Miller AB and Boeing H, 2003. Quantity and quality of dietary fat, carbohydrate, and fiber intake in the German EPIC cohorts. *Annals of Nutrition and Metabolism*, 47, 37-46.

- Lim WS, Gammack JK, Van Niekerk J and Dangour AD, 2006. Omega 3 fatty acid for the prevention of dementia. *Cochrane Database of Systematic Reviews*, 25;(1):CD005379.
- Lyhne N, Christensen T, Groth M, Fagt S, Biloft-Jensen A, Hartkopp H, Hinsch H-J, Matthiessen J, Møller A, Saxholt E and Trolle E, 2005. Danskernes kostvaner 2000-2002. Hoved-resultater (Dietary habits in Denmark 2000-2002). Danmarks Fødevarerforskning, Publikation nr. 11.
- Maillard V, Bougnoux P, Ferrari P, Jourdan ML, Pinault M, Lavillonniere F, Body G, Le Floch O and Chajes V, 2002. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. *International Journal of Cancer*, 98, 78-83.
- Makrides M, Neumann MA, Byard RW, Simmer K and Gibson RA, 1994. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. *American Journal of Clinical Nutrition*, 60, 189-194.
- Manios Y, Grammatikaki E, Papoutsou S, Liarigkovinos T, Kondaki K and Moschonis G, 2008. Nutrient intakes of toddlers and preschoolers in Greece: the GENESIS study. *Journal of the American Dietetic Association*, 108, 357-361.
- Männistö S, Ovaskainen M-L and Valsta L, eds, 2003. The national Findiet 2002 study. Publications of the National Public Health Institute, Helsinki.
- Marangoni F, Agostoni C, Lammardo AM, Giovannini M, Galli C and Riva E, 2000. Polyunsaturated fatty acid concentrations in human hindmilk are stable throughout 12-months of lactation and provide a sustained intake to the infant during exclusive breastfeeding: an Italian study. *British Journal of Nutrition*, 84, 103-109.
- Martinez M, 1992. Tissue levels of polyunsaturated fatty acids during early human development. *Journal of Pediatrics*, 120, S129-138.
- Martinez M, 1994. Polyunsaturated fatty acids in the developing human brain, red cells and plasma: influence of nutrition and peroxisomal disease. *World Review of Nutrition and Dietetics*, 75, 70-78.
- Matthys C, De Henauw S, Devos C and De Backer G, 2003. Estimated energy intake, macronutrient intake and meal pattern of Flemish adolescents. *European Journal of Clinical Nutrition*, 57, 366-375.
- McEligot AJ, Largent J, Ziogas A, Peel D and Anton-Culver H, 2006. Dietary fat, fiber, vegetable, and micronutrients are associated with overall survival in postmenopausal women diagnosed with breast cancer. *Nutrition and Cancer*, 55, 132-140.
- Mensink GBM, Heseke H, Richter A, Stahl A and Vohmann C, 2007. Forschungsbericht: Ernährungsstudie als KiGGS-Modul (EsKiMo). Bonn.
- Mensink RP, Zock PL, Kester AD and Katan MB, 2003. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *American Journal of Clinical Nutrition*, 77, 1146-1155.
- Meyer KA, Kushi LH, Jacobs DR, Jr. and Folsom AR, 2001. Dietary fat and incidence of type 2 diabetes in older Iowa women. *Diabetes Care*, 24, 1528-1535.
- Michaelsen KF, 1997. Nutrition and growth during infancy. The Copenhagen Cohort Study. *Acta Paediatrica. Supplement*, 420, 1-36.
- Michaelsen KF and Jorgensen MH, 1995. Dietary fat content and energy density during infancy and childhood; the effect on energy intake and growth. *European Journal of Clinical Nutrition*, 49, 467-483.
- Miller GJ, 2005. Dietary fatty acids and the haemostatic system. *Atherosclerosis*, 179, 213-227.

- Moreira P, Padez C, Mourao I and Rosado V, 2005. Dietary calcium and body mass index in Portuguese children. *European Journal of Clinical Nutrition*, 59, 861-867.
- Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL and Katan MB, 2005. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. *Circulation*, 112, 1945-1952.
- Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ and Willett WC, 2006. Trans fatty acids and cardiovascular disease. *New England Journal of Medicine*, 354, 1601-1613.
- Mozaffarian D and Rimm EB, 2006. Fish intake, contaminants, and human health: evaluating the risks and the benefits. *JAMA*, 296, 1885-1899.
- Mozaffarian D, 2008. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. *American Journal of Clinical Nutrition*, 87, 1991S-1996S.
- Mozaffarian D and Clarke R, 2009. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. *European Journal of Clinical Nutrition*, 63 Suppl 2, S22-33.
- Naumann E, Carpentier YA, Saebo A, Lassel TS, Chardigny JM, Sebedio JL and Mensink RP, 2006. Cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid (CLA) do not affect the plasma lipoprotein profile in moderately overweight subjects with LDL phenotype B. *Atherosclerosis*, 188, 167-174.
- Nelson GJ, Schmidt PC, Bartolini G, Kelley DS, Phinney SD, Kyle D, Silbermann S and Schaefer EJ, 1997. The effect of dietary arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. *Lipids*, 32, 427-433.
- Nestel P, Clifton P and Noakes M, 1994. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. *Journal of Lipid Research*, 35, 656-662.
- Nicklas TA, Webber LS, Koschak M and Berenson GS, 1992. Nutrient adequacy of low fat intakes for children: the Bogalusa Heart Study. *Pediatrics*, 89, 221-228.
- Niinikoski H, Viikari J, Ronnema T, Lapinleimu H, Jokinen E, Salo P, Seppanen R, Leino A, Tuominen J, Valimaki I and Simell O, 1996. Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project. *Circulation*, 94, 1386-1393.
- NNR (Nordic Nutrition Recommendations), 2004. Integrating nutrition and physical activity. Nordic Council of Ministers, Copenhagen, 436 pp.
- Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr., Brehm BJ and Bucher HC, 2006. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Archives of Internal Medicine*, 166, 285-293.
- Ocke MC, van Rossum CTM, Fransen HP, Buurma EJM, de Boer EJ, Brants HAM, Niekerk EM, van der Laan JD, Drijvers JJMM and Ghameshlou Z, 2008. Dutch National Food Consumption Survey - Young Children 2005/2006. Report 350070001/2008, Bilthoven.
- Ordovas JM, 2009. Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. *American Journal of Clinical Nutrition*, 89, 1509S-1517S.
- Otto SJ, Houwelingen AC, Antal M, Manninen A, Godfrey K, Lopez-Jaramillo P and Hornstra G, 1997. Maternal and neonatal essential fatty acid status in phospholipids: an international comparative study. *European Journal of Clinical Nutrition*, 51, 232-242.



- Otto SJ, van Houwelingen AC, Badart-Smook A and Hornstra G, 2001. Changes in the maternal essential fatty acid profile during early pregnancy and the relation of the profile to diet. *American Journal of Clinical Nutrition*, 73, 302-307.
- Øverby NC and Andersen LF, 2002. Ungkost, 2000. Landsomfattende kostholdundersøkelse blant elever i 4.- og 8. klasse i Norge. Sosial -og helsedirektorat, avdeling for ernærning, Oslo.
- Paturi M, Tapanainen H, Reinivuo H and Pietinen P, eds, 2008. The National FINDIET 2007 Survey. National Public Health Institute, Helsinki.
- Paturi M, Tapanainen H, Reinivuo H and Pietinen P, 2008. The National FINDiet 2007 Survey. Report B23/2008. KTL-National Public Health Institute, Helsinki.
- Piers LS, Walker KZ, Stoney RM, Soares MJ and O'Dea K, 2003. Substitution of saturated with monounsaturated fat in a 4-week diet affects body weight and composition of overweight and obese men. *British Journal of Nutrition*, 90, 717-727.
- Pietinen P, 1994. Dietary fat and blood pressure. *Annals of Medicine*, 26, 465-468.
- Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes D and Virtamo J, 1997. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *American Journal of Epidemiology*, 145, 876-887.
- Plourde M and Cunnane SC, 2007. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Applied Physiology, Nutrition, and Metabolism*, 32, 619-634.
- Pomerleau J, McKee M, Robertson A, Kadziauskiene K, Abaravicius A, Vaask S, Pudule I and Grinberga D, 2001. Macronutrient and food intake in the Baltic republics. *European Journal of Clinical Nutrition*, 55, 200-207.
- Precht D, Molkestin J, Destailats F and Wolff RL, 2001. Comparative studies on individual isomeric 18:1 acids in cow, goat, and ewe milk fats by low-temperature high-resolution capillary gas-liquid chromatography. *Lipids*, 36, 827-832.
- Prentice AM and Goldberg GR, 2000. Energy adaptations in human pregnancy: limits and long-term consequences. *American Journal of Clinical Nutrition*, 71, 1226S-1232S.
- Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL and Henderson MM, 2006. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*, 295, 629-642.
- Raff M, Tholstrup T, Sejrnsen K, Straarup EM and Wiinberg N, 2006. Diets rich in conjugated linoleic acid and vaccenic acid have no effect on blood pressure and isobaric arterial elasticity in healthy young men. *Journal of Nutrition*, 136, 992-997.
- Riccardi G, Giacco R and Rivellese AA, 2004. Dietary fat, insulin sensitivity and the metabolic syndrome. *Clinical Nutrition*, 23, 447-456.
- Riserus U, 2008. Fatty acids and insulin sensitivity. *Current Opinion in Clinical Nutrition and Metabolic Care*, 11, 100-105.



- Riserus U, Arner P, Brismar K and Vessby B, 2002. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. *Diabetes Care*, 25, 1516-1521.
- Riserus U, Vessby B, Arnlov J and Basu S, 2004. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. *American Journal of Clinical Nutrition*, 80, 279-283.
- Rodler I, Bíró L, Greiner E, Zajkás G, Szórád I, Varga A, Domonkos A, Ágoston H, Balázs A, Mozsáry E, Vitrai J, Hermann D, Boros J, Németh R and Kéki Z, 2005. Táplálkozási vizsgálat Magyarországon, 2003–2004. Energia- és makrotápanyagbevitel [Dietary survey in Hungary, 2003–2004. Energy and macro-nutrient intake]. *Orvosi Hetilap [Hung Med J]*, 146, 1781–1789.
- Rouillier P, Senesse P, Cottet V, Valleau A, Faivre J and Boutron-Ruault MC, 2005. Dietary patterns and the adenocarcinoma sequence of colorectal cancer. *European Journal of Nutrition*, 44, 311-318.
- Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E and Williamson DA, 2009. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *New England Journal of Medicine*, 360, 859-873.
- Sacks FM and Katan M, 2002. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. *American Journal of Medicine*, 113 Suppl 9B, 13S-24S.
- SACN (Scientific Advisory Committee on Nutrition), 2004. Advice on fish consumption: benefits and risks. TSO, London.
- SACN (Scientific Advisory Committee on Nutrition), 2007. Update on trans fatty acids and health – Position statement by the Scientific Advisory Committee on Nutrition. TSO, London.
- Salas-Salvado J, Marquez-Sandoval F and Bullo M, 2006. Conjugated linoleic acid intake in humans: a systematic review focusing on its effect on body composition, glucose, and lipid metabolism. *Critical Reviews in Food Science and Nutrition*, 46, 479-488.
- Salem N, Jr., Wegher B, Mena P and Uauy R, 1996. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. *Proceedings of the National Academy of Sciences of the United States of America*, 93, 49-54.
- Salmeron J, Hu FB, Manson JE, Stampfer MJ, Colditz GA, Rimm EB and Willett WC, 2001. Dietary fat intake and risk of type 2 diabetes in women. *American Journal of Clinical Nutrition*, 73, 1019-1026.
- Sanders TA, Ellis FR and Dickerson JW, 1978. Studies of vegans: the fatty acid composition of plasma choline phosphoglycerides, erythrocytes, adipose tissue, and breast milk, and some indicators of susceptibility to ischemic heart disease in vegans and omnivore controls. *American Journal of Clinical Nutrition*, 31, 805-813.
- SCF (Scientific Committee on Food), 1992. Report on nutrient and energy intakes for the European Community, 31st Series. European Commission, Luxembourg.
- Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, Demmelmair H, Illig T, Koletzko B and Heinrich J, 2006. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Human Molecular Genetics*, 15, 1745-1756.
- Schirmer MA and Phinney SD, 2007. Gamma-linolenate reduces weight regain in formerly obese humans. *Journal of Nutrition*, 137, 1430-1435.

- Schulz M, Hoffmann K, Weikert C, Nothlings U, Schulze MB and Boeing H, 2008. Identification of a dietary pattern characterized by high-fat food choices associated with increased risk of breast cancer: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. *British Journal of Nutrition*, 100, 942-946.
- Seppanen-Laakso T, Laakso I, Backlund P, Vanhanen H and Viikari J, 1996. Elaidic and trans-vaccenic acids in plasma phospholipids as indicators of dietary intake of 18:1 trans-fatty acids. *Journal of Chromatography B, Biomedical Applications*, 687, 371-378.
- Serra Majem L and Ribas Barba L, eds, 2007. Trends in Nutrition Status in Catalonia, Spain (1992–2003). *Public Health Nutrition*, 10, 1339–1414.
- Serra Majem L, Ribas Barba L, Salvador Castell G, Castell Abat C, Román Viñas B, Serra Farró J and et al., 2006. Avaluació de l'estat nutricional de la població catalana 2002–2003. Evolució dels hàbits alimentaris i el consum d'aliments i nutrients a Catalunya (1992–2003). Departament de Salut, Generalitat de Catalunya, Barcelona
- Serra-Majem L, Ribas-Barba L, Salvador G, Jover L, Raido B, Ngo J and Plasencia A, 2007. Trends in energy and nutrient intake and risk of inadequate intakes in Catalonia, Spain (1992-2003). *Public Health Nutrition*, 10, 1354-1367.
- Shah M, Adams-Huet B and Garg A, 2007. Effect of high-carbohydrate or high-cis-monounsaturated fat diets on blood pressure: a meta-analysis of intervention trials. *American Journal of Clinical Nutrition*, 85, 1251-1256.
- Shannon J, King IB, Moshofsky R, Lampe JW, Gao DL, Ray RM and Thomas DB, 2007. Erythrocyte fatty acids and breast cancer risk: a case-control study in Shanghai, China. *American Journal of Clinical Nutrition*, 85, 1090-1097.
- Shea S, Basch CE, Stein AD, Contento IR, Irigoyen M and Zybert P, 1993. Is there a relationship between dietary fat and stature or growth in children three to five years of age? *Pediatrics*, 92, 579-586.
- Sieri S, Krogh V, Ferrari P, Berrino F, Pala V, Thiebaut AC, Tjonneland A, Olsen A, Overvad K, Jakobsen MU, Clavel-Chapelon F, Chajes V, Boutron-Ruault MC, Kaaks R, Linseisen J, Boeing H, Nothlings U, Trichopoulou A, Naska A, Lagiou P, Panico S, Palli D, Vineis P, Tumino R, Lund E, Kumle M, Skeie G, Gonzalez CA, Ardanaz E, Amiano P, Tormo MJ, Martinez-Garcia C, Quiros JR, Berglund G, Gullberg B, Hallmans G, Lenner P, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, van Gils CH, Key TJ, Crowe FL, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Norat T and Riboli E, 2008. Dietary fat and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. *American Journal of Clinical Nutrition*, 88, 1304-1312.
- Simmer K, Patole SK and Rao SC, 2008. Longchain polyunsaturated fatty acid supplementation in infants born at term. *Cochrane Database of Systematic Reviews*, CD000376.
- Sioen I, Huybrechts I, Verbeke W, Camp JV and De Henauw S, 2007. n-6 and n-3 PUFA intakes of pre-school children in Flanders, Belgium. *British Journal of Nutrition*, 98, 819-825.
- Stoneham M, Goldacre M, Seagroatt V and Gill L, 2000. Olive oil, diet and colorectal cancer: an ecological study and a hypothesis. *Journal of Epidemiology and Community Health*, 54, 756-760.
- Syvertsen C, Halse J, Hoivik HO, Gaullier JM, Nurminiemi M, Kristiansen K, Einerhand A, O'Shea M and Gudmundsen O, 2007. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese. *Int J Obes (Lond)*, 31, 1148-1154.
- Tanasescu M, Cho E, Manson JE and Hu FB, 2004. Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. *American Journal of Clinical Nutrition*, 79, 999-1005.

- Terpstra AH, 2004. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. *American Journal of Clinical Nutrition*, 79, 352-361.
- Thiebaut AC, Kipnis V, Chang SC, Subar AF, Thompson FE, Rosenberg PS, Hollenbeck AR, Leitzmann M and Schatzkin A, 2007. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. *Journal of the National Cancer Institute*, 99, 451-462.
- Thijssen MA and Mensink RP, 2005. Fatty acids and atherosclerotic risk. In: *Atherosclerosis: Diet and Drugs*. Ed von Eckardstein A. Springer-Verlag, Berlin, Heidelberg, 165-194.
- Tricon S, Burdge GC, Kew S, Banerjee T, Russell JJ, Jones EL, Grimble RF, Williams CM, Yaqoob P and Calder PC, 2004. Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans. *American Journal of Clinical Nutrition*, 80, 614-620.
- Twisselmann B, 2006. Risks and benefits of omega 3 fats Summary of responses. *British Medical Journal*, 332, 915-916.
- Uematsu T, Nagashima S, Niwa M, Kohno K, Sassa T, Ishii M, Tomono Y, Yamato C and Kanamaru M, 1996. Effect of dietary fat content on oral bioavailability of menatetrenone in humans. *Journal of Pharmaceutical Sciences*, 85, 1012-1016.
- USDA ARS (United States Department of Agriculture - Agricultural Research Service), USDA National Nutrient Database for Standard Reference. Available from: [http://www.ars.usda.gov/main/site\\_main.htm?modecode=12-35-45-00](http://www.ars.usda.gov/main/site_main.htm?modecode=12-35-45-00)
- van Dam RM and Seidell JC, 2007. Carbohydrate intake and obesity. *European Journal of Clinical Nutrition*, 61 Suppl 1, S75-99.
- van Dam RM, Willett WC, Rimm EB, Stampfer MJ and Hu FB, 2002. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. *Diabetes Care*, 25, 417-424.
- Vessby B, Unsitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, Nalsen C, Berglund L, Louheranta A, Rasmussen BM, Calvert GD, Maffetone A, Pedersen E, Gustafsson IB and Storlien LH, 2001. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. *Diabetologia*, 44, 312-319.
- Virtanen JK, Mozaffarian D, Chiuve SE and Rimm EB, 2008. Fish consumption and risk of major chronic disease in men. *American Journal of Clinical Nutrition*, 88, 1618-1625.
- Vorster HH, Cummings JH and Veldman FJ, 1997. Diet and haemostasis: time for nutrition science to get more involved. *British Journal of Nutrition*, 77, 671-684.
- Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS and Lau J, 2006. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *American Journal of Clinical Nutrition*, 84, 5-17.
- WCRF/AICR (World Cancer Research Fund/American Institute for Cancer Research), 2007. *Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective*.
- Weggemans RM, Zock PL and Katan MB, 2001. Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans: a meta-analysis. *American Journal of Clinical Nutrition*, 73, 885-891.
- Wensing AG, Mensink RP and Hornstra G, 1999. Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects. *British Journal of Nutrition*, 82, 183-191.

- Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A and Yki-Jarvinen H, 2005. Dietary fat content modifies liver fat in overweight nondiabetic subjects. *Journal of Clinical Endocrinology and Metabolism*, 90, 2804-2809.
- Whigham LD, Watras AC and Schoeller DA, 2007. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. *American Journal of Clinical Nutrition*, 85, 1203-1211.
- WHO/FAO (World Health Organization/Food and Agriculture Organization), 2003. Expert Report: Diet, nutrition and prevention of chronic diseases. Report of a Joint WHO/FAO Expert Consultation. WHO Technical Report Series 916.
- Willett WC, 2006. Trans fatty acids and cardiovascular disease-epidemiological data. *Atherosclerosis Supplements*, 7, 5-8.
- Willett WC, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Rosner BA, Sampson LA and Hennekens CH, 1993. Intake of trans fatty acids and risk of coronary heart disease among women. *Lancet*, 341, 581-585.
- Wolff RL, Combe NA, Destailats F, Boue C, Precht D, Molkentin J and Entressangles B, 2000. Follow-up of the delta4 to delta16 trans-18:1 isomer profile and content in French processed foods containing partially hydrogenated vegetable oils during the period 1995-1999. Analytical and nutritional implications. *Lipids*, 35, 815-825.
- Yuhas R, Pramuk K and Lien EL, 2006. Human milk fatty acid composition from nine countries varies most in DHA. *Lipids*, 41, 851-858.
- Zajkas G, Biro L, Greiner E, Szorad I, Agoston H, Balazs A, Vitrai J, Hermann D, Boros J, Nemeth R, Keki Z and Martos E, 2007. [Dietary survey in Hungary, 2003-2004. Micronutrients: vitamins]. *Orvosi Hetilap*, 148, 1593-1600.

## ANNEXES

### ANNEX 1A POPULATION, METHODS AND PERIOD OF DIETARY ASSESSMENT IN CHILDREN AND ADOLESCENTS IN EUROPEAN COUNTRIES.

Country	Population	Dietary method	Year of survey	Reference
<b>AT</b>	Boys and girls aged 7-9 years	3-day record	2007	Elmadfa et al., 2009
	Boys and girls aged 10-14 years	3-day record	2007	Elmadfa et al., 2009
	Boys and girls aged 14-19 years	24-hour recall	2003-2004	Elmadfa et al., 2009
<b>BE</b>	Boys and girls aged 2.5-3 years	3-day record	2002-2003	Huybrechts and DeHenaauw, 2007; Sioen et al., 2007
	Boys and girls aged 4-6.5 years	3-day record	2002-2003	Huybrechts and DeHenaauw, 2007; Sioen et al., 2007
	Boys and girls aged 13-15 years	7-day record	1997	Matthys et al., 2003
	Boys and girls aged 15-18	2x 24-hour recall	2004	De Vriese et al., 2006
<b>CZ</b>	Boys and girls aged 4-6 years	2x 24-hour recall	n.a. <sup>1</sup>	Tláškas, Hrstková. (unpublished data) (In: Elmadfa, 2009)
	Boys and girls aged 7-9 years	2x 24-hour recall	n.a.	Tláškas, Hrstková. (unpublished data) (In: Elmadfa, 2009)
<b>DE</b>	Infants aged 12 months	3-day record	1989-2003	Hilbig and Kersting, 2006
	Children aged 18 months	3-day record	1989-2003	Hilbig and Kersting, 2006
	Children aged 2 years	3-day record	1989-2003	Hilbig and Kersting, 2006
	Children aged 3 years	3-day record	1989-2003	Hilbig and Kersting, 2006
	Boys and girls aged 6 years	3-day record	2006	Mensink et al., 2007
	Boys and girls aged 7-9 years	3-day record	2006	Mensink et al., 2007
	Boys and girls aged 10-11 years	3-day record	2006	Mensink et al., 2007
	Boys and girls aged 12 years	Dietary history (over the last 4 weeks)*	2006	Mensink et al., 2007
	Boys and girls aged 13-14 years	Dietary history (over the last 4 weeks)*	2006	Mensink et al., 2007
Boys and girls aged 15-17 years	Dietary history (over the last 4 weeks)*	2006	Mensink et al., 2007	
<b>DK</b>	Boys and girls aged 1-3 years	7-day record	1995	Andersen et al., 1996
	Boys and girls aged 4-5 years	7-day record	2000-2002	Lyhne et al., 2005
	Boys and girls aged 6-9 years	7-day record	2000-2002	Lyhne et al., 2005
	Boys and girls aged 10-13 years	7-day record	2000-2002	Lyhne et al., 2005
	Boys and girls aged 14-17 years	7-day record	2000-2002	Lyhne et al., 2005
<b>FI</b>	Infants aged 8 months	3-day record	1999	Lagstrom, 1999
	Children aged 3 years	4-day record	1999	Lagstrom, 1999
	Children aged 4 years	4 day record	1999	Lagstrom, 1999
	Children aged 4 years	3-day record	2008	Kyttälä et al., 2008

Country	Population	Dietary method	Year of survey	Reference
	Children aged 6 years	3-day record	2008	Kyttälä et al., 2008
<b>FR</b>	Boys and girls aged 4-6 years	3x 24-hour recall	2006-2007	Castetbon et al. 2009 (In: Elmadfa, 2009)
	Boys and girls aged 7-9 years	3x 24-hour recall	2006-2007	Castetbon et al. 2009 (In: Elmadfa, 2009)
	Boys and girls aged 10-14 years	3x 24-hour recall	2006-2007	Castetbon et al. 2009 (In: Elmadfa, 2009)
	Boys and girls aged 15-18 years	3x 24-hour recall	2006-2007	Castetbon et al. 2009 (In: Elmadfa, 2009)
<b>GR</b>	Boys and girls aged 4-5 years	3-day record+24-hour recall / 3-day record	2003-2004	Manios et al., 2006
<b>HU</b>	Boys and girls aged 11-14 years	3x 24-hour recall	2005-2006	Biro et al., 2007. (In: Elmadfa, 2009)
<b>IE</b>	Boys and girls 5-8 years	7-day record	2003-2004	Irish University Nutrition Alliance Irish National Children's Food Survey. <a href="http://www.iuna.net">www.iuna.net</a>
	Boys and girls 9-12 years	7-day record	2003-2004	Irish University Nutrition Alliance Irish National Children's Food Survey. <a href="http://www.iuna.net">www.iuna.net</a>
<b>IT</b>	Boys and girls 4-6 years	7-day record	n.a	D'Amicis, 2000
	Boys and girls 7-9 years	7-day record	n.a	D'Amicis, 2000
	Boys and girls 10-14 years	7-day record	n.a	D'Amicis, 2000
	Boys and girls 15-18 years	7-day record	n.a	D'Amicis, 2000
<b>NL</b>	Infants aged 9 month	2-day record (independent days)	2002	Boer et al., 2006
	Infants aged 12 months	2-day record (independent days)	2002	Boer et al., 2006
	Children aged 18 months	2-day record (independent days)	2002	Boer et al., 2006
	Boys and girls aged 2-3 years	2-day record (independent days)	2005-2006	Ocke et al., 2008
	Boys and girls aged 4-6 years	2-day record (independent days)	2005-2006	Ocke et al., 2008
	Boys and girls aged 7-9 years	2-day record	1997-1998	Hulshof et al., 2004
	Boys and girls aged 9-13 years	2-day record	1997-1998	Hulshof et al., 2004
	Boys and girls aged 14-18 years	2-day record	1997-1998	Hulshof et al., 2004
<b>NO</b>	Children aged 2 years	Food Frequency Questionnaire	1998-1999	Lande and Anderson, 2005
	Boys and girls aged 4 years	4-day record	2000	Øverby and Andersen, 2002
	Boys and girls aged 9 years	4-day record	2000	Øverby and Andersen, 2002
	Boys and girls aged 13	4-day record	2000	Øverby and Andersen, 2002
	Boys and girls aged 16-19 years	Food Frequency Questionnaire	1997	Johansson and Solvoll, 1999
<b>PL</b>	Boys and girls aged 4-6 years	24-hour recall	2000	Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009)
	Boys and girls aged 7-9 years	24-hour recall	2000	Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009)



Country	Population	Dietary method	Year of survey	Reference
	Boys and girls aged 10-14 years	24-hour recall	2000	Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009)
	Boys and girls aged 15-18 years	24-hour recall	2000	Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009)
<b>PT</b>	Boys and girls aged 7-9 years	24-hour recall	2000-2002	Moreira et al., 2005
	Boys and girls aged 13 years	24-hour recall	2000-2002	Moreira et al., 2005
<b>SI</b>	Boys and girls aged 14-17 years	Food Frequency Questionnaire	n.a.	Fidler Mis et al. (unpublished data) (In: Elmadfa, 2009)
<b>ES</b>	Boys and girls aged 10-14 years	2x 24-hour recall	2002-2003	Serra Majem and Ribas, 2007; Serra Majem et al., 2006 and 2007 (In: Elmadfa, 2009)
	Boys and girls aged 15-18 years	2x 24-hour recall	2002-2003	Serra Majem and Ribas, 2007; Serra Majem et al., 2006 and 2007 (In: Elmadfa, 2009)
<b>SE</b>	Boys and girls aged 4 years	4-day record	2003	Enghardt-Barbieri et al., 2006
	Boys and girls aged 8-9 years	4-day record	2003	Enghardt-Barbieri et al., 2006
	Boys and girls aged 11-12 years	4-day record	2003	Enghardt-Barbieri et al., 2006
<b>UK</b>	Boys and girls aged 4-6 years	7-day record	1997	Gregory et al., 2000
	Boys and girls aged 7-10 years	7-day record	1997	Gregory et al., 2000
	Boys and girls aged 11-14 years	7-day record	1997	Gregory et al., 2000
	Boys and girls aged 15-18 years	7-day record	1997	Gregory et al., 2000

<sup>1</sup>n.a. = not available

**ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~1-3 YEARS IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Infants and Toddlers</b>																				
DE	12 mo	432	34.3	5.2																
	18 mo	478	36.2	6.0																
	2 mo	458	37.0	5.9																
	3 mo	427	36.7	5.8																
FI	8 mo	215	28.8	4.1		12.6	2.3		8.7	1.5		4.9	0.8							
	13 mo	449	28	5.0		12.4	3.1		8.8	2.0		3.8	1.3							
	2 mo	398	33	4.8		14.5	3.0		10.8	2.0		4.4	1.4							
	3 mo	359	33	4.6		14.7	2.6		10.9	1.9		4.7	1.2							
NL	9 mo	333	25.6	3.7	25.0-34.2 <sup>1</sup>	11.5	1.5	9.7-13.5 <sup>1</sup>	10.9	1.7	8.7-12.9 <sup>1</sup>	5.3	1.3	3.8-7.0 <sup>1</sup>	0.1	0.1	0.0-0.2 <sup>1</sup>			
	12 mo	306	28.3	4.2	23.0-33.6 <sup>1</sup>	11.4	1.9	9.2-13.8 <sup>1</sup>	9.5	2.1	6.8-12.1 <sup>1</sup>	5.0	1.4	3.4-6.8 <sup>1</sup>	0.2	0.1	0.1-0.3 <sup>1</sup>			
	18 mo	302	27.1	3.8	22.3-32.1 <sup>1</sup>	11.8	1.8	6.4-98.0	4.5	1.3	2.9-6.2 <sup>1</sup>	3.5	1.3	2.1-5.2 <sup>1</sup>	0.3	0.1	0.2-0.5 <sup>1</sup>			
NO	2 mo	172	33.3	5.1		14.2	2.7		10.4	1.8		5.7	1.9							
<b>Pre-school children</b>																				
<b>Males</b>																				
BE	2.5-3	102	29.2	3.8		13.0	2.7		10.4	1.3		4.4	1.3					159	32	
DK	1-3	129	36			17			10			5						207		
NL	2-3	313	29		22-37	11		8-15	15		10-20			0.8		0.5-1.0				
<b>Females</b>																				
BE	2.5-3	95	30.3	5.0		13.8	2.6		10.8	2.0		4.3	1.1					165	37	
DK	1-3	149	36			17			10			4						221		
NL	2-3	313	29		23-35	11		9-14	15		11-19			0.7		0.5-1.1				

<sup>1</sup>P10-P90; <sup>2</sup>E; <sup>3</sup>P2.5-97.5

**ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~4-6 YEARS IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
BE	4-6.5	236	30.1	3.9		13.4	2.0		10.8	1.4		4.5	1.2					171	36	
CZ	4-6	641	30.0	5.3														241	111	
DE	6	106	32.6	6.1	23.4-44.3	15.3	2.9		12.5	2.2		4.8	1.0					247	103	110-480
DK	4-5	82	34.0	3.9	28-40	15.0	2.2	12-18	12.0	1.5	10-14	4.7	0.8	3.5-6.1	0.7	0.2	0.4-0.9			
FI	4	307	31.0			13.7			10.6			4.0						153	53	
	6	364	31.0			13.5			10.8			4.2						180	60	
FR	4-6	164	34.7	0.84 <sup>1</sup>		15.1														
GR	4-5	356	40.2	5.0		14.5	2.9													
IT	4-6	21	34.3	5.5		10.9	2.5		10.6	3.4		4.1	1.5					328	105	
NL	4-6	327	31.0		24-37	12.0		9-15	16.0		12-20				0.8		0.6-1.1			
NO	4	206	33.0	5.0		14.0	2.0		10.0	2.0		6.0	2.0					185	82	
PL	4-6	82	31.9	7.8		11.6	3.9		13.7	4.1		4.5	2.2					240	145	
SE	4	302	31.3	4.2	26.4-38.5	14.3	2.4	10.2-18.2	11.1	1.7	8.7-14.3	3.7	1.0	2.4-5.4	0.9	0.4	0.5-1.5	196	73	97-336
UK	4-6	184	35.5	3.9	27.9-42.5 <sup>2</sup>	14.8	2.4	10.6-19.7 <sup>2</sup>	11.5	1.6	8.5-15.0	5.5	1.3	3.1-8.5 <sup>2</sup>	1.3	0.3	0.8-2.0 <sup>2</sup>	158	71	64-330 <sup>2</sup>
<b>Females</b>																				
BE	4-6.5	228	29.7	3.2		13.5	1.7		10.6	1.5		4.4	1.0					145	30	
CZ	4-6	446	30.0	5.3																
DE	6	102	32.2	4.6	24.4-38.7	15.2	2.0		12.1	1.6		4.9	1.1					201	89	95-453
DK	4-5	77	35.0	4.5	29-42	16.0	3.1	12-18	12.0	1.7	10-14	4.8	0.8	3.6-6.3	0.6	0.2	0.4-0.9			
FI	4	307	31.0			13.7			10.6			4.0						139	51	
	6	349	31.0			1.8			10.7			4.1						156	56	
FR	4-6	162	36.3	0.5 <sup>1</sup>		15.8														
GR	4-5	389	40.5	5.0		14.4	2.9													
IT	4-6	17	33.8	3.5		10.8	2.0		9.7	2.3		4.0	1.2					327.1	107	
NL	4-6	312	31.0		25-36	12.0		10-15	15.0		12-19				0.8		0.6-1.1			
NO	4	185	32.0	5.0		14.2	3.0		10.0	2.0		6.0	2.0					174	65	
PL	4-6	84	32.5	7.0		12.0	3.3		13.6	3.9		4.7	2.2					245	176	
SE	4	288	32.1	4.6	24.6-39.5	14.6	2.5	10.9-18.7	11.5	1.9	8.5-14.5	3.7	0.9	2.5-5.3	0.9	0.3	0.5-1.6	187	68	93-312
UK	4-6	171	35.9	4.4	26.2-44.8 <sup>2</sup>	15.3	2.5	10.4-21.2 <sup>2</sup>	11.5	1.7	8.2-15.1 <sup>2</sup>	5.4	1.4	3.2-8.4 <sup>2</sup>	1.3	0.3	0.8-2.0 <sup>2</sup>	156	60	62-286 <sup>2</sup>

<sup>1</sup>SE; <sup>2</sup>P2.5-P97.5

**ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~7-9 YEARS IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
AT	7-9	146	34.1	5.3		14.4	2.7		11.7	2.4		6.1	2.0					259	111	
CZ	7-9	940	32.2	5.6																
DE	7-9	321	32.4	5.5	23.6-40.8	15.1	2.5		12.5	2.0		4.8	1.0					247	99	118-453
DK	6-9	174	34.0	3.9	27-40	15	2.2	12-19	12.0	1.5	9-14	4.7	0.7	3.4-6.0	0.6	0.2	0.4-0.9			
FR	7-9	160	36.0	0.4 <sup>1</sup>		15.1														
IE	5-8	145	33.5	4.3	25.9-40.8															
IT	7-9	29	34.8	5.9		9.4	2.2		10.9	3.1		4.6	3.1					375	193	
NL	7-9	104	33.8	6.1	24.8-44.6	13.4	2.8	9.2-17.6	11.8	2.7	8.1-16.7	6.4	1.8	3.7-10.3				155	63	
NO	9	402	32.8	5.0		14.0	3.0		10.0	2.0		6.0	2.0					225	103	
PL	7-9	101	32.0	7.5		12.0	3.8		13.3	3.6		4.6	1.9					315	220	
PT	7-9	1541	35.9	6.6		13.0	3.3		15.0	3.4		5.0	1.7							
SE	8-9	444	31.6	4.2	25.0-39.2	14.4	2.4	10.2-18.4	11.4	1.8	8.9-14.6	3.6	0.8	2.5-5.1	1.0	0.4	0.5-1.6	250	89	130-407
UK	7-10	256	35.2	3.7	28.8-42.9 <sup>2</sup>	14.3	2.1	10.5-19.3 <sup>2</sup>	11.5	1.6	8.9-14.8 <sup>2</sup>	5.7	1.5	3.5-9.4 <sup>2</sup>	1.4	0.3	0.8-2.2 <sup>2</sup>	181	67	67-335 <sup>2</sup>
<b>Females</b>																				
AT	7-9	134	34.2	5.7		14.3	3.0		11.5	2.3		6.5	2.3					262	304	
CZ	7-9	765	32.2	5.6																
DE	7-9	308	31.3	5.8	22.2-41.8	14.9	2.6		11.8	2.2		4.5	1.1					227	105	86-411
DK	6-9	157	33.0	4.3	26-40	15.0	2.3	11-18	11.0	1.7	8-14	4.6	0.7	3.7-5.7	0.6	0.2	0.4-0.9			
FR	7-9	14	36.5	0.6 <sup>1</sup>		15.5														
IE	5-8	151	34.4	3.9	27.9-41.0															
IT	7-9	21	34.9	4.7		10.9	2.4		9.9	1.8		4.3	1.8					309	119	
NL	7-9	134	34.4	6.6	24.2-45.7	13.6	2.9	9.0-19.1	11.9	2.9	7.7-17.0	6.6	2.1	3.5-10.5				147	72	
NO	9	408	31.0	5.0		14.0	3.0		10.0	2.0		6.0	2.0					200	105	
PL	7-9	103	33.2	7.6		11.8	3.6		14.2	3.8		5.1	2.6					281	194	
PT	7-9	1503	36.2	6.7		13.1	3.3		15.1	3.5		5.1	1.6							
SE	8-9	445	31.3	4.4	24.3-38.7	14.1	2.3	10.5-18.2	11.3	1.9	8.3-14.7	3.6	0.9	2.5-5.3	0.9	0.4	0.5-1.7	216	78	109-351
UK	7-10	226	35.9	4.1	26.6-44.2 <sup>2</sup>	14.5	2.3	9.2-19.2 <sup>2</sup>	11.8	1.8	8.3-15.4 <sup>2</sup>	5.9	1.5	3.4-9.4 <sup>2</sup>	1.4	0.3	0.8-2.2 <sup>2</sup>	170	67	61-329 <sup>2</sup>

<sup>1</sup>SE; <sup>2</sup>P2.5-97.5

**ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~10-14 YEARS IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
AT	10-14	248	34.5	6.2		14.5	3.3		12.0	2.5		6.1	1.9					271	146	
BE	13-15	74	36.1	4.5		15.7	2.5		14.4	2.2		6.1	1.6					265	72	
DE	10-11	199	32.1	5.8	22.9-41.6	15.1	2.6		12.4	2.2		4.6	1.0					261	118	101-493
	12	114	33.7	5.2	25.6-44.1	15.6	2.3		12.7	2.3		5.3	1.0					343	142	162-616
	13-14	214	33.5	5.5	24.4-41.1	15.5	2.4		12.7	2.0		5.2	1.2					382	165	188-709
DK	10-13	145	33.0	4.4	26-40	15.1	2.3	11-19	11	1.7	9-14	4.5	0.8	3.3-6.0	0.6	0.2	0.3-0.9			
FR	10-14	160	36.3	0.4 <sup>1</sup>	15.1	14.0														
HU	11-14	124	35.0	4.9		10.9	2.1		10.8	2.1		8.2	2.1					347	116	
IE	9-12	148	33.3	4.5	26.2-40.8															
IT	10-14	52	35.8	5.3		10.8	2.4		11.9	2.9		5.1	1.5					370	101	
NL	9-13	197	35.0	6.0	26.1-44.8	13.1	2.7	9.0-18.3	10.1	2.3	6.5-14.0	7.5	2.3	4.0-11.9	1.4	1.0	0.4-3.3			
NO	13	590	31.0	6.0		13.0	3.0		10.0	2.0		5.0	2.0					241	134	
PL	10-14	202	34.6	7.7		12.1	3.8		14.7	3.9		5.5	2.9					408	323	
PT	13	987	32.0	4.5		10.9	1.8		13.1	2.5		5.3	1.1					378	148	
SE	11-12	517	31.7	4.6	24.3-38.8	14.1	2.4	10.4-18.1	11.6	2.1	8.5-15.3	3.7		2.5-5.4	1.0	0.5	1.0-1.8	233	92	109-406
ES	10-14	66	40.8	4.1		14.3	1.8		16.7	2.5		5.7	0.9					362	34	
UK	11-14	237	35.2	4.3	26.0-43.6 <sup>2</sup>	13.8	2.2	9.8-18.6 <sup>2</sup>	11.7	1.8	8.4-15.2 <sup>2</sup>	6.1	1.4	3.8-9.5 <sup>2</sup>	1.3	0.3	0.7-2.0 <sup>2</sup>	201	80	78-401 <sup>2</sup>
<b>Females</b>																				
AT	10-14	239	33.7	7.0		14.1	3.6		11.5	2.8		6.2	2.3					228	160	
BE	13-15	89	35.5	5.0		15.4	2.7		14.1	2.4		5.9	1.3					206	66	
DE	10-11	198	32.3	6.3	21.7-41.1	14.8	2.7		12.6	2.5		4.8	1.2					253	110	94-459
	12	103	33.1	6.2	22.4-42.7	15.4	2.9		12.3	2.1		5.3	1.1					302	144	118-586
	13-14	230	32.9	5.8	23.7-41.5	15.4	2.7		12.3	2.1		5.1	1.0					298	117	133-551
DK	10-13	131	33.0	4.8	26-40	14.9	2.7	11-19	11.0	1.8	9-14	4.5	0.8	3.4-5.9	0.6	0.2	0.4-0.9			
FR	10-14	144	36.4	0.5 <sup>1</sup>	14.9	14.2														
HU	11-14	111	34.3	5.2		10.6	2.2		10.2	2.1		8.6	2.0					292	96	
IE	9-12	150	34.4	4.2	27.6-41.7															
IT	10-14	47	33.4	4.5		10.1	2.3		11.0	2.3		4.4	1.9					320	111	
NL	9-13	212	34.5	6.1	24.6-44.6	13.1	2.6	8.6-17.6	9.8	2.2	6.5-13.6	7.6	2.3	4.7-11.9	1.3	0.8	0.3-2.8			
NO	13	515	31.0	5.0		14.0	3.0		10.0	2.0		5.0	2.0					198	106	
PL	10-14	202	34.3	7.5		12.0	3.7		14.6	4.2		5.5	2.8					321	235	
PT	13	1053	32.0	4.7		10.9	1.9		13.0	2.6		5.3	1.2					360	146	
SE	11-12	499	31.3	4.6	23.4-39.4	14.0	2.3	10.4-17.9	11.4	2.1	8.1-14.7	3.7		2.5-5.4	0.9	0.4	0.5-1.7	204	87	96-375
ES	10-14	53	39.7	2.9		13.6	1.2		16.6	1.2		5.4	0.4					313	50	
UK	11-14	238	36.1	5.0	23.3-45.2 <sup>2</sup>	14.0	2.5	9.3-18.7 <sup>2</sup>	12.0	2.2	8.0-17.1 <sup>2</sup>	6.4	1.7	3.8-10.2 <sup>2</sup>	1.3	0.4	0.7-2.2 <sup>2</sup>	169	72	61-329 <sup>2</sup>

<sup>1</sup>SE; <sup>2</sup>P2.5-P97.5

**ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~15-18 YEARS IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
AT	14->19	1527	36.5	8.9		18.3	6.2		11.1	3.4		4.7	2.6					375	204	
BE	15-18	405																		
DE	15-17	294	33.8	7.0	24.0-44.1													461	242	183-795
DK	14-17	86	32	4.6	25-49	14	2.5	10-18	11	1.8	8-14	4.5	0.8	3.4-5.8	0.6	0.2	0.3-0.9			
FR	15-18	181	34.2	0.5 <sup>1</sup>	14.0															
IT	15-18	52	37.0	7.1		11.2	2.4		12.9	4.1		5.3	2.2					438	130	
NL	14-18	229	35.2	5.9	26.0-44.8	13.1	2.6	8.8-17.6	10.0	2.0	7.0-13.3	7.9	2.6	3.6-12.9	1.4	1.0	0.4-3.3	243	95	97-428
NO	16-19	92	31.0			13.0			10.8			5.1						361		
PL	15-18	174	36.8	6.9		12.1	3.8		16.0	3.8		6.3	2.9					566	366	
SI	15-18	1010	28.0	7.0		13.0	3.0		10.3	3.0		5.0	2.0					300	188	
ES	15-18	61	40.4	3.8		13.8	1.8		16.7	2.3		5.7	0.9					382	48	
UK	15-18	179	35.9	4.7	26.3-45.3 <sup>2</sup>	13.9	2.1	9.4-17.6 <sup>2</sup>	12.0	2.1	8.2-16.2 <sup>2</sup>	6.3	1.6	3.7-9.2 <sup>2</sup>	1.4	0.4	0.7-2.1 <sup>2</sup>	243	95	97-428 <sup>2</sup>
<b>Females</b>																				
AT	14->19	1422	37.4	9.6		19.1	6.7		11.1	3.5		4.8	2.9					267	141	
BE	15-18	401																		
DE	15-17	317	31.4	6.7	21.8-41.3													288	152	120-572
DK	14-17	117	31.0	4.7	23-38	14.0	2.5	10-18	11.0	1.8	8-13	4.4	0.7	3.3-5.9	0.6	0.2	0.3-0.8			
FR	15-18	222	36.4	0.3 <sup>1</sup>	14.2															
IT	15-18	47																		
NL	14-18	216	35.5	6.2	25.9-46.4	13.7	2.8	9.0-18.6	10.2	2.5	6.7-14.4	7.4	2.5	3.8-12.1	1.3	0.9	0.4-3.2			
NO	16-19	86	28.6			11.8			9.9			4.9						228		
PL	15-18	175	33.8	3.1		11.7	4.2		14.4	4.5		5.4	2.6					326	255	
SI	15-18	1214	29.0	7.0		13.0	3.0		10.0	3.0		6.0	2.0					218	139	
ES	15-18	57	41.9	3.7		13.7	1.3		17.7	1.9		6.0	1.0					314	46	
UK	15-18	210	35.9	5.4	22.7-45.6 <sup>2</sup>	13.8	2.5	8.8-19.3 <sup>2</sup>	11.7	2.2	6.6-15.6 <sup>2</sup>	6.7	1.9	3.7-10.6 <sup>2</sup>	1.3	0.4	0.7-2.2 <sup>2</sup>	177	80	53-346 <sup>2</sup>

<sup>1</sup> SE; <sup>2</sup> P2.5-P97.5



**ANNEX 1B INTAKE OF LINOLEIC ACID, CIS N-6 PUFA AND CIS N-3 PUFA AMONG CHILDREN IN EU COUNTRIES.**

Country	Age yrs	N	Linoleic acid (g/d)			Linoleic acid (E%)			Cis n-6 PUFA (g/d)			Cis n-6 PUFA (E%)			Cis n-3 PUFA (g/d)			Cis n-3 PUFA (E%)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males and Females</b>																				
BE	2.5-3	197				4.0		3.2-4.7				4.05		3.2-4.75				0.53		0.43-0.62
	4-6.5	464				4.3		3.5-4.9				4.25		3.55-4.86				0.58		0.48-0.66
<b>Males</b>																				
NL	9-13	197	16.5	7.11	6.9-30.6	6.4	2.1	3.3-10.6	16.6	7.1	6.9-31.0	6.5		3.3-10.7	1.5	0.7	0.7-3.1	0.6		0.3-1.0
	14-18	229	21.0	10.2	7.6-41.3	6.8	2.5	3.1-11.5	21.2	10.3	7.7-41.7	6.9		3.2-11.6	1.9	0.9	0.8-3.8	0.6		0.3-1.0
SE	4	302	5.0	1.6	2.7-8.1				5.2	1.7	3.0-8.5	2.9		1.9-4.3	1.2	0.4	0.6-2.1	0.7	0.2	0.4-1.0
	8-9	444	5.9	2.1	3.1-9.7				6.3	2.2	3.4-10.1	2.9		2.0-4.2	1.4	0.5	0.7-2.1	0.6	0.2	0.4-1.0
	11-12	517	5.8	2.5	2.9-10.3				6.2	2.6	3.3-10.6	3.0		2.0-4.3	1.4	0.6	0.7-2.4	0.6	0.2	0.4-1.0
UK	4-6	184							8.0	2.6	3.6-13.4 <sup>1</sup>	4.8	1.2	2.7-7.4 <sup>1</sup>	1.3	0.6	0.5-2.9 <sup>1</sup>	0.8	0.3	0.4-1.8 <sup>1</sup>
	7-10	256							9.7	3.3	4.7-18.8 <sup>1</sup>	4.9	1.4	4.0-8.4 <sup>1</sup>	1.6	0.7	0.6-3.58 <sup>1</sup>	1.4	0.3	0.8-2.2 <sup>1</sup>
	11-14	237							11.4	3.7	6.2-19.3 <sup>1</sup>	5.2	1.2	3.3-8.4 <sup>1</sup>	2.0	1.2	0.8-4.1 <sup>1</sup>	0.9	0.5	0.4-1.9 <sup>1</sup>
	15-18	179							13.3	4.6	6.1-24.8 <sup>1</sup>	5.2	1.4	3.0-7.9 <sup>1</sup>	2.2	0.9	0.6-3.8 <sup>1</sup>	0.9	0.3	0.5-1.6 <sup>1</sup>
<b>Females</b>																				
NL	9-13	212	14.7	5.7	7.3-26.4	6.6	2.2	3.6-10.7	14.9	5.8	7.3-26.4	6.6		3.7-10.8	1.4	0.6	0.5-2.6	0.6		0.3-1.0
	14-18	216	14.8	6.6	6.1-27.2	6.3	2.3	3.2-11.0	14.9	6.7	6.1-27.5	6.4		3.2-11.0	1.4	0.7	0.6-2.4	0.6		0.3-1.0
SE	4	288	5.0	1.6	2.7-8.1				4.9	1.6	2.7-7.9	3.0	0.7	2.0-4.2	1.1	0.5	0.6-1.9	0.7	0.3	0.4-1.1
	8-9	445	5.9	2.1	3.1-9.7				5.7	2.0	3.0-9.4	2.9	0.8	2.0-4.4	1.3	0.5	0.6-2.1	0.9	0.2	0.5-1.7
	11-12	399	5.8	2.5	2.9-10.3				5.6	2.5	2.7-10.2	3.0	0.9	1.9-4.5	1.2	0.5	0.5-2.3	0.7	0.2	0.4-1.1
UK	4-6	171							7.2	2.7	3.6-13.5 <sup>1</sup>	4.8	1.2	2.7-7.6 <sup>1</sup>	1.2	0.5	0.5-2.3 <sup>1</sup>	0.7	0.3	0.4-1.3 <sup>1</sup>
	7-10	226							9.0	3.0	4.7-16.7 <sup>1</sup>	5.1	1.4	2.9-8.5 <sup>1</sup>	1.4	0.5	0.7-3.0 <sup>1</sup>	0.8	0.3	0.4-1.5 <sup>1</sup>
	11-14	238							10.2	3.4	4.9-17.8 <sup>1</sup>	5.4	1.5	3.2-8.6 <sup>1</sup>	1.6	0.7	0.7-3.4 <sup>1</sup>	1.3	0.4	0.7-2.2 <sup>1</sup>
	15-18	179							10.2	4.0	4.1-18.9 <sup>1</sup>	5.3	1.7	2.9-8.7 <sup>1</sup>	1.6	0.6	0.7-3.1 <sup>1</sup>	1.2	0.3	0.7-2.2 <sup>1</sup>

<sup>1</sup> P2.5-P97.5

**ANNEX 1B DIETARY INTAKES OF ALA, EPA AND DHA BY CHILDREN IN DIFFERENT COUNTRIES.**

	ALA		EPA		DHA		references
	g/d	E%	g/d	E%	g/d	E%	
<b>Austria</b>							Elmadfa, et al., 2009
. 3-6 yr	0.8/0.7*	0.5/0.5	0.02	NA	0.08	NA	
. 7-10 yr	0.8/0.7	0.4/0.4	0.02	NA	0.07	NA	
11-14 yr	1.2/1	0.6/0.5	0.03	NA	0.1/0.09	NA	
15-18 yr	1.2/1	0.4/0.5	0.03	NA	0.09/1.0	NA	
<b>Belgium</b>							Sioen et al., 2007
2.5-3 yr	0.8	0.48	0.02	0.01	0.04	0.03	
4-6.5 yr	0.9	0.54	0.03	0.02	0.05	0.03	
<b>Sweden</b>							Enghardt-Barbieri et al., 2006
4 yr	1.0	0.6	0.04	0.02	0.10	0.06	
8-9 yr	1.1	0.5	0.04	0.02	0.13	0.06	
11-12 yr	1.1	0.6	0.04	0.02	0.12	0.06	

\* males/females  
NA Not Available

**ANNEX 2A POPULATION, METHODS AND PERIOD OF DIETARY ASSESSMENT IN ADULTS IN EUROPEAN COUNTRIES.**

Country	Population	Dietary method	Year of survey	Reference
AT	Males and females aged 19-64 years	24-hour recall	2007	Elmadfa et al., 2009
	Males and females aged 65 and over	3-day record	2007	Elmadfa et al., 2009
BE	Males and females aged 19-59 years	2x 24-hour recall	2004	De Vriese et al, 2006
	Males and females aged 60-75 years	2x 24-hour recall	2004	De Vriese et al, 2006
	Males and females aged 75+ years	2x 24-hour recall	2004	De Vriese et al, 2006
CZ	Males and females aged 19-64 years	n.a.	n.a. <sup>1</sup>	Cífková and Skodova, 2004
DE	Males and females aged 35-64 years	24-hour recall	1996-1998	Linseisen et al., 2003
	Males and females aged 19-64 years	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
	Males and females aged 19-24 years	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
	Males and females aged 25-34 years	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
	Males and females aged 35-50 years	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
	Males and females aged 51-64 years	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
	Males and females aged 65-80 years	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
	Males and Females aged 65 and over	24-hour recall + Dietary History	2005-2006	Anonymous, 2008
DK	Males and females aged 18-74 years	7-day record	2000-2002	Lyhne et al., 2005
	Males and females aged 18-24 years	7-day record	2000-2002	Lyhne et al., 2005
	Males and females aged 25-34 years	7-day record	2000-2002	Lyhne et al., 2005
	Males and females aged 35-44 years	7-day record	2000-2002	Lyhne et al., 2005
	Males and females aged 45-54 years	7-day record	2000-2002	Lyhne et al., 2005
	Males and females aged 55-64 years	7-day record	2000-2002	Lyhne et al., 2005
	Males and females aged 65-74 years	7-day record	2000-2002	Lyhne et al., 2005
EE	Males and females aged 19-65 years	24-hour recall	1997	Pomerleau et al., 2001
	Males and females aged 19-34 years	24-hour recall	1997	Pomerleau et al., 2001
	Males and females aged 35-49 years	24-hour recall	1997	Pomerleau et al., 2001
	Males and females aged 50 and over	24-hour recall	1997	Pomerleau et al., 2001
FI	Males and females aged 25-64 years	3-day record	2002	Paturi et al., 2008
	Males and females aged 65-74 years	4-day record	2002	Paturi et al., 2008
FR	Males and females aged 19-64 years	3x 24-hour recall	2006-2007	Castetbon et al. 2009. (In: Elmadfa, 2009)
	Males and females aged 65-75 years	3x 24-hour recall	2006-2007	Castetbon et al. 2009. (In: Elmadfa, 2009)

Country	Population	Dietary method	Year of survey	Reference
GR	Males and females aged 19-64 years	FFQ + 24-hour recall in sub group	1994-1999	Greek cohort EPIC study. (In: Elmadfa, 2009)
	Males and females aged 65 and over	FFQ	1994-1999	Greek cohort EPIC study. (In: Elmadfa, 2009)
HU	Males and females aged 11-14 years	3-day record	2003-2004	Rodler et al. 2007; Zajkás et al., 2007; Bíró et al., 2007 (In: Elmadfa, 2009)
	Males and females aged 18-59	3-day record	2003-2004	Rodler et al. 2007; Zajkás et al., 2007; Bíró et al., 2007 (In: Elmadfa, 2009)
	Males and females aged 60 and over	3-day record	2003-2004	Rodler et al. 2007; Zajkás et al., 2007; Bíró et al., 2007 (In: Elmadfa, 2009)
IE	Males and females 18-64 years	7-day record	1997-1999	<a href="http://www.iuna.net">Irish Universities Nutrition Alliance North/South Ireland Food Consumption Survey. www.iuna.net</a>
	Males and females 18-35 years	7-day record	1997-1999	<a href="http://www.iuna.net">Irish Universities Nutrition Alliance North/South Ireland Food Consumption Survey. www.iuna.net</a>
	Males and females 36-50 years	7-day record	1997-1999	<a href="http://www.iuna.net">Irish Universities Nutrition Alliance North/South Ireland Food Consumption Survey. www.iuna.net</a>
	Males and females 51-64 years	7-day record	1997-1999	<a href="http://www.iuna.net">Irish Universities Nutrition Alliance North/South Ireland Food Consumption Survey. www.iuna.net</a>
IT	Males and females 19-64 years	7-day record	n.a.	D'Amicis, 2000
	Males and females aged 65 and over	7-day record	n.a.	D'Amicis, 2000
LT	Males and females 19-64 years	24-hour recall	2007	Unpublished data (In: Elmadfa, 2009)
LV	Males and females 19-64 years	24-hour recall	1997	Pomerleau et al., 2001
	Males and females aged 19-34 years	24-hour recall	1997	Pomerleau et al., 2001
	Males and females aged 35-49 years	24-hour recall	1997	Pomerleau et al., 2001
	Males and females aged 50 and over	24-hour recall	1997	Pomerleau et al., 2001
NL	Males and Females aged 19-64 years	2-day record	1997-1998	Hulshof et al., 1998
	Males and Females aged 65 and over	2-day record	1997-1998	Hulshof et al., 1998
	Males and females aged 19-30 years	2x 24-hour recall	2003	Hulshof and Ocké, 2005; Kruizinga et al., 2007
NO	Males and females aged 19-64 years	FFQ	1997	Johansson and Sovoll, 1999
	Males and females aged 65 and over	FFQ	1997	Johansson and Sovoll, 1999
PL	Males and females aged 19-64 years	24-hour recall	2000	Szponar et al., 2000 unpublished data (In: Elmadfa, 2009)
	Males and females aged 65 and over	24-hour recall	2000	Szponar et al., 2000 unpublished data (In: Elmadfa., 2009)

Country	Population	Dietary method	Year of survey	Reference
PT	Males and females aged 18+ years	FFQ	n.a.	EPIPorto study (In: Elmadfa, 2009)
	Males and females aged 65 and over	FFQ	n.a.	EPIPorto study (In: Elmadfa, 2009)
RO	Males and females aged 19-64 years	personal interview	2006	National Synthesis 2006 (In: Elmadfa., 2009)
	Males and females aged 65 and over	personal interview	2006	National Synthesis 2006 (In: Elmadfa., 2009)
ES	Males and females aged 18-64 years	24-hour recall	2002-2003	Serra Majem et al., 2007
	Males and females aged 65-75 years	24-hour recall	2002-2003	Serra Majem et al., 2007
SE	Males and females aged 18-74 years	7-day record	1997-1998	Becker and Pearson, 2002
	Males and females aged 17-24 years	7-day record	1997-1998	Becker and Pearson, 2002
	Males and females aged 25-34 years	7-day record	1997-1998	Becker and Pearson, 2002
	Males and females aged 35-44 years	7-day record	1997-1998	Becker and Pearson, 2002
	Males and females aged 45-54 years	7-day record	1997-1998	Becker and Pearson, 2002
	Males and females aged 55-64 years	7-day record	1997-1998	Becker and Pearson, 2002
	Males and females aged 65 and over	7-day record	1997-1998	Becker and Pearson, 2002
UK	Males and females aged 19-64 years	7-day record	2000-2001	Henderson et al., 2003
	Males and females aged 19-24 years	7-day record	2000-2001	Henderson et al., 2003
	Males and females aged 25-34 years	7-day record	2000-2001	Henderson et al., 2003
	Males and females aged 35-49 years	7-day record	2000-2001	Henderson et al., 2003
	Males and females aged 50-64 years	7-day record	2000-2001	Henderson et al., 2003
	Males and females aged 65+ years	4-day record	1994-1995	Finch et al., 1998

<sup>1</sup>n.a. = not available

**ANNEX 2B INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~19-64 YEARS (TOTAL POPULATION) IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
AT	19-64	778	37.4	8.9		14.3	4.3		13.0	3.8		7.9	3.7					352	227	
BE	19-59	413	38.7	5.6		15.6	3.0		14.1	2.1		7.1	2.1							
DE	19-64	4912	35.8	7.7														396	209	
CZ	19-64	1094	31.3	7.8															383	205
DK	18-74	1467	33.0		26-40 <sup>1</sup>	14.0		11-18 <sup>1</sup>	12.0		9-14 <sup>1</sup>	4.7		3.7-5.9 <sup>1</sup>	0.6		0.4-0.9 <sup>1</sup>			
EE	19-65	900	36.5	12.6		14.1	5.8		13.9	5.9		5.6	3.0					348	275	
FI	25-64	730	33.1	7.9		12.9	4.1		12.0	3.5		5.9	2.2		0.4	0.2		27.7	13.0 <sup>2</sup>	
FR	19-64	852	35.5	0.3 <sup>3</sup>		14.4														
GR	19-64	8365	45.0	5.5		12.7	2.5		21.9	4.0		6.4	2.6					283	116	
HU	>18	473	38.2	5.9		11.7	2.4		12.5	2.9		8.8	2.4					463	177	
IE	18-64	662	37.0	5.2	26.8-45.1															
IT	19-64	660	35.0	6.0		10.6	2.4		12.8	3.6		4.8	2.2					378	133	
LT	19-64	849	44.9	9.1		13.5	7.0		16.9	8.0		8.9	5.4					478	265	
LV	19-64	1065	42.7	11.7																
NL	19-64	1836	36.5	6.4		14.3	3.2		12.8	2.8		7.0	2.3					250	150	
NO	19-64	1050	31.0	6.0		12.0	3.0		11.0	2.0		6.0	2.0					344	143	
PL	19-64	1106	36.7	7.9		12.3	3.9		16.2	4.3		5.7	2.4					553	382	
PT	19-64	917	28.4	4.7		8.8	2.0		12.3	2.3		4.8	0.9					324	106	
RO	19-64	177	38.9	9.0		26.3	5.0											800	430	
SE	18-74	589	34.0	5.0	26-43	15.0	3.0	10-19	13.0	2.0	9-16	4.6	1.4	3.0-7.2				349	126	185-570
ES	18-64	718	41.1			12.7			18.1			6.1						376		
UK	19-64	833	35.8	5.6	24-46.6 <sup>4</sup>	13.4	2.9	7.8-19.0 <sup>4</sup>	12.1	2.3	7.5-16.5 <sup>4</sup>				1.2	0.4	0.5-2.1 <sup>4</sup>	304	128	95-606 <sup>4</sup>
<b>Females</b>																				
AT	19-64	1345	37.3	9.3		14.9	4.6		12.3	3.6		8.1	4.0					283	176	
BE	19-59	460	36.4	6.4		15.2	3.0		13.3	2.3		6.9	2.7							
CZ	19-64	1094	31.2	8.4															277	157
DE	19-64	6016	34.8	6.7															279	2.1
DK	18-74	1684	32.0		25-38 <sup>1</sup>	14.0		10-17 <sup>1</sup>	11.0		8-14 <sup>1</sup>	4.7		3.7-4.7 <sup>1</sup>	0.6		0.4-0.8 <sup>1</sup>			
EE	19-64	1115	36.3	11.3																
FI	25-64	846	31.2	7.4		12.0	3.9		10.9	3.2		5.7	2.2		0.4	0.2		26.6	13.8 <sup>2</sup>	
FR	19-64	1499	36.7	0.2 <sup>3</sup>		14.7														
GR	19-64	1203	47.2	4.7		13.2	2.6		22.9	4.1		6.9	2.9					228	92	
HU	>18	706	36.8	5.4		11.0	2.3		11.4	2.5		9.2	2.3					327	125	



Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>IE</b>	18-64	717	37.0	6.0	26.2-46.1															
<b>IT</b>	19-64	801	33.0	5.8		10.1	2.5		11.6	3.2		4.5	1.7					311	102	
<b>LT</b>	19-64	1132	41.9	9.5		12.9	7.0		15.7	7.6		8.7	5.4					319	209	
<b>LV</b>	19-64	1235	41.8	11.3																
<b>NL</b>	19-64	2112	36.9	6.9		14.6	3.2		13.1	3.0		6.7	2.4					201	99	
<b>NO</b>	19-64	1146	31.0	6.0		12.0	3.0		11.0	2.0		5.0	2.0					260	101	
<b>PL</b>	19-64	1334	34.7	8.3		11.7	4.1		15.0	4.5		5.6	2.6					322	244	
<b>PT</b>	19-64	1472	29.9	4.5		9.4	2.0		13.0	2.9		4.9	0.9					302	103	
<b>RO</b>	19-64	341	39.7	7.7		24.8	3.8											680	340	
<b>SE</b>	18-74	626	34.0	5.0	26-41	14.0	2.0	10-18	12.0	2.0	9-16	4.7	1.4	3-7.3				291	98	149-487
<b>ES</b>	18-64	895	40.7			12.6			18.1			5.8						286		
<b>UK</b>	19-64	891	34.9	6.5	22.0-47.9 <sup>4</sup>	13.2	3.3	7.2-20.0 <sup>4</sup>	11.5	2.6	6.7-16.7 <sup>4</sup>				1.2	0.4	0.4-2.1 <sup>4</sup>	213	95	60-427 <sup>4</sup>

<sup>1</sup>P10-P90; <sup>2</sup>g/MJ; <sup>3</sup>SE; <sup>4</sup>P2.5-P97.5;

**ANNEX 2B INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~19-34 YEARS IN EU COUNTRIES.**

Country	Age Yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
DE	19-24	510	34.6	0.24 <sup>1</sup>	22.9-48.2													424	9.84 <sup>1</sup>	160-863
	25-34	690	35.8	0.26 <sup>1</sup>	25.1-46.7													419	7.76 <sup>1</sup>	176-776
DK	18-25	146	32.0	5.0	32-39	14.0	2.7	9-19	11.0	1.9	8-14	4.5	0.8	3.3-5.8	0.6	0.2	0.2-0.9			
	25-34	272	34.0	5.1	33-41	14.0	2.7	10-20	12.0	2.0	9-15	4.7	0.8	3.6-6.1	0.6	0.2	0.3-0.9			
EE	19-34	396	37.9	12.2																
IE	18-35	253	37.7	4.9	29.2-45.1															
LV	19-34	337	44.2	11.0																
NL	19-30	352	34.4	6.4	23.5-44.6	12.9	3.2	7.7-18.6	11.4	2.5	7.4-15.6	6.8	2.0	4.1-10.4	0.8	0.3	0.4-1.4			
SE	17-24	67	33.0	5.0	25-44	14.0	2	10-18	12.0	2	9-17	4.7	1.8	2.7-7.8				308	97	142-475
	25-34	128	34.0	5.0	27-43	14.0	2	10-18	13.0	2	9-16	5.0	1.7	2.9-8.7				342	118	196-570
UK	19-24	108	36.0	6.0	21.6-46.7 <sup>2</sup>	13.5	3.0	7.2-19.4 <sup>2</sup>							1.2	0.3	0.5-1.9 <sup>2</sup>	269	134	74-627 <sup>2</sup>
	25-34	219	35.8	5.4	26.0-47.2 <sup>2</sup>	13.2	2.6	8.5-18.3 <sup>2</sup>							1.2	0.4	0.6-2.0 <sup>2</sup>	298	120	120-604 <sup>2</sup>
<b>Females</b>																				
DE	19-24	510	33.2	0.26 <sup>1</sup>	22.5-44.9													263	5.43 <sup>1</sup>	110-507
	25-34	972	34.4	0.30 <sup>1</sup>	23.6-45.1													285	4.23 <sup>1</sup>	124-496
DK	18-25	213	31.0	5.0	31-39	13.0	2.6	9-17	11.0	2.0	7-14	4.4	0.8	3.2-5.9	0.6	0.2	0.3-0.9			
	25-34	315	33.0	5.1	33-41	14.0	2.8	10-19	11.0	2.0	8-14	4.8	0.8	3.5-6.1	0.6	0.2	0.3-0.9			
EE	19-34	459	37.4	11.2																
IE	18-35	269	38.0	56.4	28.4-46.1															
LV	19-34	342	41.8	11.4																
NL	19-30	398	34.2	7.3	21.8-46.2	13.1	3.4	7.2-18.7	11.2	3.0	6.4-16.6	6.5	2.3	3.3-11.0	0.9	0.4	0.4-1.7			
SE	17-24	70	32.0	6	22-41	13.0	3	9-18	12.0	2	9-16	4.7	1.6	2.9-7.6				244	94	91-383
	25-34	132	34.0	5	27-42	15.0	2	11-19	13.0	2	9-16	4.8	1.6	3.1-8.2				282	88	167-448
UK	19-24	104	35.5	7.6	24.0-51.1 <sup>2</sup>	12.9	4.0	7.4-25.5 <sup>2</sup>	12.2	2.9	7.5-17.3 <sup>2</sup>				1.1	0.4	0.6-2.2 <sup>2</sup>	196	112	41-465 <sup>2</sup>
	25-34	210	35.4	5.9	22.3-46.1 <sup>2</sup>	13.2	2.9	7.5-18.6 <sup>2</sup>	11.7	2.4	7.5-16.9 <sup>2</sup>				1.1	0.4	0.4-2.1 <sup>2</sup>	188	83	59-397 <sup>2</sup>

<sup>1</sup>SE; <sup>2</sup>P2.5-P97.5

**ANNEX 2B INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~35-64 YEARS IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
<b>DE</b>	35-64 <sup>1</sup>	1013	36.0	9.4		15.1	5.0		12.6	4.0								371	266	
	35-64 <sup>2</sup>	1032	40.3	9.5		16.5	5.2		13.7	3.7								377	255	
	35-50	2079	36.2	0.16 <sup>3</sup>	24.7-48.3													398	4.16 <sup>3</sup>	164-776
	51-64	1633	35.9	0.18 <sup>3</sup>	24.2-47.4													363	4.26 <sup>3</sup>	153-682
<b>DK</b>	35-44	330	34.0	5.2	34-42	14.0	2.7	10-18	12.0	2.0	8-15	4.9	1.0	3.5-6.5	0.7	0.2	0.3-1.0			
	45-54	312	34.0	6.3	34-44	14.0	3.1	9-19	12.0	2.5	8-16	4.8	1.0	3.4-6.3	0.7	0.2	0.3-1.1			
	55-64	242	33.0	6.0	33-42	14.0	3.1	8-19	11.0	2.3	8-15	4.7	1.0	3.4-6.3	0.7	0.2	0.2-1.0			
<b>EE</b>	35-49	319	35.0	13.2																
	50+	185	35.8	12.2																
<b>IE</b>	36-50	236	37.5	5.6	26.9-45.8															
	51-64	173	35.1	5.7	24.8-44.1															
	35-49	372	42.1	12.0																
	50+	356	41.8	11.9																
<b>SE</b>	35-44	143	35.0	5.0	26-41	15.0	2.0	10-18	13.0	2.0	9-16	4.7	1.3	3.0-7.5				353	118	189-572
	45-54	18	34.0	6.0	25-43	15.0	3.0	10-21	13.0	2.0	9-16	4.5	1.1	3.2-6.5				351	123	192-601
	55-64	68	35.0	6.0	25-45	15.0	3.0	10-22	13.0	2.0	9-16	4.5	1.1	3.1-6.3				354	115	178-564
<b>UK</b>	35-49	253	35.9	5.6	23.2-46.0 <sup>4</sup>	13.5	3.0	7.2-19.1 <sup>4</sup>							1.2	0.5	0.4-2.3 <sup>4</sup>	309	130	99-604 <sup>4</sup>
	50-64	253	35.6	5.7	23.9-46.1 <sup>4</sup>	13.4	3.1	7.7-20.3 <sup>4</sup>							1.2	0.4	0.5-2.1 <sup>4</sup>	319	127	108-663 <sup>4</sup>
<b>Females</b>																				
<b>DE</b>	35-64 <sup>1</sup>	1078	36.6	9.1		15.7	5.1		12.3	3.8								285	185	
	35-64 <sup>2</sup>	898	37.4	9.6		15.6	5.1		12.6	3.8								264	177	
	35-50	2694	35.4	0.22 <sup>4</sup>	24.4-46.7													285	2.47 <sup>4</sup>	113-508
	51-64	1840	34.9	0.13 <sup>4</sup>	24.1-47.7													272	2.93 <sup>4</sup>	117-498
<b>DK</b>	35-44	359	33.0	5.3	33-41	14.0	2.9	9-18	11.0	2.0	8-14	4.8	0.8	3.6-6.4	0.6	0.2	0.3-0.9			
	45-54	370	31.0	5.5	31-41	13.0	2.8	9-18	11.0	2.1	7-14	4.7	0.8	3.4-6.2	0.6	0.2	0.3-0.9			
	55-64	263	32.0	5.0	32-40	13.0	2.9	9-18	11.0	2.2	7-14	4.7	1.2	3.2-6.2	0.6	0.2	0.3-0.9			
<b>EE</b>	35-49	376	35.6	11.4																
	50+	280	35.3	11.3																
<b>IE</b>	36-50	286	37.0	6.1	26.0-46.2															
	51-64	162	35.2	6.6	24.2-46.3															
<b>LV</b>	35-49	396	42.2	11.1																
	50+	496	39.8	11.4																
<b>SE</b>	35-44	132	35.0	5.0	25-42	14.0	2.0	11-18	13.0	2.0	9-16	4.9	1.2	3.1-6.8				285	87	151-455
	45-54	153	34.0	5.0	26-41	14.0	2.0	10-18	12.0	2.0	9-16	4.7	1.3	3.1-7.3				307	107	148-522
	55-64	81	33.0	4.0	26-40	14.0	2.0	10-17	12.0	2.0	9-15	4.5	1.0	3.0-6.4				307	107	148-522
<b>UK</b>	35-49	318	34.7	6.3	20.8-46.1 <sup>4</sup>	13.2	3.1	7.1-19.7 <sup>4</sup>	11.3	2.6	5.7-15.9 <sup>4</sup>				1.2	0.4	0.5-2.1 <sup>4</sup>	214	92	57-423 <sup>4</sup>
	50-64	259	34.5	6.8	22.4-47.8 <sup>4</sup>	13.3	3.7	6.6-21.1 <sup>4</sup>	11.1	2.6	6.4-17.3 <sup>4</sup>				1.2	0.5	0.4-2.1 <sup>4</sup>	239	93	100-452 <sup>4</sup>

<sup>1</sup>Cohort Heidelberg; <sup>2</sup>Cohort Potsdam; <sup>3</sup>SE; <sup>4</sup>P2.5-P97.5

**ANNEX 2B INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~65 YEARS AND OVER IN EU COUNTRIES.**

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
<b>Males</b>																				
AT	65+	147	37.6	5.8		15.6	3.1		12.7	3.4		7.4	2.2					330	136	
BE	60-74	416	40.0	6.8		16.4	4.1		14.5	3.0		7.2	2.5							
	>75	389	40.2	7.9		16.7	4.6		14.0	2.9		7.0	2.8							
DE	65-80	1469	36.0	0.18 <sup>1</sup>	24.8-48.0													330	3.68 <sup>1</sup>	146-585
DK	65-75	165	34.0	5.5	23-43	14.0	3.0	9-19	12.0	2.1	8-15	4.3	1.0	2.9-5.9	0.7	0.2	0.4-1.1			
FI	65-74	229	31.4	7.9		12.0	4.5		11.1	3.5		5.7	2.0		0.4	0.2		27.7	13.0 <sup>2</sup>	
FR	65+	130	33.7	0.7 <sup>1</sup>		13.6														
GR	65+	2508	43.9	5.4		12.1	2.6		21.0	4.2		6.7	3.1					215	96	
HU	59+	138	37.5	5.9		11.4	2.5		12.0	2.9		8.7	2.3					418	182	
IT	65+	60	33.2	6.5		10.0	3.0		13.1	4.0		4.8	2.5					313	97	
NL	65+	185	37.0	7.0		15.0	4.0		12.0	3.0		7.0	2.0					231	107	
NO	65+	176	31.0	6.0		12.0	3.0		11.0	2.0		5.0	2.0					316	132	
PL	65+	176	36.0	9.2		12.8	4.2		15.4	4.9		5.3	2.6					433	311	
PT	65+	246	26.7	4.6		7.8	1.9		11.9	2.3		4.6	0.9					276	95	
RO	65+	177	41.0	9.0		25.4	4.3		15.7	4.7								810	350	
	65+	65	34.0	6.0	25-46	15.0	3	10-22	13.0	2	9-16	4.5	0.8	2.9-5.9				383	181	179-782
ES	65-75	122	37.5			10.8			17.5			5.5						263		
UK	65+	540	35.7	5.6	25.1-46.8 <sup>3</sup>	14.6	3.5	8.5-21.8 <sup>3</sup>	11.1	2.2	7.2-15.7 <sup>3</sup>	5.8	2.2	2.6-11.5 <sup>3</sup>	1.5	0.5	0.7-2.5 <sup>3</sup>			
<b>Females</b>																				
AT	65+	20	37.5	5.2		16.4	3.2		12.3	2.0		6.9	2.1					324	119	
BE	60-74	406	38.1	6.2		16.1	3.6		13.8	2.3		6.5	2.5							
	>75	355	39.6	6.9		17.7	4.8		14.0	2.9		5.9	2.0							
DE	65-80	1562	35.5	0.17 <sup>4</sup>	25.2-46.2													252	2.79 <sup>4</sup>	110-450
DK	65-75	164	32.0	5.8	23-42	14.0	3.0	9-19	11.0	2.2	7-14	4.7	1.0	3.4-6.3	0.6	0.2	0.4-1.0			
FI	65-74	234	30.1	7.3		11.4	3.9		10.4	3.2		5.6	1.9		0.4	0.2		27.0	11.7 <sup>2</sup>	
FR	65+	219	34.5	0.6 <sup>2</sup>		13.3														
GR	65+	3600	45.3	5.0		12.3	2.5		21.8	4.4		7.0	3.3					173	76	
HU	59+	235	36.3	5.5		10.9	2.0		11.3	2.5		9.1	2.2					297	113	
IT	65+	107	30.5	5.9		9.4	2.6		11.8	3.0		4.4	1.9					279	122	
NL	65+	236	37.0	7.0		15.0	4.0		12.0	3.0		7.0	3.0					195	86	
NO	65+	166	30.0	6.0		12.0	3.0		11.0	2.0		5.0	1.0					260	91	
PL	65+	277	34.1	7.9		12.6	4.0		14.3	4.4		4.8	2.3					317	204	
PT	65+	339	28.0	4.8		8.4	2.1		12.3	2.4		4.8	1.0					247	85	
RO	65+	341	39.9	8.1		24.9	4.7		15.0	3.4								690	280	
SE	65+	57	33.0	4.0	27-41	14.0	2.0	11-19	12.0	2.0	9-15	4.6	1.4	3.4-8.1				310	120	167-648

Country	Age yrs	N	Total Fat (E%)			Saturated Fatty Acids (E%)			Monounsaturated Fatty Acids (E%)			Polyunsaturated Fatty Acids (E%)			Trans Fatty Acids (E%)			Cholesterol (mg)		
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95
ES	65-75	122	38.1			11.0			17.7			5.4								209
UK	65+	735	36.1	6.1	22.6-47.7 <sup>3</sup>	15.3	4.0	7.7-23.8 <sup>3</sup>	10.9	2.2	6.4-15.5 <sup>3</sup>	5.6	2.3	1.4-11.0 <sup>3</sup>	1.6	0.5	0.7-2.7 <sup>3</sup>			

<sup>1</sup>SE; <sup>2</sup>g/MJ; <sup>3</sup>P2.5-P97.5

**ANNEX 2B INTAKE OF LINOLEIC ACID, CIS N-6 PUFA AND CIS N-3 PUFA AMONG ADULTS IN EU COUNTRIES.**

Country	Age yrs	N	Linoleic acid g/d			Linoleic acid E%			Cis n-6 PUFA g/d			Cis n-6 PUFA E%			Cis n-3 PUFA g/d			Cis n-3 PUFA E%						
			mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95	mean	SD	P5 - P95				
<b>Males</b>																								
FI	25-64	730				3.9	1.6					4.5	1.9								1.2	0.6		
	65-74	2339				3.8	1.5					4.3	1.7								1.3	0.7		
DE	35-64 <sup>1</sup>	1013	14.3	10.4								14.5	10.5					1.88	1.28		0.69	0.45		
	35-64 <sup>2</sup>	1032	18.6	12.8								18.8	12.8					2.59	1.96		0.91	0.58		
NL	19-35	352	17.8	7.3	7.5-32.1	5.8	1.9	3.2-9.0										5.85	1.87	3.12-9.06		0.70	0.28	0.33-1.25
SE	18-74	589	9.7																					
UK	19-24	102							12.6	5.4	4.9-25.4 <sup>3</sup>	5.3	1.4	3.3-9.3 <sup>3</sup>	2.10	0.75	0.89-4.24 <sup>3</sup>	1.0	0.3	0.5-1.6 <sup>3</sup>				
	25-34	198							13.1	4.6	5.4-25.8 <sup>3</sup>	5.4	1.3	3.3-8.0 <sup>3</sup>	2.30	1.10	0.99-5.22 <sup>3</sup>	1.0	0.4	0.5-2.3 <sup>3</sup>				
	35-49	253							13.1	4.9	4.8-25.6 <sup>3</sup>	5.4	1.5	2.9-8.5 <sup>3</sup>	2.31	0.92	0.86-4.46 <sup>3</sup>	1.0	0.4	0.5-1.9 <sup>3</sup>				
	50-64	253							12.6	6.1	4.5-23.9 <sup>3</sup>	5.3	1.9	2.7-9.0 <sup>3</sup>	2.29	0.96	0.81-4.71 <sup>3</sup>	1.0	0.4	0.5-2.1 <sup>3</sup>				
	65+	540							10.5	5.2	3.4-23.7 <sup>3</sup>	5.0	2.1	2.1-10.5 <sup>3</sup>	1.75	1.02	0.54-4.35 <sup>3</sup>	0.8	0.5	0.3-1.8 <sup>3</sup>				
<b>Females</b>																								
FI	25-64	846				3.9	1.7					4.4	1.9								1.2	0.5		
	65-74	234				3.7	1.5					4.2	1.7								1.3	0.6		
DE	35-64 <sup>1</sup>	1078	10.9	9.3					10.1	11.0		5.3	3.3			1.53	1.08		0.74	0.45				
	35-64 <sup>2</sup>	898	11.6	7.6					11.7	7.6		5.8	3.1			1.72	1.07		0.88	0.52				
NL	19-35	398	12.0	6.0	4.2-23.6				5.5	2.0	12.3-9.8	5.52	2.07	2.61-9.79						0.66	0.33	0.29-1.28		
SE	18-74	626	7.8																					
UK	19-24	104							10.1	5.0	3.7-21.8 <sup>3</sup>	5.6	1.7	3.6-8.3 <sup>3</sup>	1.69	0.75	0.73-3.41 <sup>3</sup>	1.0	0.4	0.6-1.7 <sup>3</sup>				
	25-34	210							9.4	4.0	3.4-20.5 <sup>3</sup>	5.6	1.8	2.9-9.9 <sup>3</sup>	1.60	0.63	0.67-3.14 <sup>3</sup>	1.0	0.3	0.5-1.9 <sup>3</sup>				
	35-49	318							9.5	3.9	3.3-18.0 <sup>3</sup>	5.3	1.6	2.8-9.0 <sup>3</sup>	1.68	0.76	0.59-3.44 <sup>3</sup>	1.0	0.4	0.4-1.8 <sup>3</sup>				
	50-64	259							8.8	3.5	3.1-16.1 <sup>3</sup>	5.0	1.5	2.5-8.1 <sup>3</sup>	1.82	0.88	0.66-3.59 <sup>3</sup>	1.1	0.6	0.5-2.3 <sup>3</sup>				
	65+	735							7.7	4.0	2.1-17.4 <sup>3</sup>	4.8	2.2	1.9-10.1 <sup>3</sup>	1.33	0.71	0.42-2.98 <sup>3</sup>	0.8	0.4	0.4-1.8 <sup>3</sup>				

<sup>1</sup>Cohort Heidelberg; <sup>2</sup>Cohort Potsdam; <sup>3</sup>P2.5-P97.5



**ANNEX 2B DIETARY INTAKES OF ALA, EPA AND DHA BY ADULTS IN DIFFERENT COUNTRIES**

	ALA		EPA		DHA		references
	men	women	men	women	men	women	
<b>g/d</b>							
<b>Austria</b>	1.5	1.3	0.08	0.07	0.2	0.2	Elmadfa et al, 2009
<b>France</b>	0.9	0.7	0.15	0.12	0.27	0.23	Astorg et al., 2004
<b>Germany *</b>	1.59	1.32	0.10	0.07	0.19	0.14	Linseisen et al., 2003
<b>Germany**</b>	2.25	1.51	0.13	0.08	0.21	0.14	
<b>The Netherlands</b>	1.95	1.26	0.03	0.03	0.07	0.05	Kruizinga et al., 2007
<b>Sweden</b>	1.6	1.2	0.1	0.1	0.24	0.21	Becker and Pearson, 1998
<b>E%</b>							
<b>Austria</b>	0.5	0.6	0.03	0.03	0.07	0.09	Elmadfa et al., 2009
<b>France</b>	0.35	0.38	0.06	0.06	0.11	0.12	Astorg et al., 2004
<b>Germany*</b>	0.6	0.6	0.04	0.03	0.07	0.07	Lineisen et al., 2003
<b>Germany**</b>	0.8	0.8	0.05	0.04	0.07	0.07	
<b>The Netherlands</b>	0.6	0.6	0.01	0.02	0.02	0.03	Kruizinga et al., 2007
<b>Sweden</b>	0.6	0.6	0.04	0.05	0.09	0.10	Becker and Pearson, 1998

\* German EPIC Cohort from center H and \*\* center P

**ANNEX 3 OVERVIEW OF DIETARY RECOMMENDATIONS SET BY DIFFERENT ORGANISATIONS**

**Recommended intakes for Nordic Countries 2004**

The Nordic countries include Norway, Finland, Sweden, Denmark, and Iceland.

**Table 6:** Recommended fat and fatty acid intakes for Nordic Countries for adults and children from 2 years of age (NNR, 2004)

	<b>Recommended intake</b>	<b>Remarks</b>
Total fat	25-35 E%	- Intake < 30 E% is desirable for obese people, while for lean people intakes of 30-35 E% are acceptable - Intakes below 15 E% are not desirable, because it may be difficult to ensure adequate intake of fat-soluble vitamins and EFA
SFA plus TFA	< 10 E%	- Lower levels may be desirable in people with hypercholesterolaemia - Intake of TFA from hydrogenated oils as low as possible
<i>Cis</i> -MUFA	10-15 E%	
PUFA of which	5-10 E%	- Higher levels of PUFA are not recommended because of potentially harmful effects of very high intakes
n-3 fatty acids	1 E%	- The lower level of intake is 3 E%, including 0.5 E% from n-3 fatty acids. For pregnant and lactating women these values are 5 E% and 1 E%
n-3 / n-6 ratio	1:3-9	
Cholesterol		- No reference value - A reduction in SFA intake is expected to decrease cholesterol intake

Reference values for cholesterol were not included, because it was anticipated that guidelines that promote an increased consumption of fruit and vegetables and a decreased consumption of SFA will lead to a reduction in cholesterol intake.

For children <6 months no guidelines have been formulated, as breastfeeding is recommended and because the the fat composition of infant formula and follow-on formula is regulated. For children 6-23 months, however, separate guidelines have been formulated.

**Table 7:** Recommended fat and fatty acids intakes for Nordic Countries for children 6-11 or 12-23 months of age (NNR, 2004)

	Age group	Recommended intake	Remarks
Total fat	6-11 months	30-45 E%	- A gradual decrease of fat intake with age from 12 to 23 months is recommended
	11-23 months	30-35 E%	
SFA plus TFA	6-11 months		- The intake of TFA should be as low as possible, because TFA may interfere with the metabolism of PUFA
	11-23 months	10 E%	- No reference value for 6-11 months
PUFA of which n-3 fatty acids	6-11 months	5-10 E% 1 E%	- The lower level of intake is 5 E%, including 1 E% from n-3 fatty acids
	11-23 months	5-10 E% 1 E%	- The lower level of intake is 4.5 E%, including 0.5 E% from n-3 fatty acids.
n-3 / n-6 ratio	6-11 months	3-9 E%	- It is mentioned that the optimum ratio is not known for the various age groups, but that the ratio of 5-15 as found in infant formulas should gradually approach the level for adults
	11-23 months		

The recommendations are based on findings from epidemiological and clinical trials on the relationships between:

- essential fatty acid deficiency and disease.
- dietary fatty acids and dyslipoproteinaemia and atherosclerosis.
- fat intake and control of body weight.
- fat intake and insulin sensitivity.
- dietary fat composition and effects on blood pressure (especially EPA and DHA), insulin sensitivity, blood coagulation and cancer.
- energy requirements to sustain the rapid growth rate during infancy.

### Dietary Reference Values for the United Kingdom

The Dietary Reference Values of fat and fatty acids for the United Kingdom were derived in 1991 (DoH, 1991). Values are provided as an average value for the population. No information for age-groups is given.

**Table 8:** Dietary Reference Values of fat and fatty acids for the United Kingdom as an average value for the population (DoH, 1991).

	DRV	Remarks
Total fat	33 E%	- 35 E% when alcohol is not included
SFA	10 E%	
TFA	<2 E% or <5 g/d	
<i>Cis</i> -MUFA	12 E%	
PUFA	6 E%	- Although it was not concluded that high dietary intakes of
.Linoleic acid	>1 E%	PUFA may be harmful, intakes should not exceed 10 E%
. $\alpha$ -linolenic acid	>0.2 E%	- A mixture of n-6 and n-3 PUFA
Cholesterol		- No reference value

The recommendations are based on findings from epidemiological and clinical trials on the relationships between:

- essential fatty acid deficiency and disease
- dietary fatty acids and dyslipoproteinaemia and atherosclerosis.
- n-3 long-chain PUFA intake and thrombus formation

There was insufficient evidence:

- for a relationship between a high intake of PUFAs with any human disease.
- for a relationship between a high intake of isomeric fatty acids with potential long term adverse effects on health.
- for the recommendation to decrease fat intake to prevent cancer. It was stressed, however, that an increase in the consumption of any fatty acid was not encouraged.
- to establish or to exclude a special role for dietary fat in the development of obesity
- for a direct effect of dietary fat on the development of either type 1 or type 2 diabetes mellitus. The UK committee however supported recommendations that in diabetes fat intake should not exceed > 30-35 E% with not more than one third of energy from SFA.

### Recommended intakes for France

The Dietary Reference Values of fat and fatty acids for France were derived in 2001 (AFSSA, 2001).

**Table 9:** Recommended intakes of fat and fatty acids for France for adult men and women (AFSSA, 2001).

	<b>Recommended intake</b>	<b>Remarks</b>
Total fat	30-35 E%	
SFA	8 E%	
TFA		- An upper consumption level for TFA is recommended for the future
<i>Cis</i> -MUFA	20 E%	
PUFA of which		
.linoleic acid	4 E%	
. $\alpha$ -linolenic acid	0.8 E%	
.LCPUFA	0.20 E%	
.DHA	0.05 E%	
n-3 / n-6 ratio	1:5	- Refers to $\alpha$ -linolenic acid to linoleic acid ratio
Cholesterol		- Recommendation only justified for hypercholesterolaemic people

For pregnant and lactating women, separate guidelines have been formulated.

**Table 10:** Recommended intakes of fat and fatty acids for France for pregnant and lactating women (AFSSA, 2001).

	<b>Women .Pregnant .Lactating</b>	<b>Recommended intake</b>	<b>Remarks</b>
Total fat	Both groups	30-35 E%	
SFA	Both groups	8 E%	
TFA	Both groups		- An upper consumption level for TFA is recommended for the future
<i>Cis</i> -MUFA	Both groups	20 E%	
PUFA of which	Both groups		
.linoleic acid		4.4 E%	
. $\alpha$ -linolenic acid		0.9 E%	
.LCPUFA		0.4 E%	
.DHA		0.1 E%	

The recommendations are based on findings from epidemiological and clinical trials on the relationships between:

- essential fatty acid deficiency and disease.
- dietary fatty acids and dyslipoproteinaemia and atherosclerosis.

Further,

- n-6 PUFAs producing ARA may promote tumor growth.
- n-3 LCPUFAs may inhibit tumor growth.

- an  $\alpha$ -linolenic acid to linoleic acid ratio of 1:5 seems to prevent cancer development

### Dietary reference intakes of fat and fatty acids for the Netherlands

The Dietary Reference Values of fat and fatty acids for the Netherlands were derived in 2001 (GR, 2001).

**Table 11:** Dietary reference intakes of fat and fatty acids for the Netherlands (GR, 2001).

	DRV	Remarks
Total fat	20-40 E%	- Fat per se does not affect body weight, but may increase energy intake. For persons with undesirable weight gain, 30-35E%
SAFA	< 10 E%	
TFA	As low as possible	
<i>Cis</i> -MUFA		
PUFA of which	<12 E%	
. linoleic acid	2.0 E%	
. $\alpha$ -linolenic acid	1.0 E%	
. EPA + DHA*	450 mg	
Cholesterol		- No reference value for cholesterol

\* Guidelines for a healthy diet 2006.

For children and for pregnant and lactating women separate dietary reference intakes have been formulated.

**Table 12:** Dietary Reference Values of fat and fatty acids for the Netherlands for adolescents < 19 years of age and for pregnant and lactating women (GR, 2001).

	Age group	DRV	Remarks
Total fat	0-6 months	45-50 E%	- For children > 2 years, a gradual decrease in fat intake is recommended
	6-11 months	35-40 E%	
	1-3 years	30-35 E%	
	1-4 years	30-35 E%	
	4-7 years	30-35 E%	
	7-10 years	30-35 E%	
	10-13 years	30-35 E%	
	13-15 years	30-35 E%	
SFA	Women		- No reference values for pregnant and lactating women were given
	. Pregnant	30-35 E%	
	. Lactating	30-35 E%	
SFA	All groups	One third of fat energy	



The recommendations are based on findings from epidemiological and clinical trials on the relationships between:

- essential fatty acid deficiency and disease.
- dietary fatty acids and dyslipoproteinaemia and atherosclerosis.
- total fat intake and the risk to develop type 2 diabetes mellitus.

There was insufficient evidence / data:

- for a relationship between a high intake of saturated fatty acids, *trans* fatty acids, oleic acid, or linoleic acid and development of cancer.
- for a relationship between a high intake of  $\alpha$ -linolenic acid and the development of prostate cancer.
- for a relationship between a high intake of fish-oil fatty acids and the development of breast cancer and colorectal cancer.
- to draw conclusions on the relationships between fatty acids and the risk to develop type 2 diabetes mellitus.
- to draw conclusions on the relationships between fatty acids and effects on the immune system.
- to conclude that total fat intake itself causes obesity under isocaloric condition. It may, however, promote energy dysbalance
- to draw conclusions on the relations between total fat intake and cancer

### Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland

Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland were derived in 2000 and revised in 2008 (D-A-CH, 2008).

**Table 13:** Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland for adolescents and adults from 15 years of age D-A-CH (2008).

	DRV	Remarks
Total fat	30 E%	- Very heavy manual labourers may need more - 25 E% may be more favourable, because intake of plant foods will be higher
SFA	< 10 E%	- Limited to long-chain SFA
TFA	< 1 E%	
<i>Cis</i> -MUFA		- No reference value
PUFA	< 7 E%	- Up to 10 E% if SFA provide more than 10 E%
of which LA	2.5 E%	
ALA	0.5 E%	
n-3 / n-6 ratio	1:5	- Refers to $\alpha$ -linolenic acid to linoleic acid ratio
Cholesterol	<300 mg per day	- A reduction in SFA intake is expected to decrease cholesterol intake

For children <15 years and for pregnant and lactating women separate guidelines have been formulated.

**Table 14:** Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland for adolescents < 15 years of age and for pregnant and lactating women D-A-CH (2008).

	Age group	DRV	Remarks
Total fat	0-4 months	45-50 E%	- For children > 2 years, a gradual decrease in fat intake is recommended
	1-4 years	35-40 E%	
	4-7 years	30-35 E%	
	7-10 years	30-35 E%	
	10-13 years	30-35 E%	
	13-15 years	30-35 E%	
	Women		
	.Pregnant	30-35 E%	
	.Lactating	30-35 E%	
SFA	All groups	One third of fat energy	

The general recommendation to decrease total fat intake - and especially of fat rich in saturated fatty acids - was based on findings from epidemiological and clinical trials showing that a close relationship existed between high-fat diets and dyslipoproteinaemia, atherosclerosis, colon cancer, and body weight.

### Population nutrient intake goals from the WHO/FAO

The population nutrient intake goals to prevent diet-related chronic diseases as formulated by the WHO/FAO (2003) are based on relationships between intakes of total fat, fatty acids and cholesterol and the chronic diseases obesity, type 2 diabetes and cardiovascular disease.

**Table 15:** Population nutrient intake goals as formulated by the WHO/FAO (WHO, 2003).

	Population nutrient intake goal	Remarks
Total fat	15-30 E%	- Up to 35 E% is acceptable for highly active groups - For women of the reproductive age at least 20 E% may be recommended
SFA	< 10 E%	
TFA	< 1 E%	
<i>Cis</i> -MUFA	By difference	
PUFA of which	6-10 E%	
.n-6 PUFA	5-8 E%	
.n-3 PUFA	1-2 E%	
Cholesterol	<300 mg per day	

---

## Acceptable macronutrient distribution ranges of fat, fatty acids and cholesterol for the United States and Canada

For the US and Canada, Acceptable Macronutrient Distribution Ranges (AMDR) for fat and various fatty acids have been formulated (IoM, 2005). For adults the AMDR of total fat is 20 to 35E%, for children 1 to 3 years of age 30 to 40 E%, and for children 4 to 18 years of age 25 to 35 E%. The ADMR for n-6 polyunsaturated fatty acids (linoleic acid) is 5 to 10 E% and for n-3 polyunsaturated fatty acids ( $\alpha$ -linolenic acid) 0.6 to 1.2 E%, of which 10% of total n-6 respectively n-3 polyunsaturated fatty acids can come from their respective LCPUFA.

No Adequate Intakes (AI), Estimated Average Requirements (EAR), and / or Recommended Daily Allowances (RDA) were formulated for SFA, TFA, *cis*-MUFA and cholesterol, because these (macro)nutrients are not essential and have no proven beneficial or independent role in the prevention of chronic diseases.

**ANNEX 4 ESTIMATED CHANGES IN BLOOD LIPIDS AND LIPOPROTEINS FOR A GROUP OF SUBJECTS WHEN ONE PERCENT OF ENERGY IN THE DIET FROM CARBOHYDRATES IS REPLACED ISOCALORICALLY BY A PARTICULAR FATTY ACID OR WHEN DAILY CHOLESTEROL INTAKE IS INCREASED BY 100 MG**

Fatty acid		Total cholesterol (mmol/L)	LDL cholesterol (mmol/L)	HDL cholesterol (mmol/L)	Total to HDL cholesterol ratio	Triacylglycerol (mmol/L)
Mixture of SFA	Change	+0.036	+0.032	+0.010	0.003	-0.021
	95% CI	0.029 to 0.043	0.025 to 0.039	0.007 to 0.013	-0.008 to 0.013	-0.027 to -0.015
.Lauric acid	Change	+0.069	+0.052	+0.027	-0.037	-0.019
	95% CI	0.040 to 0.097	0.026 to 0.078	0.021 to 0.033	-0.057 to -0.017	-0.028 to -0.011
.Myristic acid	Change	+0.059	+0.048	+0.018	-0.003	-0.017
	95% CI	0.036 to 0.082	0.027 to 0.069	0.013 to 0.023	-0.026 to 0.021	-0.027 to -0.006
.Palmitic acid	Change	+0.041	+0.039	+0.010	+0.005	-0.017
	95% CI	0.028 to 0.054	0.027 to 0.051	0.007 to 0.013	-0.008 to 0.019	-0.023 to -0.011
.Stearic acid	Change	-0.010	-0.004	+0.002	-0.013	-0.017
	95% CI	-0.026 to 0.006	-0.019 to 0.011	-0.001 to 0.006	-0.030 to 0.003	-0.024 to -0.010
<i>Cis</i> -MUFA (Oleic acid)	Change	-0.006	-0.009	+0.008	-0.026	-0.019
	95% CI	-0.012 to 0.000	-0.014 to -0.003	0.005 to 0.011	-0.035 to -0.017	-0.024 to -0.014
<i>Cis</i> -PUFA (Linoleic acid)	Change	-0.021	-0.019	+0.006	-0.032	-0.026
	95% CI	-0.027 to -0.015	-0.025 to -0.013	0.003 to 0.009	-0.042 to -0.022	-0.031 to -0.020
<i>Trans</i> -MUFA hydrogenated sources	from Change	+0.034	+0.041	-0.001	+0.025	0.000
	95% CI	0.022 to 0.045	0.025 to 0.058	-0.007 to 0.005	0.010 to 0.040	-0.010 to 0.009
Cholesterol	Change	+0.056	+0.050	0.008	0.020	
	95% CI	0.046 to 0.065	0.042 to 0.058	0.005 to 0.010	0.010 to 0.030	

Data are derived from (Mensink et al., 2003; Mozaffarian et al., 2006; Weggemans et al., 2001)

## GLOSSARY / ABBREVIATIONS

AI	Adequate Intake
ALA	Alpha linolenic acid
AMDR	Acceptable Macronutrient Distribution Ranges
AR	Average Requirement
ARA	Arachidonic acid
CHD	Coronary heart disease
CLA	Conjugated linoleic acid
DHA	Docosahexaenoic acid
DHGLA	Dihomo-gamma-linolenic acid
DRV	Dietary Reference Value
EAR	Estimated Average Requirement
EFA	Essential fatty acid
EFSA	European Food Safety Authority
EPA	Eicosapentaenoic acid
EPIC	European Prospective Investigation into Cancer and Nutrition
FFQ	Food frequency questionnaire
HOMA	Homeostasis Model Assessment
hs-CRP	High-sensitivity C-reactive protein
KANWU study	A multicenter trial performed in Kuopio, Aarhus, Naples, Wollongong, and Upsala on the effects of substituting a SFA-rich diet with a MUFA-rich diet on insulin sensitivity
LA	Linoleic acid
LTI	Lower Threshold Intake
MUFA	Monounsaturated fatty acids
n-3 PUFA	n-3 polyunsaturated fatty acids
n-6 PUFA	n-6 polyunsaturated fatty acids
OGTT	Oral glucose tolerance test

PRI	Population Reference Intakes
PUFA	Polyunsaturated fatty acids
RDA	Recommended Daily Allowance
RI	Reference Intake ranges for macronutrients
SFA	Saturated fatty acids
STRIP	Special Turku Coronary Risk Factor Intervention Project
TFA	<i>Trans</i> fatty acids
TG	Triglycerides
US	United States
VEP	Visual evoked potential